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SUMMARY 
This thesis examines methods of perioperative risk stratification and 
outcome in patients receiving multidisciplinary stage-directed treatment 
for oesophagogastric cancer. 
The hypotheses tested were: Suboptimal bioelectrical impedance 
analysis (BIA) body composition variables predict poor outcomes in 
oesophagogastric cancer (OGC) surgery; low CT-measured psoas 
muscle density (PMD) predicts poor outcomes in OGC surgery; 
suboptimal cardiopulmonary exercise (CPX) performance predicts poor 
outcomes following OGC surgery; the literature offers evidence in support 
of enhanced recovery programmes in OGC surgery; the use of an 
enhanced recovery programme in OGC surgery is feasible, safe and not 
associated with adverse outcomes. 
High values for BIA-derived measures of fat-free mass and muscle mass 
respectively predicted longer survival (p=0.047, p=0.011), but were not 
associated with reduced 30-day mortality, major morbidity or length of 
stay.  
CT-measured psoas muscle density greater than the median of 48.7 
Hounsfield Units predicted longer survival (p=0.046), but was not 
associated with reduced 30-day mortality, major morbidity or length of 
stay (LOHS). Multivariable analysis demonstrated radiological TNM stage 
(p=0.015), and both left (p=0.046) and right PMD (p=0.047), as significant 
and independent predictors of survival. 
Cardiopulmonary exercise testing results materially altered the 
management plan in 6.8% patients. Major morbidity (p=0.049) and poor 
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survival (p=0.048) were associated with a high ventilatory equivalent for 
carbon dioxide (VE/VCO2), but not with the anaerobic threshold (AT) or 
peak oxygen uptake (VO2peak). VE/VCO2 also emerged on multivariable 
analysis as an independent and significant predictor of LOHS (p=0.001).  
Systematic review and meta-analysis revealed enhanced recovery 
programmes (ERPs) in OGC surgery to be feasible, safe and cost-
effective, significantly shortening length of stay (LOHS, p<0.0001). In our 
unit, the introduction of ERPs in gastric and oesophageal cancer surgery 
respectively, significantly reduced LOHS (p=0.004; p=0.032), critical care 
stay (p<0.0001; p<0.0001) and overall cost (p=0.001; p<0.0001). 
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1.1  Epidemiology 
1.1.1  Oesophageal cancer 
Oesophageal carcinoma is the eighth commonest cancer worldwide, with 
almost 500,000 cases diagnosed in 2008, and the thirteenth commonest 
cancer in the UK, where it accounted for more than 8,000 new diagnoses 
and more than 7,600 deaths in 2011 (CRUK, 2014). The age-
standardised incidence is 9.5 per 100,000, 14.2 and 8.5 per 100,000 for 
men and women respectively in the UK (CRUK, 2014).  
The reported incidence in Wales is lower than other UK countries in 
males at 12.3 per 100,000, compared with 12.5 to 16.5 per 100,000, but 
higher than all UK countries except for Scotland in females at 6.3 per 
100,000, compared with 4.6 to 6.5 per 100,000 (CRUK, 2014).  
The almost threefold male predominance in England (2.7:1) is much 
more pronounced in adenocarcinomas (AC, 5.2:1) and almost equal 
between men and women among squamous cell carcinomas (SCC, 
1.1:1) (CRUK, 2014).  
It remains predominantly a disease of old age, with >80% of cases 
diagnosed in people over the age of 60 (CRUK, 2014). 
The last 30 years have seen a marked overall increase in the UK 
incidence of oesophageal cancer, particularly for males, in whom the 
incidence has increased by 65% between 1975 and 2011. In females, a 
more modest increase of 26% was observed to 2001, followed by a 10% 
decrease (CRUK, 2014). 
Rates of incidence as much as 74% higher have also been observed in 
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deprived populations, seemingly mostly concerning SCC, rather than AC 
(CRUK, 2014).  
Epidemiological variation is seen according to histological subtype in 
oesophageal cancer. Worldwide, SCC is the dominant type, with the 
highest incidences reported in less developed regions, where >80% of 
cases occur. The highest incidence rates are seen in Southern Africa, 
with over 20 cases per 100,000 population, and the lowest rates in 
Western Africa (men) and Southern Europe (women), at around 1 per 
100,000 (CRUK, 2014).  
Adenocarcinoma is the most common histological subtype for Caucasian 
men in the UK, in whom reported rates of adenocarcinoma are the 
highest in the world (Bollschweiler et al., 2001, Wild and Hardie, 2003). 
An increasing incidence of adenocarcinoma of the gastric cardia has 
mirrored this oesophageal AC rise across the same time period, and now 
accounts for more than 50% of gastric cancers, suggesting the possibility 
of simliar aetiology (CRUK, 2014). 
 
1.1.2  Gastric cancer 
Gastric cancer is the 15th most common malignancy in the UK with a 
decreasing incidence reported at 7.6 per 100,000 population in 2011 
(CRUK, 2014), down from 8.4 per 100,000 population in 2008 (Newnham 
A, 2003, CRUK, 2012). It accounted for over 7,000 new cases and 4,800 
deaths in 2011 (CRUK, 2014).  
The incidence in men is more than twice that in women (11.2 vs. 4.7 per 
100,000). In Wales, the incidence in men is higher than in other countries 
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within the UK at 14.6 per 100,000, compared with 10.8-14.2 per 100,000 
in the remaining UK nations (CRUK, 2014). Gastric cancer is 
predominantly a disease of advanced age, with more than half of all 
cases between 2009 and 2011 diagnosed in over 75 year-olds (CRUK, 
2014). An estimated almost one million cases were diagnosed worldwide 
in 2008. The highest incidence rates were seen in Eastern Asia, at up to 
42 per 100,000 for males and 18 per 100,000 for females.  
Most (95%) cases are adenocarcinomas, the remainder predominantly 
comprising lymphomas and leiomyosarcomas. Adenocarcinomas are 
further classified as either intestinal or diffuse type. Intestinal type is 
associated with atrophic gastritis and confers a preferable survival when 
compared with diffuse type, which is more common in the elderly, women 
and people with blood group A (CRUK, 2014).  
 
1.2  Aetiology 
The aetiology of oesophageal and gastric cancer differs according 
histological cell type. 
 
1.2.1  Squamous cell carcinoma 
The predominant risk factors for oesophageal squamous cell carcinoma 
in western countries are smoking and alcohol consumption. A synergistic 
effect has been observed, with the risk ranging from 20 to 130- fold 
higher according to certain combinations of excessive drinking and 
smoking (Castellsague et al., 1999, Freedman et al., 2007, Zambon et 
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al., 2000). The effect of alcohol on risk varies according to the volume 
consumed. Risk increases have been reported ranging from 18% for men 
and 35% for women per 10g/day alcohol consumption (Weikert et al., 
2009), to 5-fold with more than three daily drinks (Freedman et al., 2007), 
and even up to an almost 25-fold risk in men drinking 84 or more drinks 
per week (Zambon et al., 2000). The mechanism of action for alcohol is 
unclear and may be related to a combination of direct mucosal damage, 
increased susceptibility to other carcinogens, or secondary associated 
dietary deficiencies. A diet deficient in fruit and vegetables has been 
identified as the third main risk factor for oesophageal SCC in the 
developed world, with associated reductions in risk demonstrated with 
increased consumption of both fruit and vegetables (Key, 2011). 
 
Additional dietary and lifestyle factors affecting the risk of oesophageal 
SCC include childhood nutritional deficiencies, in particular riboflavin and 
vitamins A and C, as well as the high intake of nitrosamines and the 
consumption of very hot drinks (Group, 1979, Mosavi-Jarrahi and 
Mohagheghi, 2006, Pourshams et al., 2005). It is suggested that these 
factors may result in a chronic asymptomatic oesophagitis, different from 
gastro-oesophageal reflux disease, and possibly representing a precursor 
to SCC. These aetiological factors are most important in less developed 
countries, where poverty and malnutrition are prevalent. 
Traumatic oesophageal strictures following the ingestion of corrosive 
agents, particularly in childhood, are associated with a 1000-fold increase 
in the risk of carcinoma. Achalasia also confers an increase in risk, 
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estimated at 140 times greater than the general population (Brucher et 
al., 2001). Plummer-Vinson syndrome (PVS) is described as dysphagia, 
iron-deficiency anaemia, koilonychia and oropharyngeal mucosal atrophy. 
An associated increased risk of cervical oesophageal cancer has been 
reported in PVS (Ribeiro et al., 1996). Finally the rare autosomal 
dominant condition tylosis palmarum is associated with a very high 
incidence of squamous cell carcinoma (Varela et al., 2011). 
 
1.2.2  Adenocarcinoma 
The predominant risk factors for oesophageal adenocarcinoma are 
gastro-oesophageal reflux disease (GORD) and obesity. In gastric 
cancer, Helicobacter pylori is a recognised risk factor for gastric cancer, 
conferring a lifetime risk of 0.1% in infected individuals (Compare et al., 
2010), although it probably represents a minority cause of gastric cancer 
in the Western World (Kelley and Duggan, 2003).  
An estimated 4-9% of the population experience heartburn on a daily 
basis, and up to 20% weekly (Cameron, 1997). Symptomatic reflux is 
associated with a risk of oesophageal cancer almost eight times greater 
than the asymptomatic individual. With the most severe, frequent and 
enduring symptoms, a risk of up to 44-fold has been shown (Lagergen J, 
1999), although it has been argued that the presence of GORD may not 
itself represent a genuine risk factor for oesophageal cancer (Solaymani-
Dodaran et al., 2004). Rather, the resultant Barrett’s metaplasia has been 
held culpable, arising as a result of chronic reflux and potentially leading 
to a spectrum of subsequent changes through increasing grades of 
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epithelial dysplasia to invasive adenocarcinoma (Fitzgerald, 2006). 
Described over 60 years ago, Barrett’s oesophagus is the replacement of 
normal squamous epithelium of the distal oesophagus by a columnar-
lined mucosa (Barrett, 1950). The true prevalence of Barrett’s 
oesophagus is not clear, owing to its asymptomatic nature in most 
patients; indeed estimates from post-mortem studies suggesting levels as 
high as 5% (Cameron et al., 1990), while levels of 1% were found in 
unselected endoscopy patients (Cameron and Lomboy, 1992) and 12% 
of patients with reflux (Winters et al., 1987).  
The more clinically important minority, whose Barrett’s transforms into 
adenocarcinoma, are not well quantified. The various estimates of 
malignant transformation risk have ranged from 1 in 56, to 1 in 315 cases 
per patient year (Robertson et al., 1988, Miros et al., 1991, Katz et al., 
1998, Oberg et al., 2005). Segment length represents the most important 
risk factor for malignant transformation (Menke-Pluymers et al., 1993), 
with additional factors including male sex, age over 45 years, Caucasian 
ethnicity, severe reflux symptoms, obesity and heavy smoking (Watson 
A, 2005).  
Oesophageal adenocarcinoma is three to six times more common in the 
overweight (Cheng et al., 2000), the mechanism likely related to the 
increase in the incidence of gastro-oesophageal reflux and hiatus hernia 
observed in the overweight. There is emerging evidence that there are 
obesity effects independent of reflux (Lindblad et al., 2005). A gender 
difference in the obesity effect has also been observed, particular risk 
associated with the abdominal pattern of fat distribution that is 
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characteristically seen in males (Vaughan et al., 2002).  
Additional factors that have been associated with gastric cancer include 
previous gastric surgery, peptic ulcer disease, low fruit and vegetable 
intake, high salt, nitrite or nitrate intake, ionising radiation, and pernicious 
anaemia, although evidence has not been consistent (Kelley and 
Duggan, 2003).  
While socio-economic deprivation has been linked to adenocarcinoma 
risk, this link is far less pronounced than for squamous cell carcinoma. It 
may be that confounding factors prevalent in social deprivation and those 
already discussed herein, including obesity, smoking and alcohol, are 
actually responsible for the differences observed according to 
socioeconomic status. Interestingly, the rising incidence of cardia cancer 
has been predominantly observed in the professional classes (Powell and 
McConkey, 1992).  
 
1.3  Stage classifications 
The TNM staging classification system was introduced in 1986, as a 
result of an agreement between the American Joint Committee on 
Cancer (AJCC), the Japanese Joint Committee (JJC) and the 
International Union Against Cancer (UICC). The TNM system is used 
globally as the gold standard staging system. It informs the treatment 
planning, assists in determining prognosis and allows outcome 
comparison between centres. The most up-to-date version is the 7th 
edition (Sobin LH, 2009a), which came into effect in 2010.  
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1.3.1  Anatomical site 
The TNM classification of the anatomical site of the primary tumour is 
derived from the original description by the Japanese Society for 
Esophageal Diseases (Japanese Society for Oesophageal Diseases, 
1976). It divides the oesophagus into four parts:  
The cervical oesophagus begins at the lower border of the cricoid 
cartilage and reaches the thoracic inlet at the suprasternal notch. The 
upper thoracic portion originates at the thoracic inlet and reaches as far 
as the tracheal bifurcation. The mid thoracic portion is the proximal half of 
the length of oesophagus between the tracheal bifurcation and the 
oesophagogastric junction, and the lower thoracic portion is the distal half 
(Sobin LH, 2009a). 
 
1.3.2  Tumour stage 
The T stage describes the depth of the tumour’s invasion through the 
layers of the oesophageal wall. T-stage begins with in-situ disease, 
classified as either high grade dysplasia or carcinoma in situ. Stage T1 
describes tumour invading lamina propria or submucosa and is further 
subdivided into T1a when confined to the mucosa, or T1b when 
extending into the submucosa. Stage T2 describes tumour invading into 
but not through the muscularis propria. In T3 disease the tumour invades 
the adventitia, and in T4 disease the tumour invades adjacent structures. 
T4 is subdivided into T4a, when structures can be surgically removed, 
and T4b when structures are irresectable.  
 40 
 
1.3.3  Nodal stage 
The N stage describes the presence and degree of pathological lymph 
node involvement. Nodes are identified according to their anatomical site 
in relation to the primary tumour. 
Lymph node status represents one of the most important prognostic 
markers (Khan et al., 2003, Lozac'h et al., 1997, Paraf et al., 1995). 
When lymph node status is positive, the number of lymph node 
metastases is widely recognised as an important prognostic indicator (Ide 
et al., 1994, Lieberman et al., 1995, Kawahara et al., 1998, Zafirellis et 
al., 2002, Kunisaki et al., 2005, Mariette et al., 2003). For this reason, 
TNM7 incorporated additional N stage sub classifications of N1 (1-2 
nodes), N2 (3-6 nodes), or N3 (>6 nodes), which were absent in the 
preceding version, TNM6 (Sobin LH, 2002). 
 
1.3.4  Metastasis stage 
The M stage describes the presence of distant metastases. The sub 
classifications M1a and M1b were used in the 6th edition of TNM, 
according to the position of the primary tumour and the location of 
metastases (Sobin LH, 2002). These were simplified to M0 and M1 in 
TNM7, denoting the presence or absence of metastatic disease 
respectively.  
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1.3.5.1  TNM classification for gastric cancer  
(Edge et al., 2007, p120) 
TX# Primary#tumour#cannot#be#assessed.#
T0# No#evidence#of#primary#tumour.#
Tis# Carcinoma#in#situ:#intraepithelial#tumour#without#invasion#of#the#lamina#propriaa.#
T1# Tumour#invades#lamina#propria,#muscularis#mucosae,#or#submucosa.#
T1a# Tumour#invades#lamina#propria#or#muscularis#mucosae.#
T1b# Tumour#invades#submucosa.#
T2# Tumour#invades#muscularis#propria.#
T3# Tumour#penetrates#subserosal#connective#tissue#without#invasion#of#visceral#peritoneum#or#adjacent#structures.#
T4# Tumour#invades#serosa#(visceral#peritoneum)#or#adjacent#structures.#
T4a# Tumour#invades#serosa#(visceral#peritoneum).#
T4b# Tumour#invades#adjacent#structures.#
#
NX# Regional#lymph#node(s)#cannot#be#assessed.#
N0# No#regional#lymph#node#metastasis.#
N1# Metastases#in#1–2#regional#lymph#nodes.#
N2# Metastases#in#3–6#regional#lymph#nodes.#
N3# Metastases#in#≥7#regional#lymph#nodes.#
N3a# Metastases#in#7–15#regional#lymph#nodes.#
N3b# Metastases#in#≥16#regional#lymph#nodes.#
#
M0# No#distant#metastasis.#
M1# Distant#metastasis.#
aHigh-grade dysplasia includes all noninvasive neoplastic epithelia that was formerly 
called carcinoma in situ, a diagnosis that is no longer used for columnar mucosae 
anywhere in the gastrointestinal tract.  
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1.3.5.2  TNM anatomic stage/prognostic groups for gastric cancer  
(Edge et al., 2007, p120) 
0# Tis# N0# M0#
IA# T1# N0# M0#
IB#
T2# N0# M0#
T1# N1# M0#
IIA#
T3# N0# M0#
T2# N1# M0#
T1# N2# M0#
IIB#
T4a# N0# M0#
T3# N1# M0#
T2# N2# M0#
T1# N3# M0#
IIIA#
T4a# N1# M0#
T3# N2# M0#
T2# N3# M0#
IIIB#
T4b# N0# M0#
T4b# N1# M0#
T4a# N2# M0#
T3# N3# M0#
IIIC#
T4b# N2# M0#
T4b# N3# M0#
T4a# N3# M0#
IV# Any#T# Any#N# M1#
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1.3.5.3  TNM classification for oesophageal cancer  
(Edge et al., 2007, p103) 
TX# Primary#tumour#cannot#be#assessed.#
T0# No#evidence#of#primary#tumour.#
Tis# HighTgrade#dysplasia.a#
T1# Tumour#invades#lamina#propria,#muscularis#mucosae,#or#submucosa.#
T1a# Tumour#invades#lamina#propria#or#muscularis#mucosae.#
T1b# Tumour#invades#submucosa.#
T2# Tumour#invades#muscularis#propria.#
T3# Tumour#invades#adventitia.#
T4# Tumour#invades#adjacent#structures.#
T4a# Resectable#tumour#invading#pleura,#pericardium,#or#diaphragm.#
T4b# Unresectable#tumour#invading#other#adjacent#structures,#such#as#aorta,#vertebral#body,#trachea,#etc.#
#NX# Regional#lymph#nodes#cannot#be#assessed.#
N0# No#regional#lymph#node#metastasis.#
N1# Metastases#in#1–2#regional#lymph#nodes.#
N2# Metastases#in#3–6#regional#lymph#nodes.#
N3# Metastases#in#≥7#regional#lymph#nodes.#
#M0# No#distant#metastasis.#
M1# Distant#metastasis.#
aHigh-grade dysplasia includes all noninvasive neoplastic epithelia that was formerly 
called carcinoma in situ, a diagnosis that is no longer used for columnar mucosae 
anywhere in the gastrointestinal tract.  
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1.3.5.4  TNM anatomic stage/prognostic groups for oesophageal 
cancer     
(Edge et al., 2007, p103) 
Adenocarcinoma 
Stage& T& N& M& Grade&
0# Tis#(HGD)# N0# M0# 1,#X#
IA# T1# N0# M0# 1–2,#X#
IB#
T1# N0# M0# 3#
T2# N0# M0# 1–2,#X#
IIA# T2# N0# M0# 3#
IIB#
T3# N0# M0# Any#
T1–2# N1# M0# Any#
IIIA#
T1–2# N2# M0# Any#
T3# N1# M0# Any#
T4a# N0# M0# Any#
IIIB# T3# N2# M0# Any#
IIIC#
T4a# N1–2# M0# Any#
T4b# Any# M0# Any#
Any# N3# M0# Any#
IV# Any# Any# M1# Any#
 
Squamous Cell Carcinomaa 
Stage& T& N& M& Grade& Tumor&Locationb&
0# Tis#(HGD)# N0# M0# 1,#X# Any#
IA# T1# N0# M0# 1,#X# Any#
IB#
T1# N0# M0# 2–3# Any#
T2–3# N0# M0# 1,#X# Lower,#X#
IIA#
T2–3# N0# M0# 1,#X# Upper,#middle#
T2–3# N0# M0# 2–3# Lower,#X#
IIB#
T2–3# N0# M0# 2–3# Upper,#middle#
T1–2# N1# M0# Any# Any#
IIIA#
T1–2# N2# M0# Any# Any#
T3# N1# M0# Any# Any#
T4a# N0# M0# Any# Any#
IIIB# T3# N2# M0# Any# Any#
IIIC#
T4a# N1–2# M0# Any# Any#
T4b# Any# M0# Any# Any#
Any# N3# M0# Any# Any#
IV# Any# Any# M1# Any# Any#
aOr mixed histology, including a squamous component or not otherwise specified. 
bLocation of the primary cancer site is defined by the proximal tumour edge. 
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1.4  Preoperative staging 
The accuracy of radiological staging is critical in determining appropriate 
treatment options. All treatment of oesophagogastric cancer is stage-
directed and accurate staging permits identification of those patients 
whose disease is potentially curable. Equally, identifying those patients 
with incurable disease can prevent them from being subjected to 
inappropriate treatment, associated with significant potential for morbidity.  
Staging follows the TNM classification and first identifies those patients 
with metastatic disease, in whom curative treatment is not possible. 
Subsequently, more precise assessment of the local and regional 
disease is made, determining accurate T and N stages, as well as precise 
disease margins. A multimodal approach is adopted, utilising computed 
tomography (CT), endoluminal ultrasonography (EUS), endoscopic 
mucosal resection (EMR), CT-positron emission tomography (CT-PET) 
and diagnostic laparoscopy. 
 
1.5  Preoperative physiological assessment 
Oesophagogastric resectional surgery carries a significant physiological 
burden and high risk of morbidity and mortality (Centre, 2010). Various 
assessment modalities are used to measure the capacity of an individual 
to cope with such physiological insults. The information gathered using 
these assessments informs the multidisciplinary team decision on 
appropriate treatment modalities for individual patients, permitting 
interventions in the perioperative period to ensure optimisation of 
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performance status, and thereby minimise operative risk.  
 
1.5.1  ASA grade 
The American Society of Anesthesiologists’ (ASA) classification of 
preoperative physical status is widely used across the globe. Its main 
limitation is its broad non-specificity. However, it is easily applied and 
correlates with outcomes across a wide range of settings.  
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1.5.1.1  Table of ASA grades 
ASA&
Category&
Preoperative&Health&
Status& Comments,&Examples&
ASA#1# Normal#healthy#patient# No#organic,#physiologic,#or#psychiatric#disturbance;#
excludes#the#very#young#and#very#old;#healthy#with#
good#exercise#tolerance#
#
ASA#2# Patients#with#mild#
systemic#disease#
No#functional#limitations;#has#a#wellTcontrolled#
disease#of#one#body#system;#controlled#hypertension#
or#diabetes#without#systemic#effects,#cigarette#
smoking#without#chronic#obstructive#pulmonary#
disease#(COPD);#mild#obesity,#pregnancy#
#
ASA#3# Patients#with#severe#
systemic#disease#
Some#functional#limitation;#has#a#controlled#disease#
of#more#than#one#body#system#or#one#major#system;#
no#immediate#danger#of#death;#controlled#congestive#
heart#failure#(CHF),#stable#angina,#old#heart#attack,#
poorly#controlled#hypertension,#morbid#obesity,#
chronic#renal#failure;#bronchospastic#disease#with#
intermittent#symptoms#
#
ASA#4# Patients#with#severe#
systemic#disease#that#is#
a#constant#threat#to#life#
Has#at#least#one#severe#disease#that#is#poorly#
controlled#or#at#end#stage;#possible#risk#of#death;#
unstable#angina,#symptomatic#COPD,#symptomatic#
CHF,#hepatorenal#failure#
#
ASA#5# Moribund#patients#who#
are#not#expected#to#
survive#without#the#
operation#
Not#expected#to#survive#>#24#hours#without#surgery;#
imminent#risk#of#death;#multiorgan#failure,#sepsis#
syndrome#with#hemodynamic#instability,#
hypothermia,#poorly#controlled#coagulopathy#
ASA#6# A#declared#brainTdead#
patient#who#organs#are#
being#removed#for#
donor#purposes#
#
 
 
 48 
1.5.2  POSSUM score 
The Physiological and Operative Severity Score for the enumeration of 
Mortality and morbidity (POSSUM) has emerged as a useful risk 
prediction tool across many fields of surgery (Copeland et al., 1991). 
POSSUM encompasses an assessment of the patient’s physiological 
status (physiology score) across twelve variables (Table 1.5.2.1), 
combining it with a measure of the surgical burden of the operation 
(operative severity score) across six variables (Table 1.5.2.2). However, 
POSSUM has been demonstrated to have a poor predictive accuracy in 
oesophagectomy (Zafirellis et al., 2002). A modified version, developed in 
response to over-estimations of mortality, yielded more accurate 
predictions (Prytherch et al., 1998), and later, O-POSSUM was devised, 
specific to oesophagogastric surgery (Tekkis et al., 2004). Controversy 
persists regarding the predictive value of the various POSSUM scores 
with conflicting reports highlighting P-POSSUM (Nagabhushan et al., 
2007, Dutta et al., 2010) and O-POSSUM (Bosch et al., 2011) as most 
accurate.  
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1.5.2.1  POSSUM score - physiological parameters 
Age&
#&
<61#years#
61T70#years#
>70#years#
Cardiac&
##
##
#&
No#cardiac#failure#
Diuretic,#digoxin,#treatment#for#angina#or#hypertension#
Peripheral#oedema,#warfarin,#borderline#cardiomyopathy#
Raised#JVP,#cardiomegaly#
Respiratory&
##
##
#&
No#dyspnoea#
Dyspnoea#on#exertion,#mild#COAD#
Limiting#dyspnoea,#moderate#COAD#
Dyspnoea#at#rest,#pulmonary#fibrosis/consolidation#on#xTray#
ECG&
##
#&
ECG#normal#
ECG#=#AF,#rate#60T90#
ECG#=#other#abnormal#rhythm,#>4#ectopics,#Q#waves,#ST/T#changes#
Systolic&BP&
##
##
#&
110T130#mmHg#
100#T#109#or#131#T#170#mmHG#
>170,#or#90#T#99#mmHg#
<90#mmHg#
Pulse&Rate&
##
##
#&
50T80#bpm#
40#T#49,#or#81#T#100#bpm#
101#T#120#bpm#
<40,#or#>120#bpm#
Haemoglobin&
##
##
#&
13#T#16#g/dL#
11.5#T#12.9,#or#16.1#T#17#g/dL#
10#T#11.4,#or#17.1#T#18#g/dL#
<10,#or#>18#g/dL#
WBC&
##
#&
4#T#10#
10.1#T#20,#or#3.1#T#4#
>20#or#<3#
Urea&
##
##
#&
<7.6#
7.6#T#10#
10.1#T#15#
>15#
Sodium&
##
##
#&
>135#mmol/L#
131#T#135#mmol/L#
126#T#130#mmol/L#
>126#mmol/L#
Potassium&
##
##
#&
3.5#T#5#mmol/L#
3.2#T#3.4,#or#5.1#T#5.3#mmol/L#
2.9#T#3.1,#or#5.4#T#5.9#mmol/L#
<2.9,#or#>5.9#mmol/L#
GCS&
#&
15#
12#T#14#
9#T#11#
<9#
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1.5.2.2  POSSUM score – surgical parameters 
Operation&Type& Minor#
Moderate#
Major#
Complex#major#
Number&of&procedures& One#
Two#
more#than#two#
Operative&Blood&Loss& <100#ml#
101#T#499#ml#
500#T#999#
>1000#
Peritoneal&Contamination& No#soiling#
Minor#soiling#
Local#pus#
Free#bowel#content,#pus#or#blood#
Malignancy&Status& Not#malignant#
Primary#malignancy#only#
Primary#plus#nodal#mets#
Primary#plus#distant#mets#
CEPOD& Elective#
Urgent#/#'emergency'#
Emergency#(within#2hrs)#
 
 
1.5.3  Bioelectrical impedance analysis (BIA) 
BIA measures body resistance and reactance to an alternating electrical 
current and specific validated equations are applied to derive measures 
including fat-free mass and muscle mass (Kyle et al., 2004). Based on 
electrical properties described since 1871 (L., 1871), subcutaneous 
(Thomasset, 1962) and later surface electrode (Hoffer et al., 1969, 
Nyboer, 1970) techniques were developed, transforming the concept into 
a non-invasive, rapid and reproducible method of estimating body 
composition. However, little attention has been paid to these simple 
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bioelectrical measures in the surgical literature and specifically 
oesophagogastric cancer surgery.   
 
1.5.4  Cardiopulmonary exercise testing (CPX) 
CPX combines an incremental exercise stress test with direct 
measurement of exercise respiratory gas exchange as well as 
electrocardiography and, as such, represents a simulation of the 
neurohumoral stress response to surgery. Invoking this stress response 
allows an assessment to be made of the patient’s physiological capacity 
to tolerate the major surgical insult involved in oesophagogastric 
resection. 
Energy supply to respiring tissues relies principally upon aerobic 
respiration. When this supply is exhausted, anaerobic respiration occurs 
to supplement the tissues’ energy supply. The anaerobic threshold (AT) 
represents the rate of oxygen consumption at the point when a patient’s 
tissue oxygen demand exceeds supply, and AT has received much 
attention in the literature. Two additional CPX variables of interest are the 
peak oxygen uptake (VO2 peak) and the ventilatory equivalent for carbon 
dioxide (VE/VCO2). 
The role of CPX in pulmonary thoracic surgery has been studied 
extensively (Benzo et al., 2007), and published UK guidelines have been 
available for over a decade (Society, 2001). Moreover, in major 
abdominal surgery measurements of anaerobic threshold (AT), and peak 
oxygen uptake (VO2 peak) have been reported to predict short-term 
(Epstein et al., 2004, Wilson et al., 2010) and mid-term mortality (Carlisle 
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and Swart, 2007, Wilson et al., 2010), cardio-pulmonary related mortality 
(Older et al., 1993, Older et al., 1999), and length of hospital stay 
(Snowden et al., 2010).  
An AT of less than 11 ml/kg/min was shown to be associated with an 
operative mortality rate of 18% compared with a mortality rate of 0.8% in 
patients with an AT greater than 11ml/kg/min (p<0.001) in a study of 187 
elderly patients undergoing major abdominal surgery, such as abdominal 
aortic aneurysm resection or anterior resection of the rectum (Older et al., 
1993, Older et al., 1999).  These data, however, were published during 
the 1990s and both anaesthetic and surgical practice have since 
progressed.  
More recently, ATs below 10.9 ml/kg/min have been associated with an 
increased risk of mortality within 90 days, (RR 6.8%, 95% CI 1.6-29.5), an 
increased likelihood of high dependency care (457 patients with an AT of 
≤10.9 ml/kg/min vs. 390 with an AT of ≥10.9 ml/kg/min, p<0.001) and an 
increased median length of hospital stay (9 vs. 8 days, p<0.001) following 
major abdominal surgery such as elective colorectal resection, radical 
nephrectomy or cystectomy (Wilson et al., 2010). Similarly, in a study of 
patients undergoing major elective procedures such as open aortic 
aneurysm repair, liver resections and pancreatic sarcoma surgery, AT 
was found to be higher (11.9 vs. 9.1 mL/kg/min, p=0.001) in patients who 
developed one or less post-operative complication and subsequent 
LOHS was also shorter  (10 vs. 26 days, p<0.001) (Snowden et al., 
2010).  
Data regarding CPX in UGI cancer surgery, however, are thin by 
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comparison, and existing reports were, until recently, confined to 
oesophageal surgery (Nagamatsu et al., 1994, Nagamatsu et al., 2001, 
Forshaw et al., 2008). One recent study reported outcomes among 180 
patients with oesophagogastric cancer assessed using CPX, with 108 
(60%) ultimately receiving surgical treatment. The operated cohort 
comprised 43 (40%) patients with gastric cancer and 65 (60%) patients 
with oesophageal cancer. Patients with cardiopulmonary operative 
morbidity were reported to have a significantly lower AT than those 
without such morbidity (9.9 vs. 11.2 ml/kg/min, p=0.04). An AT below 9 
ml/kg/min was associated with operative cardiopulmonary morbidity using 
ROC analysis (sensitivity=74%, specificity=57%, p=0.04).  
In recent years a small body of literature has emerged examining the 
effect of intervention to improve cardiopulmonary capacity. This work has 
been founded upon the hypothesis that, to some degree, the benefits 
observed in patients with good exercise capacity may be achieved by 
training. In 2007, Lee and colleagues intervened using just such a 
programme in 25 patients with lung cancer in advance of surgery. 
Patients were provided access to attended exercise classes of 
progressively increasing frequency and intensity. Patients averaged 30 
sessions before surgery and managed to improve their VO2peak by 2.4 
ml/kg, with the best attenders improving the most (≥80% attendance, 
3.3ml/kg). However, the researchers investigation this very small sample 
do not report any exploration of the surgical outcomes of the 20 patients 
who eventually underwent surgical resection and it remains to be seen 
whether the observed improvement holds any genuine clinical relevance. 
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It would be interesting to see a group randomised to an exercise 
intervention or control group, with robust follow-up of short and long term 
outcomes, including mortality, morbidity, length of stay and, of course, 
survival. 
 
1.6  Nutrition 
In recent years, the importance of malnutrition in surgical patients has 
received significant attention. It has been demonstrated for almost three 
decades that weight loss is associated with poor outcomes after surgery 
(Windsor and Hill, 1988). 
 
1.6.1 Cachexia 
Cachexia is a complex condition characterised by abnormally low weight, 
weakness and general bodily decline. It occurs as the clinical 
consequence of a complex chronic systemic response to inflammation 
(Wigmore et al., 1997) and is present in up to 50% of patients with cancer 
(Gould et al., 2013).  
The complexities leading to the summative and profound weight losses in 
cancer have been associated with a myriad of theoretical pathological 
alterations in circulating hormones and their signaling axes. These can be 
broadly categorised as affecting appetite, protein metabolism and the 
chronic inflammatory state.  
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The capacity to ingest nutrients is restricted in many patients with 
oesophagogastric cancer by mechanical obstruction. Psychological 
barriers may arise with the learnt behaviour of consuming small and 
easily swallowed meals as dysphagia arises and progresses. Treatment 
toxicity can also diminish appetite and cause symptoms such as nausea, 
vomiting and diarrhoea (Martignoni et al., 2003). Further diminution of the 
appetite has been attributed to alterations in the feedback loop regulating 
the release of leptin from adipocytes. High levels of leptin inhibit the 
release of the potent feeding-stimulatory hormone neuropeptide Y (NPY) 
(Martignoni et al., 2003), leading to inhibition of food intake, in the face of 
increased energy requirements. 
Tumour-derived factors put forward as promoters of the cachectic 
syndrome include proteolysis inducing factor (PIF) (Tisdale, 2009), lipid 
metabolising factor (LMF) (Islam-Ali and Tisdale, 2001), mitochondrial 
uncoupling proteins (UCPs) (Kotler, 2000).  
The association of cachexia with a chronic systemic inflammatory 
response has been evidenced by high serum levels of IL-1, IL-6 and 
gamma interferon, each shown to correlate with tumour progression and 
further inhibit food intake via disruption of the NPY and leptin pathway 
described above (Martignoni et al., 2003). Tumour necrosis factor alpha 
(TNFα) is also implicated, altering messenger RNA activity for repair of 
damaged muscle tissue (Guttridge et al., 2000).  
 
Patients with upper gastrointestinal cancer are especially likely to suffer 
from substantial weight loss associated with cancer cachexia (Martignoni 
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et al., 2003). Indeed, patients with gastric cancer may suffer extreme 
weight loss of up to 30% of premorbid body weight (Martignoni et al., 
2003).  
 
1.6.2 Malnutrition and surgical outcomes  
Malnutrition has been defined as “a state in which a deficiency of energy, 
protein and/or other nutrients causes measurable adverse effects on 
tissue/body for, composition, function or clinical outcome” (MCaE, 2003). 
The National Institute for Health and Care Excellence (NICE) highlighted 
problems associated with the healthcare profession’s poor understanding 
of issues surrounding nutrition (NICE, 2005).  
Provision of nutritional support is poorly aligned with clinical need (NICE, 
2005), indeed 30-40% of those in whom nutritional intervention is 
indicated do not receive it, and up to a quarter of nutritional care provided 
is either not needed, or even has the potential to do harm (Heyland et al., 
2004). 
 
Malnourished patients are more likely to experience complications 
following elective surgery. This has been recognised since as far back as 
the 1930s (Studley, 2001, Shils, 2000) and has been reported following 
major surgery in the modern era (Sungurtekin et al., 2004). Nutritional 
indices have been shown to demonstrate increasing rates of malnutrition 
in a surgical population across their stay in hospital (Sungurtekin et al., 
2004). In addition, the ground-breaking work of Professor Henrik Kehlet 
and colleagues has brought focus onto the surgical stress response and 
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its impact on organ function, increasing oxygen demand and energy 
consumption (Kehlet, 1997). The wealth of multimodal approaches that 
have emerged following Kehlet’s work, optimising peri-operative care in 
virtually all surgical disciplines, seek to minimise these end-organ effects. 
However, data are few reporting nutritional measures in 
oesophagogastric ERAS programmes (Jiang et al., 2007, Liu et al., 2010) 
and direct assessment of the influence on outcomes of reliable, 
reproducible measures of skeletal muscle mass or specific risk indices is 
lacking in the literature.  
 
1.6.3 Skeletal muscle mass  
An increasing body of work has emerged focusing on skeletal muscle 
mass and outcomes in surgery in recent years.  
Studies have demonstrated clear relationships between CT measures of 
psoas muscle and surgical outcomes. A cohort of 163 patients 
undergoing liver transplant were examined according to the combined 
cross-sectional area of their psoas muscles at the level of the fourth 
lumbar vertebra, mortality was significantly higher and survival shorter at 
one and three years in the lowest quartile for psoas area, compared with 
the highest quartile (Englesbe et al., 2010). Sarcopaenic patients from a 
cohort of 196 patients undergoing colorectal hepatic metastatectomy, had 
a lower survival rate than those with higher skeletal muscle mass on CT 
analysis (van Vledder et al., 2012). 
In 262 patients undergoing elective abdominal aortic aneurysm repair, 
psoas muscle size reduced over time during follow-up and psoas area 
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showed a significant association with postoperative mortality (Lee et al., 
2011a). 
Indeed, CT measures of skeletal muscle mass have been built into a risk 
prediction algorithm to determine the “morphometric age” according to 
various factors observed on their CT scan (Englesbe et al., 2013). 
Applied to a cohort of 1,370 patients who underwent major abdominal 
surgery in the USA, morphometric age was a stronger predictor of 
operative mortality than chronological age and more than half of the 
patients in the morphometrically ‘oldest’ 10% were neither comorbid nor 
advanced in chronological age (Englesbe et al., 2013). This suggests that 
morphometric age can contribute novel predictive value that extends 
beyond factors traditionally assessed by the parameters age and 
comorbidity.  
The complex use of novel, simple risk predictors in this way exemplifies 
how future risk stratification may utilise readily available radiological 
imaging to new levels, with objective and precise measurements 
permitting the development of risk algorithms and perhaps leading to a 
more specific risk profile for the individual patient. 
 
1.6.4  Attenuation of muscle mass loss 
While it appears the depletion of skeletal muscle mass in upper 
gastrointestinal surgery may be attenuated by administration of pre-
operative oral carbohydrate-containing fluid or eicosapentaenoic acid 
enriched enteral nutrition, the implications of this on clinical factors, such 
as function and rehabilitation time, remain unknown (Yuill et al., 2005, 
 59 
Ryan et al., 2009).  
An American group compared the weight and fat free mass (FFM) of 
patients with stage IV solid organ cancers over 24 weeks. Administration 
of an experimental treatment containing β-hydroxy-β-methylbutyrate (3 
g/d), L-arginine (14 g/d), and L-glutamine (14 g/d [HMB/Arg/Gln]) was 
shown to be superior to an isonitrogenous control mixture of nonessential 
amino acids, with differences in weight change (+0.95 vs. -0.24kg) 
explained by significant differences observed in FFM between groups 
(1.34 +/-0.78kg vs. 1.12 +/-0.68kg, p=0.02) without any treatment-related 
complications (May et al., 2002). 
 
1.6.5  Obesity 
Obesity and underweight are defined as a BMI of 30 kg / m2 or over, and 
18.5 kg / m2 or below. Both have been shown to be associated with 
greater risk of recurrence or death following adjuvant chemotherapy for 
colon cancer, compared with patients of normal weight (Dignam et al., 
2006). Overweight and obesity have also been shown to be associated 
with reduced survival in patients with pancreatic cancer in the USA, 
regardless of disease stage or resectional status (overweight patients: 
hazard ratio, 1.26 [95% CI, 0.94-1.69], P = .04; obese patients: hazard 
ratio, 1.86 [95% CI, 1.35-2.56], P < .001) (Li et al., 2009). Within 
oesophagogastric surgery, there is limited evidence of an association 
between both anterior-posterior abdominal diameter and BMI with post-
operative complications following gastrectomy for gastric cancer, but this 
association was only observed in female patients (Lee et al., 2007). Other 
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researchers have failed to identify significant association between obesity 
(BMI) and post-operative mortality or complications after gastrectomy or 
oesophagectomy (Mullen et al., 2008). In addition, it has been 
demonstrated that BMI does not affect survival after oesophagectomy 
(Melis et al., 2011). 
 
1.6.6  Nutritional Risk Assessment Tools 
It is clear that malnutrition is both a cause and a consequence of ill-
health. It can increase susceptibility to infection, delayed wound healing, 
impaired cardiac and pulmonary function, reduced muscle strength and 
depression (NICE, 2005). Despite its far-reaching and significant 
implications a widely accepted definition for malnutrition remains elusive 
(NICE, 2005). The Malnutrition Advisory Group (MAG) is a standing 
committee of the BAPEN (formerly known as the British Association for 
Parenteral and Enteral Nutrition). MAG produced the Malnutrition 
Universal Screening Tool (MUST) (Elia Marinos, 2012) as a tool to 
identify those adults who are malnourished or at risk of malnutrition. It 
also incorporates management guidelines, which can be used by a wide 
range of healthcare workers to develop a patient care plan (Stratton et 
al., 2004, BAPEN, 2012). Similarly, WAASP (Weight, Appetite, Ability to 
eat, Stress factors, Pressure sores/wounds) is a screening tool with a 
similar objective, developed in South Wales for the assessment of 
nutrition (WAASP, 2005). 
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1.7  Enhanced recovery after surgery 
Enhanced recovery programmes (ERPs) employing holistic multimodal 
perioperative strategies have long been embedded within colorectal 
cancer surgical care and have been beneficial in reducing post-operative 
morbidity and length of hospital stay (LOHS) (Varadhan et al., 2010). 
Such improvements are achieved in the modern ERP through 
aggregation of the benefits of a number of interventions to optimise 
physiological, psychological and healthcare system factors surrounding 
major gastrointestinal surgery. Interventions are combined within a 
standardised pathway incorporating clear goals for patients and staff 
members alike. In contrast, ERPs in upper gastrointestinal (UGI) cancer 
surgery are less established.  
Reports regarding ERPs in gastric cancer surgery are few, with modest 
sample sizes and widely variable quality (He, 2010, Jeong et al., 2011, 
Jiang et al., 2007, Kiyama et al., 2003, Liu et al., 2010, So et al., 2008, 
Tang, 2013, Wang et al., 2010, Yamada et al., 2012, Feng et al., 2013, 
Chen Hu et al., 2012, Kim et al., 2012). Two existing meta-analyses of 
multimodal peri-gastrectomy ERPs have failed to include all available 
data from the literature, one pooling data from six studies (n=400) (Yu et 
al., 2014) and the other pooling data from just four studies (n=218) (Chen 
Hu et al., 2012) for meta-analysis.  
In oesophageal cancer surgery, one randomised trial (Zhao et al., 2014) 
and seven cohort studies have examined ERAS (Munitiz et al., 2010, 
Tang, 2013, Brodner et al., 1998, Tomaszek et al., 2010, Li et al., 2012, 
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Cao et al., 2012, You et al., 2012). No systematic review or meta-analysis 
of the implementation of a multimodal pathway in oesophagectomy for 
cancer exists.  
Within this thesis the literature is systematically reviewed and meta-
analysed for each of gastric and oesophageal cancer ERAS. Within 
theses meta-analyses, significant attention is paid to the populations 
studied, which were predominantly based in Eastern Asian countries 
such as China, and Japan. Few studies exist examining Western 
populations. 
 
1.8 Neoadjuvant and adjuvant therapy 
The poor prognosis associated with oesophagogastric cancer reflects the 
late onset of symptoms and consequent late presentation, with advanced 
disease. Most patients present with stage III or IV disease and therefore 
rates of curability are low. Indeed, survival rates at five years have been 
quoted as 16% for oesophageal cancer and 24% for gastric cancer in the 
United States of America (Jemal et al., 2008). While surgery remains the 
mainstay of curative treatment, in recent years chemoradiotherapeutic 
options have emerged as effective additional treatments, prolonging 
survival after major oesophagogastric resectional surgery for cancer 
(Cunningham et al., 2006, Macdonald et al., 2001, Sjoquist et al., 2011, 
van Hagen et al., 2012).  
Adjuvant chemotherapeutic approaches are based upon the concept that 
the systemic administration of agents can target systemic or distant 
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disease, where surgery alone cannot. However, with various available 
regimens, conflict exists regarding the most effective combination. 
Modern Western clinical practice in oesophageal cancer surgery has 
been guided by two important randomised trials of neoadjuvant therapy 
versus surgery alone. However, these two large trials provided conflicting 
evidence, exemplifying the need for ongoing work. The InterGroup Trial 
was conducted in the USA and failed to demonstrate a survival difference 
(Kelson, 1998). The similar OEO2 trial was conducted in the UK and 
reported a 2-year survival benefit of 9% (Allum, 1995). 
More recently, meta-analysis has concluded that survival benefits result 
from both chemotherapy (HR 0.87, 95% CI 0.79 - 0.96, p=0.005) and 
chemoradiotherapy (HR 0.78, 95% CI 0.70-0.88, p<0.0001) in 
comparison to surgery alone.  
 
1.9  Operative morbidity 
1.9.1 Clavien-Dindo Classification 
In 2004, the Swiss transplant surgeons Pierre-Alain Clavien and Daniel 
Dindo proposed a classification of operative morbidity that was simple to 
apply and broad enough to be transferrable to the majority of operative 
procedures (Dindo et al., 2004). It remains widely used and has been 
incorporated into the outcome analysis of a number of the chapters in this 
thesis.  
Major morbidity is classed as that of Clavien-Dindo (CD) grade three or 
higher, representing any morbidity requiring invasive intervention.  
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1.9.2 Clavien-Dindo classification of operative morbidity.  
(Dindo et al., 2004) 
Clavien-Dindo Grade Definition 
0 No deviation from the normal post-operative course 
I Any deviation from the normal postoperative course without the 
need for pharmacological treatment or surgical, endoscopic and 
radiological interventions. 
Allowed therapeutic regimens are: drugs as antiemetics, 
antipyretics, analgetics, diuretics and electrolytes and 
physiotherapy. This grade also includes wound infections 
opened at the bedside. 
II Requiring pharmacological treatment with drugs other than such 
allowed for grade I complications. 
Blood transfusions and total parenteral nutrition are also 
included. 
III IIIa Requiring surgical, endoscopic or radiological intervention 
intervention not under general anesthesia 
IIIb Above intervention under general anesthesia 
IV IVa Life-threatening complication (including CNS complications) +/- 
requiring IC/ICU-management with single organ dysfunction 
(including dialysis) 
IVb Above complication, with multi-organ dysfunction 
V Operative death  
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1.10 Aims and hypotheses 
In light of the areas of uncertainty highlighted above, this thesis aims to: 
1. Determine the prognostic value of bioelectrical impedance analysis body 
composition variables in oesophagogastric cancer surgery.  
2. Determine the prognostic value of CT-measured psoas muscle density in 
oesophagogastric cancer surgery.  
3. Determine the prognostic value of cardiopulmonary exercise testing in 
oesophagogastric cancer surgery. 
4. Systematically review and meta-analyse the literature on enhanced 
recovery programmes in gastric and oesophageal cancer surgery 
respectively. 
5. Assess outcomes following oesophagogastric cancer surgery following 
the introduction of an enhanced recovery programme. 
 
The hypotheses tested are: 
1. Suboptimal bioelectrical impedance analysis body composition variables 
predict poor outcomes following oesophagogastric cancer surgery.  
2. A low CT-measured psoas muscle density predicts poor outcomes 
following oesophagogastric cancer surgery. 
3. Suboptimal performance on cardiopulmonary exercise testing predicts 
poor outcomes following oesophagogastric cancer surgery. 
4. Systematic review and meta-analysis of the literature on enhanced 
recovery programmes in gastric and oesophageal cancer surgery will 
show evidence in support of their use. 
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5. The introduction of an enhanced recovery programme in 
oesophagogastric cancer surgery is feasible, safe and not associated 
with adverse outcomes. 
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CHAPTER 2 
 
A pilot study of bioelectrical impedance analysis as a 
prognostic indicator in oesophagogastric cancer surgery. 
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2.1 SUMMARY 
 
The aim of this study was to determine the predictive value of 
bioelectrical impedance analysis (BIA)-derived body composition 
measures of muscle mass and fat-free mass (FFM) and muscle mass 
(MM) in oesophagogastric cancer resectional surgery. 
A total of 83 patients (33 GCA: 50 OCA, 62m), aged 66 (24-86) years, 
were assessed in the South East Wales Cancer Network using BIA 
during pre-operative assessment of patients with oesophago-gastric 
cancer undergoing surgical resection between August 2011 and October 
2013.  
FFM and MM correlated with existing nutritional risk assessment tools: 
WAASP (FFM, p=0.026; MM, p=0.027) and MUST (FFM, p=0.023; MM, 
p=0.040). 
No significant association between FFM or MM and operative morbidity or 
mortality was identified. Multivariable analysis demonstrated FFM 
(p=0.004) and MM (p=0.010) as independent and significantly predictors 
of length of hospital stay. 
Cumulative survival was more favourable in those with high FFM 
(X2=3.955, p=0.047) and MM (X2=6.403, p=0.011). 
BIA-derived measures of body composition have emerged as novel 
predictive measures of outcome in oesophagogastric surgery. Low values 
for fat-free mass and muscle mass were associated with poor outcomes. 
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2.2 INTRODUCTION 
 
Oesophagogastric cancer is associated with a poor prognosis, owing to 
late onset of symptoms and consequent late presentation with advanced 
disease (Centre, 2010). With rates of operative morbidity quoted at 30% 
and 19%, mortality rates at 4.5% and 6% respectively, oesophagectomy 
and gastrectomy are associated with considerable operative risk (Centre, 
2010). Furthermore, survival rates at five years have been quoted at just 
16% for oesophageal cancer and 24% for gastric cancer (Jemal et al., 
2008). Even among patients treated with curative intent, survival at one 
year is reported at 76% and 78% respectively (Centre, 2010).   
It is well-known that body composition can be rapidly and significantly 
altered by cancer, and patients with oesophagogastric cancer are 
especially likely to experience substantial weight loss (Martignoni et al., 
2003). Factors contributing to weight loss are numerous, including 
hormonal changes within a chronic inflammatory response, leading to 
inhibition of food intake in the face of increased nutritional requirements 
(Martignoni et al., 2003). The observed sequelae have been incorporated 
into definitions of malnutrition syndromes of cachexia and sarcopaenia. 
Clear parallels exist between these definitions, cachexia characterised by 
abnormally low weight, weakness and general bodily decline (Wigmore et 
al., 1997), while sarcopaenia implies a functional impairment related to 
suboptimal skeletal muscle mass (Janssen et al., 2002).  
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For many years, weight loss and poor skeletal muscle function have been 
shown to be relevant to surgery, associated with increased risk of 
adverse outcomes including operative morbidity and prolonged stay in 
hospital (Windsor and Hill, 1988). Up to 50% of patients with cancer can 
be classified as cachectic (Wigmore et al., 1997) and, in resectional 
oesophagogastric cancer surgery, with implicit periods of reduced or 
absent nutritional intake, malnutrition may be compounded. 
There is limited evidence of an association between gross measures of 
body composition, such as abdominal diameter and BMI, with post-
operative complications following gastrectomy (Lee et al., 2007). 
However, other researchers have failed to identify significant associations 
between BMI and post-operative mortality or complications after 
gastrectomy or oesophagectomy (Mullen et al., 2008). In addition, it has 
been demonstrated that BMI does not reduce survival after 
oesophagectomy (Melis et al., 2011).  
More specific measures of body composition using computerised 
tomography have emerged as predictive of outcomes in colorectal 
metastasis resection (Peng et al., 2011), but little evidence exists 
investigating the predictive value of such specific measures of body 
composition for outcomes after OG surgery. Novel derived measures of 
body composition have emerged with the advent of Bioelectrical 
Impedance Analysis (BIA).  
In addition to simple resistance, the body exerts a second force of 
resistance to an alternating current passed through it, known as 
reactance. This is the resistance resulting from the storage of some 
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charge between cell membranes. BIA measures both resistance and 
reactance and specific validated equations are applied to derive a wide 
range of measures including the commonly used phase angle (see 2.2.1) 
and body composition measures including fat-free mass (FFM) and 
muscle mass (MM) (Kyle et al., 2004). Based on electrical properties 
described since 1871 (L., 1871), subcutaneous (Thomasset, 1962) and 
more recently surface electrode (Hoffer et al., 1969, Nyboer, 1970) 
techniques were developed, transforming the concept into a non-
invasive, rapid and reproducible method of estimating body composition. 
Little attention has been paid to these simple measures in the surgical 
literature and specifically OG cancer surgery.   
The aim of this study, therefore, was to determine the predictive value of 
BIA-derived body composition measures of muscle mass and fat-free 
mass in oesophagogastric cancer resectional surgery. 
 
2.2.1. Graph to illustrate manipulation of resistance and reactance in 
phase angle derivation (Adapted from Kyle et al. Clin Nutr (2004) 23, 1226-1243) 
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2.3. METHODS 
 
A total of 83 patients in the South East Wales Cancer Network consented 
and were assessed using bioelectrical impedance analysis during pre-
operative assessment of patients with oesophago-gastric cancer 
undergoing surgical resection between August 2011 and October 2013.  
 
2.3.1 Exclusion criteria 
Exclusion criteria were non-operative management and the absence of 
fully informed consent. No patient refused to participate.  
Analysis was performed on all 83 patients (table 1), with a median (range) 
age of 66 (24-84) years. There were 62 (75%) males, 50 (60%) 
oesophageal and 33 (40%) gastric cancers. Treatment intent was 
curative in all patients. Data relating to the pre-operative status, operative 
procedure and outcome were collected prospectively for all patients.  
 
2.3.2 Variables 
Pre-operative assessment was performed on all patients in the standard 
manner for the unit. This involved the clinical history and examination, 
together with risk assessment indicators including cardiopulmonary 
exercise testing and Physiological and Operative Severity Score for the 
enUmeration of Mortality and morbidity (POSSUM) scores (Copeland et 
al., 1991). Nutritional data was collected including the WAASP score 
(Weight, Appetite, Ability to eat, Stress factors, Pressure sores/wounds) 
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(Cardiff and Vale NHS Trust, 2005) and MUST score (Malnutrition 
Universal Screening Tool) (Elia Marinos, 2012). 
Other data collected included age, gender, American Society of 
Anesthesiologists (ASA) grade (Anesthesiologists, 1963), Welsh Index of 
Multiple Deprivation overall (WIMD) (2008), radiological and 
histopathological stage of disease (TNM7) (Sobin LH, 2009b), anatomical 
site of surgery, surgical procedure performed, 30-day mortality, 30-day 
morbidity related to the Clavien-Dindo grade (CD) (Dindo et al., 2004), 
intensive therapy unit (ITU) length of stay (ITU LOS), high dependency 
length of stay (HDU LOS), critical care length of stay in days (CC LOS) 
and total length of hospital stay (LOHS) in days.  
 
2.3.3 BIA measurement 
BIA variables were measured using the Maltron Bioscan 920 bioelectrical 
impedance analyser (Maltron International Ltd., Rayleigh, Essex, UK). 
Patients were fasted for two hours prior to assessment and the bladder 
voided within the 30 minutes preceding measurement. The height (to 
nearest 0.1cm) and weight (to nearest 0.1kg) were measured using a 
calibrated stadiometer and a balance-beam scale. These measurements 
were made in duplicate and averaged. The body mass index was 
calculated as the weight (kg) divided by height (m) squared (kg/m2). 
BIA measurements were made following 10 minutes of inactivity with the 
patient supine upon a non-conducting surface as follows: The skin on the 
dorsum of the right hand and foot was prepared with 70% alcohol 
cleanser and allowed to dry. An electrical current of 50kHz and 0.8mA 
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was applied to the skin via four adhesive electrodes and the whole body 
resistance and reactance were measured as shown in the schematic 
below (2.3.3.1). The phase angle was calculated using the equation arc 
tangent resistance/reactance x (180o/π).  
 
Figure 2.3.3.1. BIA test schematic 
 
 
2.3.4 Outcome measures 
The primary outcome measure was survival in months from diagnosis. 
Additional outcome measures included morbidity related to Clavien-Dindo 
grade (Dindo et al., 2004), LOHS, HDU LOS, ITU LOS, CC LOS and 
correlation with two existing nutritional risk measures (WAASP and 
Imperceivable 
alternating 
current 
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MUST). A Clavien-Dindo grade of ≥III represents morbidity requiring 
therapeutic intervention beyond pharmacological treatment or superficial 
wound opening and was considered to represent major morbidity in this 
study. 
 
2.3.5 Statistical analysis 
Statistical analysis was performed using the Statistical Programme for the 
Social Sciences (SPSS v20.0.2, IBM Corporation, Armonk, New York, 
USA). Grouped data were expressed as median (range) and non-
parametric analyses were used throughout. Statistical significance was 
determined as p<0.05. Categorical data were compared using the χ2 test, 
except where groups contained counts of fewer than five, when Fisher’s 
exact test (Fisher, 1922) was used. Grouped continuous data were 
compared using the Mann-Whitney U-test (Mann and Whitney, 1947). 
Spearman’s rank correlation coefficient (Spearman, 1904) was used to 
determine correlation. BIA-derived variables were grouped into quintiles 
for assessment and the upper two quintiles were compared with the lower 
three. Univariable analysis of the predictive value of pre-operative factors 
for LOHS was performed using the Mantel-Cox log rank method of 
Kaplan and Meier model (Kaplan and Meier, 1958). This incorporated 
LOHS into the model in place of survival, using discharge from hospital 
as the event and resulting in the construction of LOHS plots. Multivariable 
analysis of factors significantly influencing LOHS was performed using 
the Cox regression analysis model (Cox, 1972). Kaplan-Meier plots were 
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created to demonstrate survival in the manner originally described 
(Kaplan and Meier, 1958).  
 
2.3.6 Power 
A power calculation was performed for the primary outcome measure of 
survival using the Altman method (Whitley and Ball, 2002). This was 
based on a sample of existing data from the same unit with a standard 
deviation of 7.5 months. With alpha set at 0.05 and powered at 80%, a 
total of 70 patients were required in order to detect a 5-month survival 
difference at two years. 
 
2.4 RESULTS 
 
2.4.1 Details of the patients 
Details of the 83 patients studied are shown in Table 1. The surgical 
procedures performed are shown in Table 2. 
 
2.4.2 Correlation with existing nutritional risk tools 
Significant correlation was identified between BIA body composition 
variables and established nutritional risk assessment tools, with a low MM 
correlating with poor WAASP (Rho -0.354, p=0.027) and MUST (Rho -
0.331, p=0.040) scores. Similarly, a low FFM correlated with poor 
WAASP (Rho -0.357, p=0.026) and MUST (Rho -0.364, p=0.023) scores.  
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2.4.3 Operative morbidity and mortality 
No significant association was identified according to grouped quintiles 
(upper 2 vs. lower 3) between FFM and operative morbidity (41% vs. 
43%, p=0.562), CD class ≥II (29% vs. 36%, p=0.488) or CD class ≥III 
(12% vs. 20%, p=0.301). Neither was a significant association identified 
between MM and operative morbidity (45% vs. 39%, p=0.643), CD class 
≥II (39% vs. 35%, p=0.725) or CD class ≥III (19% vs. 17%, p=0.827). 
Using the same groups, although neither FFM nor MM was significantly 
associated with operative mortality, non-significant higher incidences of 
operative death were seen in the groups with lower FFM and MM (0% vs. 
9%, p=0.092).  
 
2.4.4 Length of stay 
Analysis of lengths of stay is shown in Table 3. While median LOHS did 
not differ significantly between groups spilt by FFM (13.5 vs. 13 kg, 
p=0.609) or MM (15 vs. 13 kg, p=0.228) quintiles, a longer stay in HDU 
was observed among those patients who recorded a high MM (1 vs. 0 
day, p=0.007).  
Despite the absence of a significant difference in median LOHS between 
these grouped quintiles, univariable analysis identified FFM and MM 
among a number of variables significantly predicting LOHS (Table 4). 
Indeed, multivariable analysis demonstrated both FFM and MM to be 
significant and independent predictors of LOHS (Table 5). 
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2.4.5 Survival 
Median follow up (or time to death) was 25 months (range 2-37 months), 
with a 2-year survival of 68.9% (31/45) and a median survival of 18 
months. Survival analysis demonstrated significant differences between 
the upper two and lower three quintiles for FFM (median 18 vs. 18 
months, p= 0.047, Figure 1) and MM (median 21 vs. 16 months, p=0.011, 
Figure 2) respectively.  
 
2.5 DISCUSSION 
 
This is the first study to investigate the predictive value of BIA-derived 
measures of body composition in oesophagogastric surgery, related to 
outcomes.  
The principal findings were that BIA-derived measures of fat-free mass 
and muscle mass were significant predictors of outcome after 
oesophagogastric resection for cancer in this cohort. A low FFM and MM 
was associated with poor survival and both FFM and MM emerged as 
independent and significant predictors of length of hospital stay.  
It is well known that patients presenting with upper gastrointestinal cancer 
are especially likely to suffer substantial weight loss associated with 
cancer cachexia (Martignoni et al., 2003). This gross weight loss is 
recognised as multifactorial and, in addition to mechanical factors 
causing obstruction of the gastrointestinal tract, tumour-derived factors 
have been shown to promote proteolysis (Tisdale, 2009) and lipid 
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metabolism (Islam-Ali and Tisdale, 2001). A chronic systemic 
inflammatory state is observed as cancer progresses, associated with 
significant disruption of hormonal satiety pathways, including those 
involving leptin and neuropeptide Y, leading to inhibition of food intake 
(Martignoni et al., 2003). Furthermore, iatrogenic factors, such as 
chemotherapeutic toxicity can compound patients’ difficulty in maintaining 
satisfactory nutrition (Martignoni et al., 2003). And whilst patients are in 
this vulnerable catabolic state, tumour necrosis factor alpha (TNFα) alters 
muscle repair, impairing effective muscle regeneration in the event that 
nutritional intake can be achieved (Guttridge et al., 2000). 
It follows then, that measures of body composition may afford insight into 
a patient’s potential outcomes both on grounds of disease progression 
and an individual’s premorbid capacity to cope with the multifactorial 
assault on the body’s composition.  
 
As the first study to examine BIA-derived measures of FFM and MM in 
relation to outcomes following oesophagogastric surgery for cancer, this 
represents a novel area of investigation. Other strengths include 
prospective data collection of a consecutive series of patients through an 
established and experienced MDT, whose results are well audited and 
stand up to international comparison (Centre, 2010), all surgery 
performed by specialist surgeons. A large consecutive series minimised 
the risk of selection bias. 
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In contrast, there are several potential limitations to this study. The 
dataset includes oesophagogastric cancer resections ranging from 
subtotal gastrectomy to three-stage oesophagectomy. The physiological 
burden of surgery was therefore variable according to the extent of the 
procedure required. However, this is representative of the workload within 
this large centralised unit with good throughput. Further analysis of 
subgroups will be feasible in future and may yield more specific data 
according to procedure type and other variables.  
Values for FFM and MM were unadjusted. This may allow for the 
influence of confounders such as gender. However, gender was formally 
assessed in analyses and no association the reported outcomes 
emerged. Furthermore, BMI was included in univariable and multivariable 
analyses, and along with FFM and MM, it emerged as independent 
predictors of LOHS.  
 
Measures of FFM and MM in this study correlated with existing nutritional 
risk measures, which supported their utility in assessing risk in this 
vulnerable group.  
Patients in the upper two quintiles for MM were observed to stay 
significantly longer at level II than those in the lower three quintiles. It is 
not clear why this occurred. I interrogated the data further to seek an 
explanation for this and identified a non-significant disparity in mean level 
III stay between groups, patients with lower MM staying longer at level III. 
In this unit, fit patients often require only level II care and those in level III 
beds often return to level I directly from level III. Therefore it is possible 
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that a type II statistical error has prevented a reciprocal picture of longer 
level III stay in patients with low MM from emerging. This possible 
explanation fits with the findings for CC LOS (levels II and III combined), 
for which no significant difference was identified between groups.  
Similarly, since the study was powered to detect a difference in survival, it 
is possible that a type II statistical error was responsible for the absence 
of a statistical difference in LOHS between FFM and MM groups, while 
more detailed statistical analysis suggested the existence of a significant 
influence in this cohort.  
 
Further work is warranted to investigate the relationship between 
emerging measures of nutritional assessment, nutritional risk measures 
and to explore interventions to modify such identifiable nutritional risk 
factors in oesophagogastric cancer surgery.  
Some exploration of pre-operative exercise exists in the literature. In the 
elderly, physical activity does not seem to prevent the loss of skeletal 
muscle (Raguso et al., 2006), but some review evidence suggests that 
pre-operative exercise therapy prior to abdominal surgery can lead to 
improved clinical outcomes, including shorter hospital stay and reduced 
postoperative complication rates (Valkenet, 2011). However, the literature 
surrounding this is both thin and relatively contradictory. Two recent 
systematic reviews of the effects on cardiopulmonary function, outcome 
and recovery after abdominal surgery yield inconclusive findings (Lemanu 
et al., 2013, Pouwels, 2014). They did suggest that there may be 
potential for improvement in complication rates, particularly pulmonary 
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complications, but further research is necessary and consensus 
regarding intervention choice is, so far, lacking (Valkenet, 2011, Lemanu 
et al., 2013, Pouwels, 2014). Allied to ERAS, upon which several 
chapters later in this thesis focus, this area of research may ultimately 
yield further benefit to patients by adding potential further pre-operative 
interventions to improve the post-operative course following major 
abdominal surgery such as oesophagogastric resection.  
 
 
2.6 CONCLUSION 
 
BIA-derived measures of fat-free mass and muscle mass were significant 
predictors of outcome after oesophagogastric resection for cancer. A low 
FFM and MM was associated with poor survival and both FFM and MM 
emerged as independent and significant predictors of length of hospital 
stay.  
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2.7  TABLES AND FIGURES 
 
2.7.1  Table 1. Details of the patients 
 
Variable Total 
n 83 
Site  (gast:oes) 33:50 
Histology (ACA:SCC:HGD) 76:6:1 
Gender (m:f) 62:21 
Age (years) 66 (24-86) 
BMI (kg/m2) 26 (15-44) 
ASA (I-II:III-IV) 57:26 
FFM (kg) 58.4 (33.0-97.4) 
Muscle mass (kg) 27.7 (8.0-94.0) 
PhA (degrees) 7.80 (4.53-15.13) 
WAASP score 14 (7-22) 
MUST score 1 (0-3) 
P-POSSUM morb (%) 41.58 (17.00-86.99) 
P-POSSUM mort (%) 2.36 (0.80-43.05) 
O-POSSUM mort (%) 7.09 (1.04-41.75) 
WIMD  853 (2-1886) 
LOHS (days) 13 (4-52) 
CCLOS (days) 1 (0-17) 
HDU LOS (days) 1 (0-13) 
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ITU LOS (days) 0 (0-17) 
Operative morbidity 35 (42%) 
CD ≥2 28 (33.7%) 
CD ≥3 14 (16.9%) 
30-day mortality 4 (4.8%) 
Survival (months) 18 (2-37) 
Median follow up (months) 25 (9-45) 
 
Figures are given as median (range) unless stated. n, number; Site, disease site 
(gastric:oesophageal); histology, histopathological cell type; ACA, 
adenocarcinoma; SCC, squamous cell carcinoma; HGD, high grade dysplasia; 
m:f, male to female ratio; BMI, body mass index; ASA, American Society of 
Anesthesiologists score; FFM, fat-free mass; MM, muscle mass; PhA, phase 
angle; POSSUM, physiological and operative severity score for the enumeration 
of mortality and morbidity (P – generic score; O – oesophageal score; Mort, 
mortality; morb – morbidity); WIMD, Welsh index of multiple deprivation rank; 
WAASP, Weight, Appetite, Ability to eat, Stress factors, Pressure sores/wounds; 
MUST, Malnutrition Universal Screening Tool; LOHS, length of hospital stay; CC 
LOS, critical care stay; ITU LOS, intensive therapy unit stay; HDU LOS, high 
dependency unit stay; CD class, Clavien-Dindo classification of operative 
morbidity. 
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2.7.2  Table 2. Details of the procedures 
 
Procedure n (%) 
TG 14 (16.9) 
STG 14 (16.9) 
3SO 2  (2.4) 
TTO 7 (8.4) 
THO 34 (41.0) 
O&C 12 (14.5) 
TOTAL 83  
N, number; TG, total gastrectomy; STG, subtotal gastrectomy; 3SO, 
three-stage oesophagectomy; TTO, trans-thoracic oesophagectomy; 
THO, trans-hiatal oesophagectomy; O&C, Open and close procedure 
(inoperable cancer). 
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2.7.3  Table 3. Influence of FFM and MM on lengths of stay. 
 
Variable Fat Free Mass  p-value Muscle Mass p-value 
Upper 2 
Quintiles 
Lower 3 
Quintiles 
 Upper 2 
Quintiles 
Lower 3 
Quintile
s 
 
LOHS 
(days) 
13.5 (4-
41) 
13 (4-52) 0.609 15 (4-52) 13 (3-35) 0.228 
CC LOS 
(days) 
1 (0-2) 1 (0-17) 0.680 1 (0-15) 1 (0-17) 0.097 
ITU LOS 
(days) 
0 (0-1) 0 (0-17) 0.537 0 (0-2) 0 (0-17) 0.691 
HDU LOS 
(days) 
1 (0-2) 0 (0-13) 0.232 1 (0-13) 0 (0-5) 0.007 
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2.7.4  Table 4. Univariable analysis to determine factors influencing 
LOHS using the Mantel-Cox log rank method of Kaplan and Meier. 
 
Variable χ2 df p value 
FFM 234.683 68 <0.0001 
WIMD 231.946 66 <0.0001 
PhA 230.909 65 <0.0001 
MM 212.471 61 <0.0001 
BMI 185.835 57 <0.0001 
O Possum mortality 125.146 49 <0.0001 
P POSSUM morbidity 85.935 41 <0.0001 
P POSSUM mortality 83.129 40 <0.0001 
Age  49.856 34 <0.0001 
pT stage 36.872 4 <0.0001 
CD class 27.597 6 <0.0001 
pN stage 7.727 3 0.052 
WAASP score 21.488 13 0.064 
pM stage 4.905 2 0.086 
Rad stage 5.491 3 0.139 
ASA 3.051 2 0.217 
MUST score 1.929 3 0.587 
Site 0.212 1 0.645 
Histology 0.092 1 0.762 
Gender 0.026 1 0.872 
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χ2, chi square value; df, degrees of freedom; FFM, fat-free mass; WIMD, Welsh 
index of multiple deprivation rank; PhA, phase angle;  MM, muscle mass; BMI, 
body mass index; POSSUM, physiological and operative severity score for the 
enumeration of mortality and morbidity (P – generic score; O – oesophageal 
score; Mort, mortality; morb – morbidity); pT, pN and pM stage, tumour, nodal 
and metastasis histopathological stage of disease according to TNM7 
classification; CD class, Clavien-Dindo classification of operative morbidity; 
WAASP, Weight, Appetite, Ability to eat, Stress factors, Pressure sores/wounds; 
MUST, Malnutrition Universal Screening Tool; ASA, American Society of 
Anesthesiologists score; Site, disease site (oesophagus, stomach); Histology, 
histopathological cell type. 
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2.7.5  Table 5. Multivariable analysis of factors influencing length of 
hospital stay. Backward Log Rank Cox Regression 
 
HR, hazard ratio; CI, confidence interval; CD class, Clavien-Dindo classification 
of operative morbidity; BMI, body mass index; PhA, phase angle; FFM, fat-free 
mass; POSSUM, physiological and operative severity score for the enumeration 
of mortality and morbidity (P – generic score; O – oesophageal score); MM, 
muscle mass; WAASP, Weight, Appetite, Ability to eat, Stress factors, Pressure 
sores/wounds; pN stage, nodal histopathological stage of disease according to 
TNM7 classification; WIMD, Welsh index of multiple deprivation rank. 
Variable HR 95% CI p value 
CD class 0.342 0.179-0.654 0.001 
BMI 0.580 0.425-0.792 0.001 
PhA 0.357 0.182-0.701 0.003 
FFM 1.420 1.119-1.801 0.004 
O POSSUM mort 0.658 0.493-0.879 0.005 
P POSSUM mort 3.070 1.390-6.779 0.006 
P POSSUM morb 0.882 0.805-0.879 0.007 
MM 0.672 0.497-0.909 0.010 
WAASP 1.219 1.038-1.430 0.016 
pN stage 0.534 0.272-1.045 0.067 
Age 1.072 0.994-1.156 0.071 
WIMD 1.001 1.000-1.003 0.124 
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2.7.6  Table 6. Univariable analysis to determine factors influencing 
survival using the Mantel-Cox log rank method of Kaplan and Meier. 
 
Variable χ2 df p value 
FFM 224.177 8 <0.0001 
WIMD 211.964 80 <0.0001 
PhA 220.981 79 <0.0001 
MM 204.312 74 <0.0001 
BMI 169.368 65 <0.0001 
O Possum Mort 121.978 49 <0.0001 
P POSSUM morb 111.261 41 <0.0001 
P POSSUM mort 104.563 40 <0.0001 
CD class 94.303 6 <0.0001 
LOHS 67.002 24 <0.0001 
ITU LOS 53.926 4 <0.0001 
CC LOS 50.339 8 <0.0001 
WAASP score 46.441 13 <0.0001 
pM stage 16.510 2 <0.0001 
pT stage 17.663 4 0.001 
Age  56.701 37 0.020 
MUST score 8.737 3 0.033 
ASA 5.335 2 0.069 
Rad stage 4.588 3 0.205 
pN stage 4.305 3 0.230 
Histology 2.351 2 0.309 
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HDU LOS 6.837 6 0.336 
Site 0.345 1 0.557 
Gender 0.015 1 0.902 
χ2, chi square value; df, degrees of freedom; FFM, fat-free mass; WIMD, Welsh 
index of multiple deprivation rank; PhA, phase angle; MM, muscle mass; BMI, 
body mass index; POSSUM, physiological and operative severity score for the 
enumeration of mortality and morbidity (P – generic score; O – oesophageal 
score; Mort, mortality; morb – morbidity); CD class, Clavien-Dindo classification 
of operative morbidity; LOHS, length of hospital stay; ITU LOS, intensive 
therapy unit stay; CC LOS, critical care stay; WAASP, Weight, Appetite, Ability 
to eat, Stress factors, Pressure sores/wounds; pT, pN and pM stage, tumour, 
nodal and metastasis histopathological stage of disease according to TNM7 
classification; MUST, Malnutrition Universal Screening Tool; ASA, American 
Society of Anesthesiologists score; Rad stage, radiological stage; Histology, 
histopathological cell type; HDU LOS, high dependency unit stay; Site, disease 
site (oesophagus, stomach). 
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2.7.7  Table 7. Multivariable analysis of factors influencing survival. 
Backward Log Rank Cox Regression 
 
HR, hazard ratio; CI, confidence interval; pT stage, tumour histopathological 
stage of disease according to TNM7 classification; ASA, American Society of 
Anesthesiologists score; ITU LOS, intensive therapy unit stay. 
 
Variable HR 95% CI p value 
pT stage 5.276 1.414-19.685 0.013 
ASA 0.112 0.015-0.854 0.035 
ITU LOS 1.639 1.023-2.625 0.040 
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2.7.8  Figure 1. Kaplan-Meier plot to demonstrate cumulative 
survival according to fat-free mass. 
 
 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-
Cox) 
3.955 1 .047 
Test of equality of survival distributions for the different 
levels of FFM Upper 2 vs lower 3 Quintiles. 
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2.7.9  Figure 2. Kaplan-Meier plot to demonstrate cumulative 
survival according to muscle mass. 
 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-
Cox) 
6.403 1 .011 
Test of equality of survival distributions for the different 
levels of Muscle Upper 2 vs lower 3 Quintiles. 
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CHAPTER 3 
 
 
CT-measured sarcopaenia predicts survival in upper 
gastrointestinal cancer 
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3.1 SUMMARY 
 
The aim of this study was to determine the predictive value of 
computerised tomography (CT)-derived average psoas muscle density 
(PMD) with regard to outcomes following in oesophagogastric cancer 
resectional surgery. 
The pre-operative staging CTs of 100 patients with oesophago-gastric 
cancer (49 GCA: 51 OCA, 74m), aged 66 (36-85) years, were assessed 
for left, right and max (the greater of the two) PMD in Hounsfield units 
(HU). Patients underwent surgical resection within the South East Wales 
Cancer Network between May 2009 and June 2011. The primary 
outcome measure was survival and secondary outcomes included major 
morbidity (Clavien-Dindo class ≥3), mortality and length of hospital stay 
(LOHS). 
No statistically significant difference was identified in major morbidity 
(22% vs. 18%, p=0.617), 30-day mortality (4% vs. 2%, p=0.558) or LOHS 
(14 vs. 14 days, p=0.781) according to PMD (<median vs. ≥median). 
Multivariable analysis demonstrated maximum PMD (HR 1.897, 95% CI 
1.175-3.062, p=0.009) and pathology TNM stage (HR 1.467, 95% CI 
1.076-2.000, p=0.015) as significant and independent predictors of 
survival. 
CT measures of PMD have emerged as novel, simple and readily 
available predictors of outcome in oesophagogastric surgery. Risk 
assessment for oesophagogastric cancer surgery may benefit from 
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incorporation of muscle density measures and further work should seek 
to determine whether specific predictive cut-off values exist.  
 
3.2 INTRODUCTION 
 
Oesophagogastric cancer is associated with a poor prognosis, owing to 
late onset of symptoms and consequent late presentation with advanced 
disease. Survival rates at five years have been quoted as 16% for 
oesophageal cancer and 24% for gastric cancer (Jemal et al., 2008). 
Surgery remains the mainstay of curative treatment, with 
chemoradiotherapeutic options having emerged as effective adjuncts, 
prolonging survival after major resectional surgery for oesophagogastric 
cancer (Cunningham et al., 2006, Macdonald et al., 2001, Sjoquist et al., 
2011, van Hagen et al., 2012). 
It has been clear for many decades that malnutrition is associated with 
poor outcomes after surgery (Studley, 2001, Shils, 2000). Patients with 
upper gastrointestinal cancer are especially likely to suffer from 
substantial weight loss (Martignoni et al., 2003) associated with cancer 
cachexia, with mechanical obstructive factors contributing to difficulties in 
maintaining adequate nutritional intake in many of these patients.  
Malnutrition has been known to correlate positively with postoperative 
complications for over three decades (Smale et al., 1981, Meguid and 
Meguid, 1985) and in the modern era, the importance of nutrition in 
surgical patients has received rejuvenated attention (Sungurtekin et al., 
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2004) alongside extensive work on multimodal optimisation of surgical 
care, pioneered by Henrik Kehlet (Kehlet, 1997). However, reports 
containing data on nutritional measures in oesophagogastric ERAS 
programmes are few (Jiang et al., 2007, Liu et al., 2010) and direct 
assessment of the influence on outcomes of reliable, reproducible 
measures of skeletal muscle mass or specific risk indices in this disease 
is lacking in the literature.  
The TNM staging process (Sobin LH, 2009b) involves computerised 
tomographic (CT) imaging, including the abdomen. Numerous studies 
have utilised the psoas muscles in such imaging to determine skeletal 
muscle parameters (Englesbe et al., 2010, Englesbe et al., 2013, 
Englesbe et al., 2012, Sabel et al., 2011, Harbaugh et al., 2013, Lee et 
al., 2011b), demonstrating poor surgical outcomes in those deemed 
sarcopaenic. The density of psoas muscles is easily and precisely 
measured from CT images, using standard radiology programmes 
(Mourtzakis et al., 2008, MacDonald et al., 2011, Baracos et al., 2012). 
The aim of this study, therefore, was to assess the clinical prognostic 
value of pre-operative CT-measured psoas muscle density in the 
management of patients diagnosed with potentially curable 
oesophagogastric cancer. The primary outcome measure was and 
cumulative survival in months from diagnosis. Secondary outcome 
measures included 30-day mortality and 30-day operative morbidity. A 
secondary study aim was to determine whether a statistically significant 
difference in PMD exists between genders. The setting was a UK regional 
cancer network serving a population of 1.4 million. 
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3.3  METHODS 
 
Approval of the local ethics committee was obtained to prospectively 
collect and analyse data on the medical and surgical outcome and results 
of investigations of all patients considered for surgery for UGI cancer. The 
ethics committee did not require written informed consent from 
participating subjects. 
 
3.3.1  Details of the patients  
One hundred consecutive patients diagnosed with oesophagogastric 
cancer by the South East Wales Cancer Network Multi Disciplinary Team 
and undergoing surgical resection with curative intent were assessed for 
psoas muscle density.  
 
3.3.2  CT analysis 
Patients were diagnosed between May 2009 and June 2011 and 
underwent computerised tomography (CT) of the abdomen as part of 
their pre-operative staging. We employed a previously described 
technique (Lee et al., 2011a) for analysis of psoas muscle density, which 
has been widely used over recent years (Sabel et al., 2011, Englesbe et 
al., 2010, Harbaugh et al., 2013, Lee et al., 2011a, Englesbe et al., 2012, 
Lee et al., 2011b). In short, a single axial CT image at the upper border of 
the 4th lumbar vertebra was isolated for examination. This study differed 
from previous reports in that semi-automation, the process by which 
 100 
software delineates the borders of the muscle, was not available. Each 
psoas muscle was delineated manually using IMPAX system (AGFA 
Healthcare, Belgium). The cross sectional area, perimeter and mean 
density of each delineated area were automatically calculated by the 
imaging package.  
Where restaging CT was performed after chemoradiotherapy, the post-
treatment scan was used. Data relating to the pre-operative status, 
operative procedure and outcome were collected prospectively. 
 
3.3.3  Data collected 
Data collected included age, gender, American Society of 
Anesthesiologists grade (ASA) (Anesthesiologists, 1963), Physiological 
and Operative Severity Score for the enUmeration of Mortality and 
morbidity (POSSUM) scores (Copeland et al., 1991), Welsh Index of 
Multiple Deprivation overall (WIMD) and health (H-WIMD) deprivation 
scores (2008), radiological and histopathological stage of disease (TNM7) 
(Sobin LH, 2009b), cancer site (oesophageal or gastric), 30-day mortality, 
operative morbidity related to the Clavien-Dindo grade (CD) (Dindo et al., 
2004), length of hospital stay (LOHS) and cumulative survival.  
 
3.3.4  Outcome measures 
The primary outcome measure was cumulative survival in months from 
diagnosis. This was expressed in months, with the significance expressed 
using the log rank statistic. Secondary outcome measures included 
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LOHS, operative morbidity using the Clavien-Dindo classification (Dindo 
et al., 2004) and 30-day mortality. 
 
3.3.5  Statistical analysis 
Statistical analysis was performed using SPSS® (IBM® SPSS® Statistics 
v20.0.0.2, IBM Corporation, Armonk, New York, USA). Grouped data 
were expressed as median (range) and non-parametric analyses were 
used throughout. Two-tailed tests were used and statistical significance 
was determined as p<0.05. Categorical data were compared using the χ2 
test, except where groups contained counts of fewer than five, when 
Fisher’s exact test (Fisher, 1922) was used. Grouped continuous data 
were compared using the Mann-Whitney U-test (Mann and Whitney, 
1947). Univariable analysis of the predictive value of pre-operative factors 
for survival was performed using the Mantel-Cox log rank method 
(Kaplan and Meier, 1958). Multivariable analysis of factors significantly 
influencing LOHS was performed using the Cox regression analysis 
model (Cox, 1972).  
 
3.3.6  Power 
The size of the dataset was powered to detect a survival difference of 8 
months, between groups split about the median PMD. This was 
calculated using the Altman method (Whitley and Ball, 2002), using the 
standard deviation from an earlier consecutive sample of 100 patients 
from the same unit. Alpha was set at 0.05 and a power of 80% was used 
and a group size of 90 was suggested.  
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3.4  RESULTS  
 
3.4.1  Details of the patients 
The median (range) maximum psoas muscle density was 48.7 (-5.5-72.1 
Hounsfield Units) and additional psoas muscle measurements are shown 
in Table 1. Remaining details of the patients are shown in Table 2. Forty-
nine patients were treated for gastric cancer and fifty-one for 
oesophageal cancer. Details of the surgery performed are shown in Table 
3. 
 
3.4.2  Survival 
Cumulative survival at two years was 70% overall (70/100), 64% (32/50) 
in patients with PMD <median and 76% (38/50) in patients with PMD 
≥median (X2=1.714, p=0.190). By three years of follow-up cumulative 
survival was 38% (26/69) overall, 18% (6/33) in patients with PMD 
<median and 56% (20/36) in patients with PMD ≥median (X2=10.241, 
p=0.001). Median follow-up (or time to death) overall was 37.5 (range 3-
59) months; in patients with PMD <median, 30 months (range 3-55); and 
in patients with PMD ≥median, 42 months (range 5-59). Kaplan-Meier 
analysis demonstrated survival to be significantly longer in patients with 
PMD ≥median (X2=0.046, p=0.046, Figure 1).  
Univariable analysis demonstrated the maximum psoas measurement 
(max PMD), radiological TNM stage and pathological TNM stage to be 
significantly associated with cumulative survival (Table 4).  
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Multivariable analysis revealed max PMD as the strongest predictor of 
survival in this cohort, a greater psoas density predicting a longer survival 
(Table 5; HR 1.897, 95% CI 1.175-3.062, p=0.009). Pathology TNM stage 
also emerged as a significant and independent predictor of survival, more 
advanced disease predicting shorter survival (Table 5; p=0.032). 
 
3.4.3  Operative Morbidity and Mortality 
Major operative morbidity (CD ≥III) occurred in 20 patients (20%), 
including three deaths (3%). No statistically significant difference was 
observed in CD ≥III (11 vs. 9, p=0.617) or mortality (2 vs. 1, p=0.558) 
according to PMD < median or ≥median, respectively. 
 
3.4.4  Length of Hospital Stay 
The median (range) LOHS was 14 (2-72) days overall. No statistically 
significant differences were observed between PMD groups in LOHS, CC 
LOS, ITU LOS, or HDU LOS (p>0.05, Table 2). 
 
3.4.5 Influence of gender on PMD 
Gender did not significantly influence PMD within this cohort (p=0.418). 
However, statistically significant differences in both PM area and PM 
perimeter were identified between males and females (p<0.0001). 
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3.5 DISCUSSION:  
 
This is the first study to report surgical outcomes of a contemporary 
cohort of oesophagogastric cancer patients in relation to radiological 
skeletal muscle density.   
The principle finding was that max PMD was a significant and 
independent predictor of survival in patients undergoing 
oesophagogastric surgery for cancer, a high PMD associated with longer 
survival.  
This study’s strengths include prospective data collection for the 
maintenance of an accurate database for a consecutive series of patients 
through an established and experienced MDT, whose results are well 
audited and stand up to international comparison (Centre, 2010), all 
surgery performed by specialist surgeons. All psoas measurements were 
performed manually by a single author (AJB) and checked by a 
Consultant Radiologist co-author (SAR). This allowed confirmation of 
accuracy of methods and prevented inter-rater inconsistency of psoas 
delineation or axial slice level.  
In contrast, there are several potential limitations to this study. No 
adjustment was applied to account for differences in stature or gender. 
However, the hypothesis that gender would not influence PMD was 
upheld within this cohort (p=0.418), while hypotheses that gender would 
not influence PM area or PM perimeter were rejected upon statistical 
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analysis (p<0.0001). This suggested that it was appropriate to use 
unadjusted PMD values, but not area or perimeter values.  
This study explored just a single dimension of skeletal muscle, without a 
concurrent objective assessment of function. It may be useful to combine 
CT measured psoas muscle measurements with functional parameters 
such as hand-grip strength. 
 
Cachexia is a complex condition associated with myriad pathological 
alterations in hormonal and other signaling axes, promoting a 
characteristic chronic systemic inflammatory response (Wigmore et al., 
1997). Cachexia implicitly confers a pathological cause for the weight 
loss, weakness and general decline observed (Wigmore et al., 1997). In 
efforts to assess skeletal muscle aspects of malnutrition, the concept of 
sarcopaenia has been used. Definitions of sarcopaenia vary, but have in 
common their inherent reliance upon quantification of skeletal muscle 
parameters (Cherin, P., 2009, Janssen et al., Baumgartner et al., 1998), 
yet reference ranges for these measures of skeletal muscle have been 
slow to emerge. 
Previous studies have shown a relationship between CT measures of 
psoas muscle and surgical outcomes. In a cohort of 163 patients 
undergoing liver transplant, mortality was significantly higher and survival 
shorter at one and three years in those with the smallest psoas area 
(Englesbe et al., 2010). In 262 patients undergoing elective abdominal 
aortic aneurysm repair, psoas muscle size reduced over time during 
follow-up and psoas area showed a significant association with 
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postoperative mortality (Lee et al., 2011a). Sarcopaenic patients from a 
cohort of 196 patients undergoing colorectal hepatic metastatectomy, had 
a lower survival rate than those with higher skeletal muscle mass on CT 
analysis (van Vledder et al., 2012). 
Indeed, CT measures of skeletal muscle mass have been built into a risk 
prediction algorithm to determine the “morphometric age” according to 
various factors observed on their CT scan (Englesbe et al., 2013). 
Applied to a cohort of 1,370 patients who underwent major abdominal 
surgery in the USA, morphometric age was a stronger predictor of 
operative mortality than chronological age and more than half of the 
patients in the morphometrically ‘oldest’ 10% were neither comorbid nor 
advanced in chronological age (Englesbe et al., 2013). This suggests that 
morphometric age could contribute novel predictive value that extends 
beyond factors traditionally assessed by the parameters age and 
comorbidity.  
The complex use of novel, simple risk predictors in this way exemplifies 
how future risk stratification may utilise readily available radiological 
imaging to new levels, with objective and precise measurements 
permitting the development of risk algorithms and perhaps leading to a 
more specific risk profile for the individual patient. 
 
Further research should seek to provide useful reference ranges for, and 
examine the influence on outcomes of indices of sarcopaenia including 
those examined herein and various other CT, anthropometric and 
functional measures. With mounting evidence that muscle mass 
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influences outcomes following surgery, randomised clinical trials should 
be considered in order to determine the most appropriate treatment 
modality in patients identified as being sarcopaenic. Additionally, further 
work should seek to determine whether more specific predictive cut-off 
values exist. 
 
 
3.5 CONCLUSION:  
 
The findings of this study suggest that CT measured max PMD 
represents a novel, simple and readily available, independent predictor of 
survival following oesophagogastric surgery. Incorporation of muscle 
density measures in risk assessment may assist patients and clinicians in 
decision-making regarding therapeutic options in oesophagogastric 
cancer.  
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3.7  TABLES AND FIGURES 
 
3.7.1  Table 1. Psoas muscle parameters 
 
Variable Left Right Maximum 
value 
PMD (HU) 45.2  
(-5.6-72.1) 
47.3  
(-16.4-67.4) 
48.7  
(-5.5-72.1) 
PM area (mm2) 1109.0 
(434.7-1915) 
1091.5  
(527.2-1750) 
1166.5  
(527.2-1915.0) 
PM perimeter (mm) 146.8  
(96.9-202.0) 
32.0  
(106.5-183.3) 
148.3  
(106.5-202.0) 
 
Values given as median (range). Maximum value = greater value from left and 
right psoas muscle measurements. PMD, psoas muscle density; HU, Hounsfield 
units; PM, psoas muscle. 
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3.7.2  Table 2. Details of the patients 
Variable All patients Max PMD p-value 
  <median >median  
Operated (n) 100 50 50 - 
Site (Oes:Gast) 51:49 25:25 26:24 0.841 
Age (years)  65.5 (36-85) 67 (47-82) 64 (36-85) 0.158 
Gender (male:female) 74:26 38:12 36:14 0.648 
BMI (kg/m2) 27 (15-50) 27 (20-37) 25 (15-30) 0.251 
ASA  I 1 2 2 0.596§ 
II 37 19 18 
III 23 13 10 
IV 2 2 0 
POSSUM  P morb 41.9  
(14.6-81.0) 
44.3 
(19.5-81) 
29.7  
(14.6-75.6) 
0.333 
P mort 2.1  
(0.6-11.8) 
2.2  
(0.8-11.8) 
1.9  
(0.6-8.7) 
0.357 
O mort  6.5  
(0.7-27.7) 
10.4  
(3.6-23.2) 
6.9  
(0.7-27.7) 
0.072 
WIMD rank 878  
(18-1890) 
845  
(18-1860) 
948  
(37-1890) 
0.368 
Health WIMD 735 
 (10-1885) 
731  
(10-1881) 
764  
(14-1885) 
0.807 
Rad stage HGD 2 0 2 0.335§ 
I 25 11 14 
II 26 13 13 
III 45 24 21 
IVa 2 2 0 
pTNM 
stage 
HGD 3 1 2 0.348§ 
I 23 10 13 
II 24 14 10 
III 25 9 16 
IV 7 5 2  
No resection 18 11 7 
Operative 
morbidity 
(Clavien-Dindo 
class) 
 
(30-day mortality) 
0 48 26 22 0.423 
I 5 3 2 
II 22 12 10 
III 6 3 3  
 
0.558 
IV 11 6 5 
V 3 2 1 
LOHS (days) Total 14 (2-72) 14 (4-72) 14 (2-62) 0.781 
 CC LOS 1 (0-70) 1 (0-70) 1 (0-36) 0.714 
 ITU LOS 0 (0-70) 0 (0-70) 0 (0-32) 0.580 
 HDU LOS 1 (0-13) 1 (0-13) 1 (0-11) 0.779 
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Legend for 3.7.2 
Figures in parentheses are range. §, X2 test across all groups within variable; ± 
some data unavailable for ASA grade; n, number; Oes, oesophagus; Gast, 
gastrectomy; BMI, body mass index; ASA, American Society of Anesthesiologists 
grade; POSSUM, physiological and operative severity score for the enumeration 
of mortality and morbidity (P – generic score; O – oesophageal score; Mort – 
mortality; morb - morbidity); WIMD, Welsh index of multiple deprivation rank; 
Health WIMD, health related WIMD rank; Rad stage, radiological stage according 
to TNM7 classification; HGD, high grade dysplasia; pTNM stage, TNM7 tumour, 
nodal, metastasis stage; LOHS, length of hospital stay; LOS, length of stay (CC, 
critical care unit; ITU, intensive therapy unit; HDU, high dependency unit). 
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3.7.3  Table 3. Surgical treatment 
 
Operation Intention to 
treat 
Actual 
STG 23 20 
TG 26 17 
THO 25 22 
TTO 23 20 
3SO 3 3 
Open & close - 16 
Palliative bypass - 2 
 
STG, subtotal gastrectomy; TG, total gastrectomy; THO, trans-hiatal 
oesophagectomy; TTO, trans-thoracic oesophagectomy; TSO, three-stage 
oesophagectomy; Open & close, irresectable disease with no bypass; Palliative 
bypass, irresectable disease with bypass. 
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3.7.4  Table 4. Univariable analysis to determine factors influencing 
survival using the Mantel-Cox log rank method of Kaplan and Meier. 
Variable χ2 df p value 
Rad stage 14.807 2 0.001 
Path stage 14.826 2 0.001 
Max PMD median 3.979 1 0.046 
Max PM perimeter median 2.619 1 0.106 
Morbidity 2.049 1 0.152 
P POSSUM morb quint 6.358 4 0.174 
Right PMD median 1.611 1 0.204 
Histology 2.189 2 0.335 
ASA 0.855 1 0.355 
P POSSUM mort quint 4.280 4 0.369 
O Possum Mort quint 3.510 4 0.476 
Site 0.478 1 0.490 
Max PM area median 0.329 1 0.566 
WIMD 2.464 4 0.651 
Age  2.370 4 0.668 
LOHS quintile 1.788 4 0.775 
Left PMD median 0.036 1 0.850 
Gender 0.019 1 0.889 
 
χ2, chi square value; df, degrees of freedom; Rad stage, radiological stage 
according to TNM7 classification; Path stage, histopathological stage of disease 
according to TNM7 classification; PMD, psoas muscle density (right, left or 
maximum from both right and left measurements); max PM perimeter, maximum 
psoas muscle perimeter; POSSUM, physiological and operative severity score 
for the enumeration of mortality and morbidity (P – generic score; O – 
oesophageal score; Mort, mortality; morb – morbidity); Histology, 
histopathological cell type (HGD, adenocarcinoma, squamous cell carcinoma); 
ASA, American Society of Anesthesiologists score; Site, disease site 
(oesophagus, stomach); WIMD, Welsh index of multiple deprivation rank; max 
PM area, maximum psoas muscle area; LOHS, length of hospital stay.
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3.7.5  Table 5. Multivariable analysis of factors influencing 
cumulative survival.  
Variable Category n Mean survival  HR 95% CI p value 
Max PMD >median 43 36.1 +/- 15.2 Reference group 0.009 
 <median 39 28.6 +/-14.1 1.897 1.175-3.062  
       
Path Stage III-IV 32 31.0 +/- 14.4 Reference group 0.032 
 II 24 31.2 +/- 16.2 0.746 0.424-1.315  
 I 26 44.0 +/- 7.4 0.494 0.292-0.837  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HR – Hazard Ratio; 95% confidence interval; PMD, psoas muscle density (left or 
right measurements). 
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3.7.6  Figure 1. Kaplan-Meier plot demonstrating cumulative survival 
according to maximum PMD in patients undergoing surgery for 
oesophagogastric cancer. 
 
 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-
Cox) 3.979 1 .046 
Test of equality of survival distributions for the different 
levels of >median MaxAvHU. 
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CHAPTER 4  
 
Prognostic value of cardiopulmonary exercise testing in 
gastric cancer surgery 
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4.1 SUMMARY 
 
The aim of this study was to assess the predictive value of CPX in 
patients with gastric cancer related to outcome. 
Seventy-four consecutive were assessed using CPX (median age 72 
years; 55 male). Primary outcome measures were operative morbidity, 
length of hospital stay (LOHS) and survival.  
Median (range) anaerobic threshold (AT), VO2peak and VE/VCO2 were 
10.3ml/kg/min (5.5-15.5), 15.0ml/kg/min (7.6-27.3) and 32.0 (20.0-51.0) 
respectively. Five patients’ treatment (6.8%) was altered because of CPX 
findings (mean AT = 7.0 ml/kg/min). Major operative morbidity (Clavien-
Dindo ≥III) was associated with a greater VE/VCO2 (median 37.0 vs. 
32.0, p=0.049), but was unrelated to AT (p=0.116) and VCO2 (p=0.627). 
Survival was significantly longer in patients with a VE/VCO2 less than 34 
(24 vs. 17 months, p=0.048). 
CPX assessment of UGI cancer patients provided risk stratification, which 
predicted operative morbidity and survival. A number of patients’ 
management was materially altered as a result of the CPX assessment. 
Further research to determine critical CPX predictive values is justified. 
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4.2  INTRODUCTION 
 
4.2.1  Risk stratification  
Risk stratification is an important component of contemporary anaesthetic 
and surgical practice, nowhere more so than in the arena of upper 
gastrointestinal (UGI) cancer surgery, which by its very nature carries 
significant inherent risk. Gastric cancer is the 15th most common 
malignancy in the UK with a decreasing incidence reported at 7.6 per 
100,000 population in 2011 (CRUK, 2014), down from 8.4 per 100,000 
population in 2008 (Newnham A, 2003, CRUK, 2012) and patients 
frequently present with advanced disease allied to significant 
cardiopulmonary operative morbidity.  
 
4.2.2  Surgical risk   
The Royal College of Surgeons of England has defined patients with a 
predicted hospital mortality of ≥5% as high-risk (Health., 2011) and UK 
National Audit figures report hospital mortality of 6.0% (95%CI 4.8-7.4) 
after gastrectomy (Centre, 2010). Subjective assessment underestimates 
operative risk (Findlay, 2011), and objective assessment of pre-operative 
physiological cardiopulmonary reserve by means of CPX can provide 
additional information in this regard (Simpson, 2009, Ridgway and 
Howell, 2010, Hennis et al., 2011, Moyes et al., 2013). 
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4.2.3  CPX testing 
CPX combines an incremental exercise stress test with direct 
measurement of exercise respiratory gas exchange as well as 
electrocardiography and, as such, represents a simulation of the 
neurohumoral stress response to surgery. Figure 4.2.3 shows a patient 
undergoing CPX testing. 
 
Figure 4.2.3. CPX testing equipment in use 
 
 
The role of CPX in pulmonary thoracic surgery has been studied 
extensively (Benzo et al., 2007), and published UK guidelines have been 
available for over a decade (Society, 2001). Moreover, in major 
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abdominal surgery measurements of anaerobic threshold (AT), and peak 
oxygen uptake (VO2 peak) have been reported to predict short (Epstein et 
al., 2004, Wilson et al., 2010) and mid-term mortality (Carlisle and Swart, 
2007, Wilson et al., 2010), cardio-pulmonary related mortality (Older et 
al., 1993, Older et al., 1999), and length of hospital stay (LOHS) 
(Snowden et al., 2010).  
Data regarding CPX in UGI cancer surgery, however, are scant by 
comparison, and existing reports are predominantly confined to 
oesophageal surgery (Nagamatsu et al., 1994, Nagamatsu et al., 2001, 
Forshaw et al., 2008). One recent study included gastric resections and 
reported a correlation between AT and the development of 
cardiopulmonary complications (Moyes et al., 2013).  
 
4.2.4  Aims 
The aim of this study, therefore, was to assess the clinical prognostic 
value of CPX in the risk stratification of patients diagnosed with 
potentially curable gastric cancer within the framework of an Enhanced 
Recovery After Surgery (ERAS) programme. The primary outcome 
measures were operative morbidity, LOHS in days, and survival in 
months from diagnosis. The setting was a UK regional cancer network 
serving a population of 1.4 million. 
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4.3  METHODS 
 
Approval of the local ethics committee was obtained to prospectively 
collect and analyse data on the medical and surgical outcome and results 
of investigations of all patients considered for surgery for UGI cancer. The 
ethics committee did not require written informed consent from 
participating subjects. 
 
4.3.1  Patient testing  
Seventy-four consecutive patients diagnosed with gastric cancer by the 
South East Wales Cancer Network Multi Disciplinary Team and with initial 
curative intent to treat were referred for CPX testing between April 2009 
and August 2013 as a component of pre-operative assessment. Analysis 
was performed on these 74 patients (table 1). The median (range) age 
was 72 (47-87) years and 55 (74%) were male.  
 
4.3.2  Treatment  
Treatment intent was curative in all patients at the time of referral for CPX 
and eventual treatment modality was surgical in 61 (82.4%), definitive 
chemoradiotherapy in 4 (5.4%) and palliative in 9 (12.2%) patients. Data 
relating to the pre-operative status, operative procedure and outcome 
were collected prospectively.  
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4.3.3  Data collected 
The pre-operative assessment process was defined in this study as the 
process from diagnosis to either the time of anaesthesia for definitive 
surgery or a decision not to operate. This period included the completion 
of the radiological staging process. Data collected included age, gender, 
smoking history, American Society of Anesthesiologists grade (ASA) 
(Anesthesiologists, 1963), Physiological and Operative Severity Score for 
the enUmeration of Mortality and morbidity (POSSUM) scores (Copeland 
et al., 1991), Detsky score (Detsky et al., 1986), Revised Cardiac Risk 
Index (RCRI) (Lee et al., 1999), Welsh Index of Multiple Deprivation 
overall (WIMD) and health (H-WIMD) deprivation scores (2008), 
radiological and histopathological stage of disease (TNM7) (Sobin LH, 
2009b), cancer site, 30-day mortality, operative morbidity related to the 
Clavien-Dindo grade (CD) (Dindo et al., 2004), critical care length of stay 
in days (CC LOS), LOHS and survival.  
 
4.3.4  CPX testing  
CPX fitness was measured at a single centre using the Medgraphics CPX 
UltimaTM (Medical Graphics, St Paul, Minnesota, USA), with 
BreezesuiteTM and Welch Allyn® (Welch Allyn, Inc., NY, USA) software. 
Measurements of the ventilatory minute volume, oxygen consumption 
and carbon dioxide production were taken during standard cycle 
ergometry. Wasserman nine-panel plots (Wasserman, 2005) were used 
to derive AT, VO2 peak, the ventilatory equivalent for carbon dioxide 
(VE/VCO2).  
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4.3.5  Pre-operative planning  
Multidisciplinary discussion and stratification of individual patient risk 
informed decisions regarding the planned post-operative level of care and 
invasive monitoring.  
 
4.3.6  Outcome measures 
Primary outcome measures were operative morbidity, related to Clavien-
Dindo grade (Dindo et al., 2004), operative mortality, length of hospital 
stay (LOHS) in days and survival in months from date of diagnosis. A 
Clavien-Dindo grade of III or greater (CD ≥III) represents operative 
morbidity requiring therapeutic intervention beyond pharmacological 
treatment or superficial wound opening and was considered to represent 
major operative morbidity in this study. Secondary outcome measures 
included change in treatment modality as a result of CPX performance, 
change in post-operative level of care requirement prediction as a result 
of CPX performance, critical care related cancellation rates and critical 
care length of stay (CC LOS). 
 
4.3.7  Statistical analysis 
Statistical analysis was performed using SPSS® (IBM® SPSS® Statistics 
v20.0.0.2, IBM Corporation, Armonk, New York, USA). Grouped data 
were expressed as median (range) and non-parametric analyses were 
used throughout. Statistical significance was determined as p<0.05. 
Categorical data were compared using the χ2 test, except where groups 
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contained counts of fewer than five, when Fisher’s exact test (Fisher, 
1922) was used. Grouped continuous data were compared using the 
Mann-Whitney U-test (Mann and Whitney, 1947). Spearman’s rank 
correlation coefficient (Spearman, 1904) was used to determine 
correlation. Univariable analysis of the predictive value of pre-operative 
factors for LOHS was performed using the Mantel-Cox log rank method of 
Kaplan and Meier (Kaplan and Meier, 1958). This incorporated LOHS into 
the model in place of survival, using discharge from hospital as the event 
and resulting in the construction of LOHS plots. Multivariable analysis of 
factors significantly influencing LOHS was performed using the Cox 
regression analysis model (Cox, 1972). Survival analysis was conducted 
using the conventional method described by Kaplan and Meier (Kaplan 
and Meier, 1958). 
 
 
4.4  RESULTS  
 
4.4.1  CPX variables 
Median (range) values for CPX variables are shown in Table 2. One 
patient was unable to record results because of intolerance of the 
exercise test.  
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4.4.2  Overall morbidity and LOHS  
Of the 61 patients managed surgically, major operative morbidity (CD ≥III) 
occurred in 7 patients (11.5%), including two deaths (3.3%), and the 
median (range) LOHS was 11.0 (4-52) days.  
 
4.4.3  Anaerobic threshold  
Suboptimal AT (<11ml/kg/min), recorded in 49 (66.2%) patients, was 
associated with high ASA grade (≥III, 63% vs. 36%, p=0.026), but not 
operative morbidity, LOHS, CC LOS, age, BMI, other measured risk 
stratification scores (including POSSUM, Detsky, RCRI), cancer 
radiological stage or histopathological stage.  
 
4.4.4  ASA grade 
Poor AT (determined as <9ml/kg/min) was recorded in 22 (29.7%) 
patients and was associated with high ASA grade (≥III, 73% vs. 46%, 
p=0.036) alone. 
ASA grade ≥III patients’ CPX variables were suboptimal when compared 
with ASA grade I and II patients; lower AT (median 9.5 vs. 10.7 
ml/kg/min, p=0.023) and lower VO2peak (median 13.3 vs. 17.3 ml/kg/min, 
p=0.005). LOHS (median 14.0 vs. 11 days, p=0.018), but not CC LOS 
(median 1 vs. 1 days, p=0.083), was significantly longer in this comorbid 
group. Higher risk scores were also observed in patients with ASA ≥III: P-
POSSUM morbidity (median 50.2 vs. 40.9%, p=0.002), P-POSSUM 
mortality (2.8 vs. 2.1%, p=0.003), and Detsky (5 vs. 5, p<0.0001).  
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4.4.5  Correlation with risk assessment tools 
Significant correlation was identified between CPX variables and 
established risk assessment tools, with poor performance correlating with 
higher risk scores in each case. AT correlated with ASA (Rho -0.278, 
p=0.017). VO2peak correlated with ASA (Rho -0.335, p= 0.004) and 
Detsky score (Rho -0.247, p=0.038). No correlation with POSSUM scores 
was identified. 
 
4.4.6  Changes in treatment modality 
Treatment modality was changed in the course of pre-operative 
assessment in 13 patients (17.6%), and directly as a result of CPX in 5 
patients (6.8%). Within this subgroup of 5 patients, mean (range) AT was 
7.0 (5.5-9.2) ml/kg/min, VO2peak 9.9 (8.7-12.4) ml/kg/min and VE/VCO2 
36.8 (28.0-48.0). The eventual treatment modality was palliative in four 
patients and outpatient monitoring of high-grade dysplasia in the fifth 
patient. 
 
4.4.7  Operative morbidity and mortality 
Operative morbidity of CD grade ≥III was associated with a higher ASA 
grade (Rho=0.275, p=0.032) and greater VE/VCO2 (median 37.0 vs 32.0, 
p=0.049), but not AT and VO2 peak (p=0.116 and p=0.627 respectively). 
This was demonstrated by Receiver Operator Characteristic (ROC) 
analysis, performed for CPX variables (Figure 1).  
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Operative mortality did not correlate with any CPX variables: AT (rho=-
0.084, p=0.518), VO2 peak (rho=-0.177, p=0.179) or VE/VCO2 
(rho=0.209, p=0.113).  
 
4.4.8  Length of hospital stay 
Univariable analysis of factors influencing LOHS is shown in Table 5. 
Upon multivariable analysis, ASA grade and the operation type emerged 
as a significant and independent predictor of LOHS, but none of the 
examined CPX variables emerged as such. 
 
4.4.9  Survival 
Cumulative survival at two years was 63.6% (n=28/44) overall, 87.0% 
(20/23) in patients with VE/VCO2 <34 and 38.1% (8/21) in patients with 
VE/VCO2 ≥34 (p=0.001). Median follow-up (or time to death) overall was 
28 months (range 0-46); in patients with VE/VCO2 <34, 33 months (range 
15-40); and in patients with VE/VCO2 ≥34, 19 months (range 0-46). 
Cumulative survival was significantly longer in patients with a VE/VCO2 
<34 (24 vs. 17 months, p=0.048, Figure 2).  
 
 
4.5  DISCUSSION 
 
This study represents the largest contemporary cohort of gastric cancer 
patients undergoing CPX assessment and surgery, related to outcomes. 
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The principal findings were that a low VE/VCO2 was predictive of major 
morbidity and associated with poor survival with a cut-off of 34. AT and 
VO2 peak were not significantly associated with operative morbidity, 
mortality or survival. CPX variables also correlated significantly with 
established risk assessment tools including ASA grade and Detsky score.  
For over a decade a high VE/VCO2 has been associated with poor 
outcome. As long as fifteen years ago, Older and colleagues reported 
using a VE/VCO2 of >35 in criteria for admission to HDU following major 
abdominal surgery (Older et al., 1999). In 2002, a VE/VCO2 of ≥34 was 
reported to be associated with a five-fold increase in risk of death in non-
surgical patients with heart failure (Gitt et al., 2002). Since then, studies in 
surgery have specifically examined VE/VCO2 as a predictor of operative 
morbidity and mortality, LOHS and survival.  
In major abdominal surgical patients, Wilson and colleagues found that a 
VE/VCO2 of ≥34 had 88% sensitivity and 47% specificity for in-hospital 
mortality (Wilson et al., 2010). In 108 patients undergoing major hepatic 
resection, Junejo and colleagues reported 47% sensitivity and 84% 
specificity for operative morbidity at a VE/VCO2 of ≥34.5 (Junejo et al., 
2012). A recent paper from West and colleagues demonstrated a higher 
ratio to be associated with increased risk of operative morbidity in 
colorectal cancer surgery, with a cut-off of 32.9 providing most predictive 
value. West and colleagues also reported VE/VCO2 to be associated with 
prolonged LOHS (West et al., 2014). However, Hennis and colleagues 
reported that outcomes in 106 patients undergoing Roux-en-Y gastric 
bypass surgery for obesity were not predicted by VE/VCO2 (Hennis et al., 
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2012) and in upper GI cancer, previous studies have not reported 
outcomes related to VE/VCO2 (Forshaw et al., 2008, Moyes et al., 2013, 
Nagamatsu et al., 2001).  
Regarding AT, previous reports have identified critical prognostic values 
of 9 ml/kg/min in UGI cancer resection (Moyes et al., 2013), and 11 
(Older et al., 1993, Older et al., 1999), 10.9 (Wilson et al., 2010) and 10.1 
ml/kg/min (Snowden et al., 2010) in major abdominal surgery. In contrast, 
no critical prognostic value for AT was identified in the present study. An 
AT of less than 11 ml/kg/min has been shown to be associated with an 
operative mortality rate of 18% compared with a mortality rate of 0.8% in 
patients with an AT greater than 11ml/kg/min (p<0.001) in a study of 187 
elderly patients undergoing major abdominal surgery such as abdominal 
aortic aneurysm resection or anterior resection of the rectum (Older et al., 
1993, Older et al., 1999).  These data were, however, published in 1993 
and 1999 respectively and anaesthetic and surgical practice have since 
advanced. More recently, ATs below 10.9 ml/kg/min have been 
associated with an increased risk of mortality within 90 days, (RR 6.8%, 
95% CI 1.6-29.5), an increased likelihood of high dependency care (457 
patients with an AT of ≤10.9 ml/kg/min vs. 390 with an AT of ≥10.9 
ml/kg/min, p<0.001) and an increased median length of hospital stay (9 
vs. 8 days, p<0.001) following major abdominal surgery such as elective 
colorectal resection, radical nephrectomy or cystectomy (Wilson et al., 
2010). Similarly, in a study of patients undergoing major elective 
procedures such as open aortic aneurysm repair, liver resections and 
pancreatic sarcoma surgery, AT was found to be higher (11.9 vs. 9.1 
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mL/kg/min, p=0.001) in patients who developed one or less post-
operative complication and subsequent LOHS was also shorter (10 vs. 26 
days, p<0.001) (Snowden et al., 2010). Recently, and within the context 
of UGI cancer resection, patients with cardiopulmonary operative 
morbidity were reported to have a significantly lower AT than those 
without cardiopulmonary operative morbidity (9.9 vs. 11.2 ml/kg/min, 
p=0.04) (Moyes et al., 2013). The authors reported that an AT below 9 
ml/kg/min was associated with operative cardiopulmonary morbidity using 
ROC analysis (sensitivity=74%, specificity=57%, p=0.04). This paper 
reported outcomes on 180 patients assessed using CPX, 108 (60%) 
ultimately receiving surgical treatment, including 43 (40%) patients with 
gastric cancer (39 resected). The mean AT was greater than in the 
present study (10.8 vs. 10.3 ml/kg/min), arguably because of the absence 
of oesophageal patients herein. 
The overall complication rate in the present study’s cohort was 
comparable with that reported by Moyes et al. [15/39 (38.5%) vs. 19/61 
(31.1%), p=0.451], as was the cardiopulmonary complication rate [5/39 
(12.8%) vs. 9/61 (14.8%), p=0.786].  ROC analysis did not identify a 
critical predictive threshold for CPX variables for cardiopulmonary or all 
operative morbidity in our cohort, which was not explained by a significant 
difference in operative morbidity in comparison to the dataset reported by 
Moyes et al. 
Early studies such as Older’s (Older et al., 1999) used CPX to stratify 
post-operative care requirement, and it is this type of use that has proved 
of most interest to our Anaesthetic colleagues. Those patients whose 
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overall performance was suboptimal were highlighted as an ‘at risk’ group 
and provision made for a higher level of care in the immediate 
postoperative period. This was not necessarily reliant upon specific 
numeric values from the CPX tests, but based on the overall impression 
of the experienced clinician, acting as Anaesthetist and Exercise 
Physiologist, and was often a team decision. By introducing this method 
of risk stratification, those patients whose performance was satisfactory 
could be reasonable spared the requirement for a confirmed critical care 
bed to be available prior to surgery taking place, since they were unlikely 
to require higher level of care than level 1, which would take place on the 
specialist upper gastrointestinal surgical ward. In a climate of extreme 
critical care bed pressure, this offered an important solution to some of 
the psychologically, financially and potentially oncologically detrimental 
effects of cancelling of operations because of bed unavailability. The 
development of a reliable risk calculation tool or the incorporation of 
existing tools may help to formalize this process in future. 
This study’s strengths include prospective data collection of a 
consecutive series of patients through an established and experienced 
MDT whose results are well audited and stand up to international 
comparison (Centre, 2010), with all surgery performed by specialist 
surgeons. Moreover, the dataset consisted of a large consecutive series, 
minimising the risk of selection bias. 
In contrast, there are several potential limitations to this study. Clearly this 
was not a randomised control trial and so no comparison group exists to 
confirm the impact of CPX on patient care. Although this study represents 
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the largest cohort of patients with gastric cancer undergoing CPX 
assessment to date, the numbers remain relatively small when sub-
analysed. The possibility exists, therefore, that some critical CPX values 
have failed to emerge owing to the influence of selection bias, type II 
statistical error, or both.  
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4.6  CONCLUSION 
 
In conclusion, CPX remains a relatively rare clinical commodity. Indeed, 
only 17% of NHS Trusts reported access to CPX testing as a risk 
assessment tool in 2008 (Simpson, 2009). The findings of this study 
suggest that significant thresholds of AT and VO2 peak for prediction of 
outcomes may not exist. VE/VCO2 was found to be of greater predictive 
value than other CPX variables in terms of major morbidity and survival. 
A VE/VCO2 cut-off of 34 emerged as a significant predictor of survival a 
lower figure predicting longer survival. Furthermore, allied to other risk 
assessment tools in a multidisciplinary team environment, CPX provided 
benefits in risk stratification, informing and influencing decisions relating 
to the appropriate treatment modality and the optimum level of post-
operative critical care required. A number of patients’ management was 
materially altered as a result of the CPX assessment. Further research to 
determine additional critical predictive values and potential thresholds of 
specific individual CPX derived variables in patients diagnosed with upper 
GI cancer is justified. 
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4.7 TABLES AND FIGURES 
 
4.7.1  Table 1. Details of the patients 
Variable n 
n 74 
Operated 61 (82%) 
Age (range) in years  72.0 (47-87) 
Gender (male:female) 55:19 (74:26%) 
BMI (range) 27.0 (18-50) 
ASA  I 1   (1%) 
II 33 (45%) 
III 39 (53%) 
IV 1   (1%) 
POSSUM  P morbidity 45.5 (14.6-85.8) 
P mortality 2.4 (0.6-15.9) 
O mortality 13.6 (1.4-41.8) 
Destky score 5 (0-30) 
Lee RCRI 1 (1-3) 
WIMD rank 860 (103-1893) 
Health WIMD 764 (46-1880) 
Rad stage I 16 (22%) 
II 20 (27%) 
III 35 (47%) 
IVa 3   (4%) 
Opertion type TG 23 (43%) 
STG 20 (33%) 
THO 4   (7%) 
Open & close 14 (23%) 
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Variable n 
pTNM stage HGD 4   (7%) 
 I 11 (18%) 
 II 10 (16%) 
 III 14 (23%) 
 IV 8   (13%) 
 No specimen 
resected 
27 (44%) 
Cardiopulmonary operative morbidity 9   (15%) 
Operative morbidity 
(Clavien-Dindo score) 
0 41 (67%) 
I 6   (10%) 
II 7   (11%) 
III 4   (7%) 
IV 1   (2%) 
(30-day mortality) V 2   (3%) 
Percentages refer to the proportion of the whole cohort of 74 patients except for 
surgery, pTNM stage and morbidity classes. Figures are given as median 
(range) or number (percentage). n – number; BMI – body mass index; ASA – 
American Society of Anesthesiologists score; POSSUM - physiological and 
operative severity score for the enumeration of mortality and morbidity (P – 
generic score; O – oesophageal score; Mort – mortality; morb – morbidity); 
RCRI – revised cardiac risk index; WIMD – Welsh index of multiple deprivation 
score; Health WIMD – health related WIMD score; Rad stage – radiological 
stage; TG – total gastrectomy; STG – subtotal gastrectomy; THO – total hiatal 
oesophagectomy (oesophagogastrectomy); Open & Close – irresectable 
disease; pTNM stage – TNM7 tumour, nodal, metastasis stage; CPR – complete 
pathological response. 
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4.7.2  Table 2. CPX variables 
 
Variable  
AT (ml/min/kg) 10.3 (5.5-15.5) 
VO2peak (ml/min/kg) 15.0 (7.6-27.3) 
VE/VCO2  32.0 (20.0-51.0) 
 
Values given as median (range). AT – anaerobic threshold; VO2peak – peak 
oxygen uptake; VE/VCO2 – ventilatory equivalent for carbon dioxide. 
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4.7.3  Table 3. Changes in treatment modality. 
 
Primary reason for change Eventual treatment n (%) 
CPX performance Palliation 
All 
5 (6.8) 
5 (6.8) 
 
Upstaged by laparoscopy or 
biopsy 
dCRT 
Palliation 
All 
2 (2.7) 
4 (5.4) 
6 (8.1) 
 
Upstaged on CT dCRT 
All 
2 (2.7) 
2 (2.7) 
 
TOTAL  13 
(17.6) 
 
Percentages in parentheses refer to the proportion of the whole cohort of 74 
patients. n – number; CPX – cardiopulmonary exercise testing; dCRT – 
definitive chemo-radiation therapy; CT – computerised tomography. 
 
 137 
 
4.7.4  Table 4. Performance details of patients whose management 
was changed by CPX. 
 
Patient Rad 
stage 
Age 
(years) 
AT 
(ml/min/kg) 
VO2 peak 
(ml/min/kg) 
VE/VCO2  
1 II 54 5.5 12.4 28.0 
2 I 82 6.6 9.2 41.0 
3 III 82 6.8 8.7 48.0 
4 I 81 9.2 9.2 30.0 
5 III 72 § § § 
Mean   74 7.0 9.9 36.8 
 
Rad stage – radiological stage; AT – anaerobic threshold; VO2peak – peak 
oxygen uptake; VE/VCO2 – ventilatory equivalent for carbon dioxide; § - 
performance so poor values unrecordable. 
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4.7.5  Table 5. Univariable analysis to determine influence of pre-
operative assessment factors on length of hospital stay using the 
Mantel-Cox log rank method of Kaplan and Meier. 
Variable 2 df p-value 
Radiology stage 19.436 3 <0.0001 
Operation type  12.800 2 0.002 
ASA 9.723 1 0.002 
pT Stage 11.283 5 0.046 
Detsky score 8.077 4 0.089 
AT quartile 5.692 3 0.128 
Health WIMD quintile 6.828 4 0.145 
pM Stage 5.125 3 0.163 
pN Stage 5.588 4 0.232 
VE/VCO2 quartile 3.986 3 0.263 
WIMD quintile 4.946 4 0.293 
Gender 0.808 1 0.369 
Age 2.863 4 0.581 
POSSUM physiology score quartile 0815 3 0.846 
VO2 peak quartile 0.655 3 0.884 
Lee RCRI 0.231 2 0.891 
P POSSUM morbidity quartile 0.577 3 0.902 
O POSSUM mortality quartile 0.422 3 0.936 
P POSSUM mortality quartile 0.229 3 0.973 
χ2 - chi square value; df – degrees of freedom; Rad stage – radiological TNM7 
stage; Operation type – resection type according to anatomy; ASA – American 
Society of Anesthesiologists score; pT / pN / pM stage – TNM7 tumour / nodal / 
metastasis stage; Detsky -  Detsky score; AT – anaerobic threshold; Health 
WIMD, health related depreivation score; VE/VCO2 – ventilatory equivalent for 
carbon dioxide; WIMD – Welsh index of multiple deprivation rank; POSSUM - 
physiological and operative severity score for the enumeration of mortality and 
morbidity (P – generic score; O – oesophageal score; Mort – mortality; morb – 
morbidity); VO2peak – peak oxygen uptake; Lee RCRI – revised cardiac risk 
index.
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4.7.6  Table 6. Multivariable analysis of factors influencing length of 
hospital stay.  
Variable Category n Mean LOHS HR 95% CI p value 
ASA  III-IV 19 15.9 Reference group <0.0001 
 I-II 28 10.5 4.414 1.982-9.832  
       
Operation type TG 23 17.3 Reference group <0.0001 
 STG 19 10.0 0.210 0.102-0.434  
 
HR – Hazard Ratio; 95% confidence interval; ASA – American Society of 
Anesthesiologists score; Operation type – resection type according to anatomy; 
TG, total gastrectomy; STG, subtotal gastrectomy; Oes, oesophagogastric 
resection; Open & close, unresectable tumour - resection not completed.  
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4.7.7  FIGURE 1. Receiver Operator Characteristic (ROC) curves for 
CPX variables as predictors of operative morbidity.  
The diagonal reference line indicates no discrimination. Probability values 
are shown for ROC analysis and Mann Whitney U (MWU) tests.
 
Variable AUC 95% CI p value 
   (ROC) (MWU) 
AT 0.562 0.287-0.837 0.598 0.587 
VO2 peak 0.558 0.308-0.808 0.623 0.638 
VE/VCO2 0.729 0.576-0.883 0.050 0.049 
 
AUC, area under curve; 95% CI, 95% confidence interval; ROC, receiver 
operator characteristic; MWU, Mann-Whitney U statistic; AT, anaerobic 
threshold; VO2peak – peak oxygen uptake; VE/VCO2 – ventilatory equivalent for 
carbon dioxide. 
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4.7.8  FIGURE 2. Kaplan-Meier plot demonstrating cumulative 
survival according to VE/VCO2 in patients undergoing CPX 
assessment for gastric cancer. 
 
VE/VCO2 – ventilatory equivalent for carbon dioxide. 
 
p=0.047 
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CHAPTER 5 
 
Prognostic value of cardiopulmonary exercise testing in 
oesophageal cancer surgery 
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5.1 SUMMARY 
 
The aim of this chapter was to assess the predictive value of CPX in 
patients with oesophageal cancer related to outcome. 
One hundred and twenty-three consecutive patients were assessed using 
CPX (median age 65 years; 101 male). Primary outcome measures were 
operative morbidity, length of hospital stay (LOHS) and survival.  
Median (range) anaerobic threshold (AT), VO2 peak and VE/VCO2 were 
11.2ml/kg/min (6.8-22.3), 18.8ml/kg/min (8.5-43.0) and 30.0 (11.0-48.0) 
respectively. Thirteen patients’ treatment (10.6%) was altered because of 
CPX findings (median AT = 9.3 ml/kg/min). Major operative morbidity 
(Clavien-Dindo ≥III) was associated with a greater VE/VCO2 (median 32.0 
vs. 27.0, p=0.027) and lower VO2 peak (median 17.1 vs. 20.1, p=0.012), 
but no significant difference in AT (11.1 vs. 11.2, p=0.437). ROC analysis 
confirmed this significant relationship for VE/VCO2 (AUC 0.689, p=0.027) 
and VO2 peak (AUC 0.271, p=0.012). Multivariate analysis revealed VO2 
peak to be an independent and significant predictor of LOHS (p=0.028) 
and survival was significantly longer in patients with a VO2 peak greater 
than 22 ml/kg/min (18 vs. 16 months, p=0.037). Cumulative survival was 
significantly longer in patients with a VO2 peak greater than 22 ml/kg/min.  
CPX assessment of patients with oesophageal cancer provided risk 
stratification, which predicted operative morbidity and survival. A number 
of patients’ management was materially altered as a result of the CPX 
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assessment. Further research to determine critical CPX predictive values 
is justified. 
 
 
5.2  INTRODUCTION 
 
5.2.1  Risk stratification  
Risk stratification is an important component of contemporary anaesthetic 
and surgical practice, nowhere more so than in the arena of upper 
gastrointestinal (UGI) cancer surgery, which by its very nature carries 
significant inherent risk. Oesophageal cancer is the 13th most common 
malignancy in the UK with an increasing incidence reported at 9.5 per 
100,000 population (Newnham A, 2003, CRUK, 2012), and patients 
frequently present with advanced disease allied to significant 
cardiopulmonary operative morbidity.  
5.2.2  Surgical risk   
UK National Audit figures report hospital mortality at 3.8% (95%CI 3.1-
4.7) after gastrectomy (Centre, 2010), approaching the Royal College of 
Surgeons of England definition of high-risk surgery ≥5% (Health., 2011). 
It has been shown that subjective assessment underestimates operative 
risk (Findlay, 2011), and that pre-operative objective assessment of 
physiological cardiopulmonary reserve using CPX can provide additional 
information in this regard (Simpson, 2009, Ridgway and Howell, 2010, 
Hennis et al., 2011, Moyes et al., 2013). 
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5.2.3  CPX testing 
CPX provides direct measurement of exercise respiratory gas exchange 
with concurrent electrocardiography, during an incremental exercise 
stress test. As such, it represents a simulation of the neurohumoral stress 
response to surgery.  
Following extensive study of the role of CPX in pulmonary thoracic 
surgery (Benzo et al., 2007), published UK guidelines have been 
available for over a decade (Society, 2001). Reports in major abdominal 
surgery have shown anaerobic threshold (AT), and peak oxygen uptake 
(VO2 peak) measurements to predict short (Epstein et al., 2004, Wilson et 
al., 2010) and mid-term mortality (Carlisle and Swart, 2007, Wilson et al., 
2010), cardio-pulmonary related mortality (Older et al., 1993, Older et al., 
1999), and length of hospital stay (LOHS) (Snowden et al., 2010).  
Studies examining CPX in oesophageal cancer surgery, however, are 
few in number. These have demonstrated significantly higher incidences 
of cardiopulmonary complications in patients with a poor VO2 peak 
(Nagamatsu et al., 2001, Nagamatsu et al., 1994, Forshaw et al., 2008) 
and AT  (Nagamatsu et al., 1994, Moyes et al., 2013). 
 
5.2.4  Aims 
The aim of this study, therefore, was to assess the clinical prognostic 
value of CPX in the risk stratification of patients diagnosed with 
potentially curable oesophageal cancer within the framework of an 
enhanced recovery after surgery (ERAS) programme. The primary 
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outcome measures were operative morbidity, LOHS in days, and survival 
in months from diagnosis. The setting was a UK regional cancer network 
serving a population of 1.4 million. 
 
 
5.3  METHODS 
 
Approval of the local ethics committee was obtained to prospectively 
collect and analyse data on the medical and surgical outcome and results 
of investigations of all patients considered for surgery for UGI cancer. The 
ethics committee did not require written informed consent from 
participating subjects. 
 
5.3.1  Patient testing  
One hundred and twenty-three consecutive patients diagnosed with 
oesophageal cancer by the South East Wales Cancer Network Multi 
Disciplinary Team and referred for CPX testing with initial curative intent 
to treat between April 2008 and November 2013 were studied. Analysis 
was performed on these 123 patients (table 1). The median (range) age 
was 65 (35-86) years and 101 (82.1%) were male.  
 
5.3.2  Treatment  
Treatment intent was curative in all patients at the time of referral for CPX 
and eventual treatment modality was surgical in 78 (63.4%), definitive 
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chemoradiotherapy in 18 (14.6%), palliative in 24 (19.5%) and 
endoscopic mucosal resection in 3 (2.4%) patients. Data relating to the 
pre-operative status, operative procedure and outcome were collected 
prospectively.  
 
5.3.3  Data collected 
The pre-operative assessment process was defined in this study as the 
process from diagnosis to either the time of anaesthesia for definitive 
surgery or a decision not to operate. This period included the completion 
of the radiological staging process. Data collected included age, gender, 
smoking history, American Society of Anesthesiologists grade (ASA) 
(Anesthesiologists, 1963), Physiological and Operative Severity Score for 
the enUmeration of Mortality and morbidity (POSSUM) scores (Copeland 
et al., 1991), Welsh Index of Multiple Deprivation overall (WIMD) and 
health (H-WIMD) deprivation scores (2008), radiological and 
histopathological stage of disease (TNM7) (Sobin LH, 2009b), cancer 
site, 30-day mortality, operative morbidity related to the Clavien-Dindo 
grade (CD) (Dindo et al., 2004), critical care length of stay in days (CC 
LOS), LOHS and survival.  
 
5.3.4  CPX testing  
CPX fitness was measured at a single centre using the Medgraphics CPX 
UltimaTM (Medical Graphics, St Paul, Minnesota, USA), with 
BreezesuiteTM and Welch Allyn® (Welch Allyn, Inc., NY, USA) software. 
Measurements of the ventilatory minute volume, oxygen consumption 
 148 
and carbon dioxide production were taken during standard cycle 
ergometry. Wasserman nine-panel plots (Wasserman, 2005) were used 
to derive AT, VO2 peak and the ventilatory equivalent for carbon dioxide 
(VE/VCO2).  
 
5.3.5  Pre-operative planning  
Multidisciplinary discussion and stratification of individual patient risk 
informed decisions regarding the planned post-operative level of care and 
invasive monitoring.  
 
5.3.6  Outcome measures 
Primary outcome measures were operative morbidity, related to Clavien-
Dindo grade (Dindo et al., 2004), operative mortality, length of hospital 
stay (LOHS) in days and survival in months from date of diagnosis. A 
Clavien-Dindo grade of III or greater (CD ≥III) represents operative 
morbidity requiring therapeutic intervention beyond pharmacological 
treatment or superficial wound opening and was considered to represent 
major operative morbidity in this study. Secondary outcome measures 
included change in treatment modality as a result of CPX performance, 
change in post-operative level of care requirement prediction as a result 
of CPX performance, critical care related cancellation rates and critical 
care length of stay (CC LOS). 
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5.3.7  Statistical analysis 
Statistical analysis was performed using SPSS® (IBM® SPSS® Statistics 
v20.0.0.2, IBM Corporation, Armonk, New York, USA). Grouped data 
were expressed as median (range) and non-parametric analyses were 
used throughout. Statistical significance was determined as p<0.05. 
Categorical data were compared using the χ2 test, except where groups 
contained counts of fewer than five, when Fisher’s exact test (Fisher, 
1922) was used. Grouped continuous data were compared using the 
Mann-Whitney U-test (Mann and Whitney, 1947). Spearman’s rank 
correlation coefficient (Spearman, 1904) was used to determine 
correlation. Univariable analysis of the predictive value of pre-operative 
factors for LOHS was performed using the Mantel-Cox log rank method of 
Kaplan and Meier (Kaplan and Meier, 1958). This incorporated LOHS into 
the model in place of survival, using discharge from hospital as the event 
and resulting in the construction of LOHS plots. Multivariable analysis of 
factors significantly influencing LOHS was performed using the Cox 
regression analysis model (Cox, 1972). Survival analysis was conducted 
using the conventional method described by Kaplan and Meier (Kaplan 
and Meier, 1958). 
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5.4  RESULTS  
 
5.4.1  CPX variables  
Median (range) values for CPX variables are shown in Table 2. Two 
patients were unable to record results because of intolerance of the 
exercise test.  
 
5.4.2  Overall morbidity and LOHS  
Of the 78 patients managed surgically, major operative morbidity (CD ≥III) 
occurred in 13 patients (16.7%), including two deaths (2.6%), and the 
median (range) LOHS was 15.0 (4-62) days.  
 
5.4.3  Anaerobic threshold  
Suboptimal AT (<11ml/kg/min), recorded in 34 (44%) operated patients, 
was not associated with operative morbidity (p=0.751), LOHS (p=0.728), 
CC LOS (p=0.859), age (p=0.232), ASA grade (p=0.650), cancer 
radiological stage (p=0.742), or histopathological stage (p=0.188).  
 
5.4.4  Changes in treatment modality 
Treatment modality was changed in the course of pre-operative 
assessment in 45 patients (36.6%), and directly as a result of CPX in 13 
patients (10.6%). Within this subgroup of 13 patients, median (range) AT 
was 9.3 (6.8-12.2) ml/kg/min, VO2peak 11.8 (8.5-15.6) ml/kg/min and 
VE/VCO2 36.0 (28.0-48.0). The reasons for changes and the eventual 
treatment modality are shown in Table 3. 
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5.4.5  Operative morbidity and mortality 
Operative morbidity of CD grade ≥III was associated with a higher ASA 
grade (X2=17.216, p=0.001), greater VE/VCO2 (median 32.0 vs. 27.0, 
p=0.027) and lower VO2 peak (median 17.1 vs. 20.1, p=0.012), but no 
significant difference in AT (11.1 vs. 11.2, p=0.437). This was 
demonstrated by Receiver Operator Characteristic (ROC) analysis, 
performed for CPX variables (Figure 1).  
Operative mortality did not correlate with any CPX variable: AT (rho=-
0.022, p=0.851), VO2 peak (rho=-0.004, p=0.975) or VE/VCO2 
(rho=0.191, p=0.093).  
 
5.4.6  Length of hospital stay 
Univariable analysis of factors influencing LOHS is shown in Table 5. 
Upon multivariable analysis, VO2 peak emerged as a significant and 
independent predictor of LOHS (Table 6, p=0.032). 
 
5.4.7  Survival 
Cumulative survival at one year was 87.8% (n=86/98) overall, 96.3% 
(26/27) in patients with VO2 peak ≥22 ml/kg/min and 84.5% (60/71) in 
patients with VO2 peak <22 ml/kg/min (p=0.101). Median follow-up (or 
time to death) overall was 17 months (range 1-63), 18 (5-40) months in 
patients with VO2 peak ≥22 ml/kg/min and 16 (1-63) months in patients 
with VO2 peak <22 ml/kg/min. Cumulative survival was significantly 
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longer in patients with a VO2 peak ≥22 ml/kg/min (18 vs. 16 months, 
p=0.021, Figure 2).  
 
 
5.5  DISCUSSION 
 
This study represents the largest contemporary cohort of oesophageal 
cancer patients undergoing CPX assessment and surgery, related to 
outcomes. The principal findings were that a low VO2 peak and a high 
VE/VCO2 were associated with operative morbidity, and VO2 peak was 
an independent and significant predictor of LOHS and predicted survival 
with a cut-off of 22 ml/kg/min. AT was not significantly associated with 
operative morbidity.  
For over a decade a high VE/VCO2 has been associated with poor 
outcome. As long as fifteen years ago, Older and colleagues reported 
using a VE/VCO2 of >35 in criteria for admission to HDU following major 
abdominal surgery (Older et al., 1999). In 2002, a VE/VCO2 of ≥34 was 
reported to be associated with a five-fold increase in risk of death in non-
surgical patients with heart failure (Gitt et al., 2002). Since then, studies in 
surgery have specifically examined VE/VCO2 as a predictor of operative 
morbidity and mortality, LOHS and survival.  
In major abdominal surgical patients, Wilson and colleagues found that a 
VE/VCO2 of ≥34 had 88% sensitivity and 47% specificity for in-hospital 
mortality (Wilson et al., 2010). In 108 patients undergoing major hepatic 
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resection, Junejo and colleagues reported 47% sensitivity and 84% 
specificity for operative morbidity at a VE/VCO2 of ≥34.5. A recent paper 
from West and colleagues demonstrated a higher ratio to be associated 
with increased risk of operative morbidity in colorectal cancer surgery, 
with a cut-off of 32.9 providing most predictive value. This paper also 
reported VE/VCO2 to be associated with prolonged LOHS (West et al., 
2014). However, Hennis and colleagues reported that outcomes in 106 
patients undergoing gastric bypass surgery were not predicted by 
VE/VCO2 (Hennis et al., 2012) and in upper GI cancer, previous studies 
have not reported significant differences in outcomes related to VE/VCO2 
(Forshaw et al., 2008, Moyes et al., 2013, Nagamatsu et al., 2001, 
Nagamatsu et al., 1994).  
Few studies have found a significant difference in outcome according to 
VO2 peak. Groups in Japan and England have demonstrated a 
significantly lower VO2 peak in patients with cardiopulmonary 
complications following oesophagectomy (Nagamatsu et al., 2001, 
Nagamatsu et al., 1994, Forshaw et al., 2008), but a more recent study, 
from an author of the English paper, did not replicate this finding in 
patients undergoing oesophagectomy in Glasgow (Moyes et al., 2013).  
Regarding AT, previous reports have identified critical prognostic values 
of 9 ml/kg/min in UGI cancer resection (Moyes et al., 2013), and 11 
(Older et al., 1993, Older et al., 1999), 10.9 (Wilson et al., 2010) and 10.1 
ml/kg/min (Snowden et al., 2010) in major abdominal surgery. In contrast, 
no critical prognostic value for AT was identified in the present study. An 
AT of less than 11 ml/kg/min has been shown to be associated with an 
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operative mortality rate of 18% compared with a mortality rate of 0.8% in 
patients with an AT greater than 11ml/kg/min (p<0.001) in a study of 187 
elderly patients undergoing major abdominal surgery such as abdominal 
aortic aneurysm resection or anterior resection of the rectum (Older et al., 
1993, Older et al., 1999).  These data were, however, published in 1993 
and 1999 respectively and anaesthetic and surgical practice have since 
advanced. More recently, ATs below 10.9 ml/kg/min have been 
associated with an increased risk of mortality within 90 days, (RR 6.8%, 
95% CI 1.6-29.5), an increased likelihood of high dependency care (457 
patients with an AT of ≤10.9 ml/kg/min vs. 390 with an AT of ≥10.9 
ml/kg/min, p<0.001) and an increased median length of hospital stay (9 
vs. 8 days, p<0.001) following major abdominal surgery such as elective 
colorectal resection, radical nephrectomy or cystectomy (Wilson et al., 
2010). Similarly, in a study of patients undergoing major elective 
procedures such as open aortic aneurysm repair, liver resections and 
pancreatic sarcoma surgery, AT was found to be higher (11.9 vs. 9.1 
mL/kg/min, p=0.001) in patients who developed one or less post-
operative complication and subsequent LOHS was also shorter (10 vs. 26 
days, p<0.001) (Snowden et al., 2010). Recently, and within the context 
of UGI cancer resection, patients with cardiopulmonary operative 
morbidity were reported to have a significantly lower AT than those 
without cardiopulmonary operative morbidity (9.9 vs. 11.2 ml/kg/min, 
p=0.04) (Moyes et al., 2013). The authors reported that an AT below 9 
ml/kg/min was associated with operative cardiopulmonary morbidity using 
ROC analysis (sensitivity=74%, specificity=57%, p=0.04). This paper 
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reported outcomes on 180 patients assessed using CPX, 108 (60%) 
ultimately receiving surgical treatment, including 65 (60%) patients with 
oesophageal cancer (64 resected). The mean AT was marginally lower 
than in the present study (10.8 vs. 11.2 ml/kg/min), arguably because of 
the absence of patients with gastric cancer herein. 
The overall complication rate in the present study’s cohort was slightly 
lower than that reported in this recent study (44/78 (56.4%) vs. 56/64 
(87.5%), p=0.001), as was the cardiopulmonary complication rate (26/78 
(33.3%) vs. 36/64 (56.3%), p=0.007).   
Early studies such as Older’s (Older et al., 1999) used CPX to stratify 
care requirement in the peri-operative period. Indeed this type of use has 
proved of particular interest to the medical team comprising surgical and 
anaesthetic specialists. Using the large volume of information yielded by 
the CPX test, as opposed to simply focusing on individual numeric 
values, allows the team to make overall judgements regarding 
anaesthetic approaches, monitoring requirements, goal-direction for fluid 
therapy, timing of extubation, and postoperative destination (ITU / HDU).  
Those patients whose overall performance was suboptimal were 
highlighted as an ‘at risk’ group and provision made for a level three care 
(ITU), whereas those patients whose CPX performance was satisfactory 
could be given level two care (HDU) postoperativel and could often be 
extubated earlier and discharged from critical care directly to the 
specialist upper gastrointestinal surgical ward. Without relying upon 
specific numeric values from the CPX tests, this was based on the overall 
impression of the experienced clinician, acting as Anaesthetist and 
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Exercise Physiologist, and was often a team decision. In a climate of 
extreme critical care bed pressure, this offered an important solution to 
some of the psychologically, financially and potentially oncologically 
detrimental effects of cancelling of operations because of bed 
unavailability. The development of a reliable risk calculation tool or the 
incorporation of existing tools may help to formalize this process in future. 
 
This study’s strengths include prospective data collection of a 
consecutive series of patients through an established and experienced 
MDT whose results are well audited and stand up to international 
comparison (Centre, 2010), all surgery performed by specialist surgeons. 
Moreover, the dataset consisted of a large consecutive series, minimising 
the risk of selection bias. 
In contrast, there are several potential limitations to this study. Clearly this 
was not a randomised control trial and so no comparison group exists to 
confirm the impact of CPX on patient care. Although this study represents 
the largest cohort of patients with oesophageal cancer undergoing CPX 
assessment to date, the numbers remain relatively small when sub-
analysed. The possibility exists, therefore, that critical CPX values for 
some outcomes have failed to emerge owing to the influence of selection 
bias, type II statistical error, or both.  
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5.6  CONCLUSION 
 
In conclusion, CPX remains a relatively rare clinical commodity. Indeed, 
only 17% of NHS Trusts reported access to CPX testing as a risk 
assessment tool in 2008 (Simpson, 2009). The findings of this study 
suggest that significant thresholds of AT for prediction of outcomes may 
not exist. VO2 peak was found to be of greater predictive value than other 
CPX variables for operative morbidity, LOHS and survival. Multivariable 
analysis demonstrated VO2 peak to be an independent, significant 
predictor of LOHS, and a cut-off of 22 ml/kg/min emerged as a significant 
predictor of survival. Furthermore, allied to other risk assessment tools in 
a multidisciplinary team environment, CPX provided benefits in risk 
stratification, informing and influencing decisions relating to the 
appropriate treatment modality and the optimum level of post-operative 
critical care required. A number of patients’ management was materially 
altered as a result of the CPX assessment. Further research to determine 
additional critical predictive values and potential thresholds of specific 
individual CPX derived variables in patients diagnosed with oesophageal 
cancer is justified. 
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5.7 TABLES AND FIGURES 
5.7.1  Table 1. Details of the patients 
Variable n 
n 123 
Operated 78 (63%) 
Age (range) in years  65.0 (35-86) 
Gender (male:female) 101:22 (82:18%) 
ASA  I 5   (4%) 
II 35 (28%) 
III 18 (15%) 
IV 2   (2%) 
 Unknown 63 (51%) 
POSSUM  P morbidity 41.6 (20.9-74.8) 
P mortality 2.0 (0.8-7.3) 
O mortality 7.3 (1.6-23.5) 
WIMD rank 1057 (5-1886) 
Health WIMD 915 (4-1551) 
Rad stage HGD 4   (3%) 
I 39 (32%) 
II 31 (25%) 
III 37 (30%) 
IVa 12 (10%) 
Operation type THO 49 (63%) 
TTH 16 (21%) 
TSO 3   (38%) 
Salvage 1   (1%) 
Open & 
close 
9   (12%) 
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pTNM stage HGD 2   (3%) 
 I 20 (26%) 
 II 21 (27%) 
 III 22 (78%) 
 IV 4   (5%) 
 No 
specimen 
resected 
9   (12%) 
Cardiopulmonary 
operative morbidity (%) 
 26 (33%) 
Operative morbidity 
(Clavien-Dindo score) 
(%) 
0 34 (44%) 
I 5   (6%) 
II 26 (33%) 
III 7   (9%) 
IV 4   (5%) 
(30-day mortality) V 2   (2%) 
 
Percentages refer to the proportion of the whole cohort of 74 patients except for 
surgery, pTNM stage and morbidity classes. Figures are given as median 
(range) or number (percentage). n – number; ASA – American Society of 
Anesthesiologists score; POSSUM - physiological and operative severity score 
for the enumeration of mortality and morbidity (P – generic score; O – 
oesophageal score; Mort – mortality; morb – morbidity); WIMD – Welsh index of 
multiple deprivation score; Health WIMD – health related WIMD score; Rad 
stage – radiological stage; THO – trans-hiatal oesophagectomy; TTO – trans-
thoracic oesophagectomy; TSO – three-stage oesophagectomy; Salvage – 
salvage oesophagectomy; Open & close – irresectable disease; pTNM stage – 
TNM7 tumour, nodal, metastasis stage; CPR – complete pathological response. 
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5.7.2  Table 2. CPX variables 
 
Variable 
 
AT (ml/min/kg) 11.2 (6.8-22.3) 
VO2peak (ml/min/kg) 18.8 (8.5-43.0) 
VE/VCO2  30.0 (11.0-48.0) 
 
Values given as median (range). AT – anaerobic threshold; VO2peak – peak 
oxygen uptake; VE/VCO2 – ventilatory equivalent for carbon dioxide; OUES – 
oxygen uptake efficiency slope. 
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5.7.3  Table 3. Changes in treatment modality. 
 
Primary reason for change Eventual treatment n (%) 
CPX performance EMR 1 (0.8) 
 dCRT 6 (4.9) 
 Palliation 6 (4.9) 
 All 13 
(10.6) 
Upstaged on CT dCRT 5 (4.1) 
 Palliation 5 (4.1) 
 All 10 (8.2) 
Upstaged on PET-CT Palliation 6 (4.9) 
 All 6 (4.9) 
Upstaged on EUS Palliation 1 (0.8) 
 All 1 (0.8) 
Upstaged by laparoscopy Palliation 2 (1.6) 
 All 2 (1.6) 
Upstaged after NeoAdj dCRT 2 (1.6) 
 Palliation 1 (0.8) 
 All 3 (2.4) 
Suitable for EMR EMR 2 (1.6) 
 All 2 (1.6) 
Patient choice dCRT 5 (4.0) 
 Palliation 3 (2.4) 
 All 8 (6.4) 
TOTAL  45 
(36.6) 
Percentages given as a proportion of all tested 123 individuals. n – number; 
CPX – cardiopulmonary exercise testing; EMR – endoscopic mucosal resection; 
dCRT – definitive chemo-radiation therapy; CT – computerised tomography. 
 
 162 
5.7.4  Table 4. Performance details of patients whose management 
was changed by CPX. 
 
Patient Rad 
stage 
Age 
(years) 
AT 
(ml/min/kg) 
VO2 peak 
(ml/min/kg) 
VE/VCO2  
1 4 74 6.8 8.5 41.0 
2 1 79 7.0 11.0 29.0 
3 1 79 8.3 10.5 35.0 
4 3 60 8.8 11.0 45.0 
5 3 51 8.8 12.4 28.0 
6 2 73 9.1 10.5 34.0 
7 2 69 9.5 13.4 36.0 
8 2 67 9.7 11.8 30.0 
9 1 73 10.8 14.2 48.0 
10 2 71 10.8 § § 
11 2 71 11.7 15.6 38.0 
12 3 59 12.2 14.9 36.0 
13 2 86 § § § 
Median  2 71 9.3 11.8 36.0 
 
Rad stage – radiological stage; AT – anaerobic threshold; VO2peak – peak 
oxygen uptake; VE/VCO2 – ventilatory equivalent for carbon dioxide; § - 
performance so poor values unrecordable. 
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5.7.5  Table 5. Univariable analysis to determine influence of pre-
operative assessment factors on length of hospital stay using the 
Mantel-Cox log rank method of Kaplan and Meier. 
Variable 2 df p value 
Operation type  25.126 2 <0.0001 
VO2 peak quartile 6.331 3 0.097 
Age group 6.740 4 0.150 
VE/VCO2 quartile 5.117 3 0.163 
AT quartile 4.648 3 0.199 
Radiology Stage 4.621 3 0.202 
ASA  1.577 1 0.209 
P POSSUM morbidity quartile 4.194 3 0.241 
P POSSUM mortality quartile 3.059 3 0.383 
Gender 0.462 1 0.497 
WIMD quintile 3.298 4 0.509 
O POSSUM mort quartile 1.608 3 0.658 
Physiology score quartile 1.283 3 0.733 
Health WIMD quintile 1.365 4 0.850 
 
χ2 - chi square value; df – degrees of freedom; VO2peak – peak oxygen uptake; 
VE/VCO2 – ventilatory equivalent for carbon dioxide; AT – anaerobic threshold; 
ASA – American Society of Anesthesiologists score; POSSUM - physiological 
and operative severity score for the enumeration of mortality and morbidity (P – 
generic score; O – oesophageal score; Mort – mortality; morb – morbidity); 
WIMD – Welsh index of multiple deprivation rank;
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5.7.6  Table 6. Multivariable analysis of factors influencing length of 
hospital stay.  
 
Variable Category n Mean 
LOHS 
HR 95% CI p value 
VO2peak Lower  9 28.7 Reference group 0.032 
(Quartile) Lower middle 24 17.6 2.236 0.925-5.407  
 Upper middle 19 16.2 3.752 1.504-9.359  
 Upper  24 16.9 2.957 1.202-7.278  
       
Operation type  
(Oesophagectomy) 
Transhiatal 49 19.2 Reference group <0.0001 
TTO / 3SO 19 18.9 0.912 0.515-1.646  
Open & close 8 9.5 6.711 2.902-15.518  
 
HR – Hazard Ratio; 95% confidence interval; VO2peak, peak oxygen 
uptake; TTO, transthoracic oesophagectomy; 3SO, three-stage 
oesophagectomy; Open & close, no resection performed. 
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5.7.7  Figure 1. Receiver Operator Characteristic (ROC) curves for 
CPX variables as predictors of major morbidity.  
The diagonal reference line indicates no discrimination. Probability values 
are shown for ROC analysis and Mann Whitney U (MWU) tests. 
 
Variable AUC 95% CI p value 
   (ROC) (MWU) 
AT 0.689 0.313-0.614 0.463 0.437 
VO2 peak 0.271 0.107-0.436 0.012 0.012 
VE/VCO2 0.689 0.520-0.858 0.038 0.027 
AUC, area under curve; 95% CI, 95% confidence interval; AT, anaerobic 
threshold; VO2peak – peak oxygen uptake; VE/VCO2 – ventilatory equivalent for 
carbon dioxide. 
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5.7.8  Figure 2. Kaplan-Meier plot demonstrating cumulative survival 
according to VO2peak in patients undergoing CPX assessment for 
oesophageal cancer. 
 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-
Cox) 5.298 1 .021 
Test of equality of survival distributions for the different 
levels of VO2 >22. 
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CHAPTER 6 
 
Systematic review and meta-analysis of enhanced 
recovery programmes in gastric cancer surgery 
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6.1 SUMMARY 
 
This chapter constitutes a systematic review and meta-analysis, 
performed to determine the influence of enhanced recovery programmes 
(ERPs) on outcomes after gastric cancer surgery. Medline, Embase, the 
Cochrane library and ClinicalTrials.gov were searched for studies on 
outcomes of gastrectomy in enhanced recovery or fast-track 
programmes. The primary outcome measure was post-operative length of 
hospital stay (LOHS), and secondary outcome measures were selected 
based on inclusion in two or more studies. Statistical analysis was 
performed using standardised mean difference (SMD) and odds ratio 
(OR) as the summary statistics.  
Thirteen studies, including nine randomised trials, totaling 1629 patients 
with gastric cancer were analysed. LOHS was significantly shorter after 
ERP when compared with control patients (CON, SMD -1.02, 95% 
confidence interval -1.47 to -0.56, p<0.001), but with significant 
heterogeneity between studies (I2=93%, p<0.001). ERP was also 
associated with reduced serum inflammatory response (CRP: SMD -0.56, 
95% CI -1.09 to -0.03, p=0.04; IL-6: SMD -0.62, 95% CI -0.94 to -0.29, 
p<0.001), less weight loss (SMD -0.79, 95% CI -1.11 to -0.46, p<0.001), 
and lower cost (SMD -1.02, 95% CI -1.59 to -0.45, p<0.001), as well as a 
trend toward shorter duration of intravenous infusion (SMD -2.70, 95% CI 
-5.35 to -0.05, p=0.05). Inclusion in an ERP was not associated with 
increased post-operative morbidity (OR 0.82, 95% CI 0.64 to 1.05, 
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p=0.12) or hospital readmission (OR 1.61, 95% CI 0.83 to 3.12, p=0.16). 
In conclusion, multimodal, standardised perioperative gastrectomy care 
appears feasible, safe and cost effective. 
 
 
6.2  INTRODUCTION 
 
Enhanced recovery programmes (ERPs) have long been embedded 
within colorectal cancer surgical care and have been beneficial in 
reducing post-operative morbidity and lengths of hospital stay (LOHS) 
(Varadhan et al., 2010). In contrast, ERPs in upper gastrointestinal (UGI) 
cancer surgery are less developed. Reports regarding ERPs in gastric 
cancer surgery are few, with modest sample sizes and widely variable 
quality (He, 2010, Jeong et al., 2011, Jiang et al., 2007, Kiyama et al., 
2003, Liu et al., 2010, So et al., 2008, Tang, 2013, Wang et al., 2010, 
Yamada et al., 2012, Feng et al., 2013, Chen Hu et al., 2012, Kim et al., 
2012). Two existing meta-analyses of multimodal peri-gastrectomy ERPs 
have failed to include all available data from the literature, one pooling 
data from six studies (n=400) (Yu et al., 2014) and the other pooling data 
from just four studies (n=218) (Chen Hu et al., 2012) for meta-analysis. 
The populations studied in these previous meta-analyses have been 
predominantly Eastern Asian, most arising from China and Japan.  
Gastric cancer surgery is pervaded by several controversies including the 
relative benefit of neoadjuvant and adjuvant chemotherapy, operative 
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approach (laparoscopic vs. open), the level of the lymphadenectomy and 
the benefit of early enteral nutrition, all of which may materially influence 
outcome (Nygren et al., 2003, Weimann et al., 2006, Centre, 2010, 
Liberati et al., 2009). Gastric cancer surgery in particular, is frequently 
performed in malnourished patients (Nygren et al., 2009), which, if 
severe, may be associated with a higher incidence of post-operative 
complications, which can in turn impede recovery (Weimann et al., 2006). 
Indeed, the UK National Audit reported post-operative morbidity of 19.4 
per cent and in-hospital mortality of 6.0 per cent (95% CI 4.8-7.4) in 
patients undergoing gastrectomy for cancer (Centre, 2010). 
Consequently there may have been a relative reluctance to introduce an 
UGI specific ERP, certainly in the West, because of perceived risks 
related to the potential for adverse early post-operative outcomes. 
The aim of this systematic review and meta-analysis was, therefore, to 
evaluate all existing available evidence regarding the implementation of 
an ERP in surgery for gastric cancer. 
  
 
6.3  METHODS 
 
6.3.1  Data sources, search methods and selection criteria. 
A systematic review of published work was conducted in accordance with 
the Preferred Reporting Items for Systematic Review and Meta-Analyses 
(PRISMA) guidelines (Fig. 1). (Liberati et al., 2009) Sources searched 
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were: MEDLINE via Ovid (January 1966 to April 2014), Embase (no date 
restriction), the Cochrane Library database (Cochrane Central Register of 
Controlled Trials; no date restriction) and World Health Organization 
International Clinical Trials Registry Platform (ICTRP; no date restriction) 
for studies reporting outcomes after gastrectomy in an enhanced 
recovery programme. 
No limitation was placed on language or publication type, but non-English 
language studies without extractable data were excluded. Relevant 
studies were identified using the MeSH subject headings gastric cancer 
and surgery. These results were combined with MeSH terms; 
perioperative care, multimodal treatment, early ambulation, length of stay, 
morbidity, mortality, hospital readmission, and the additional non-MeSH 
terms enhanced recovery, ERAS and fast-track. Variants such as 
stomach and gastrectomy were also accommodated in the literature 
search. The ClinicalTrials.gov website was also searched for randomised 
controlled trials (RCTs) involving enhanced recovery in gastric cancer 
surgery. Further articles were identified by hand searching of references 
and using the PubMed related articles function. The related article results 
were cross-referenced with full results from previous searches. The last 
search date was April 1st, 2014. Outcome events were identified for 
inclusion if they were reported in an extractable form in two or more 
studies. The review search algorithm is shown in Table 6. 
 
6.3.2  Data extraction 
Data were extracted independently by two authors (AJB and DSYC). The 
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following details were extracted from each study: first author, year of 
publication, study design (randomised, comparison, case series, 
prospective or retrospective), number of participants in each group (ERP 
and Control), inclusion criteria, details of pathways, quality of study and 
outcome events.  
 
6.3.3  Inclusion and exclusion criteria 
Studies reporting outcomes in patients undergoing gastrectomy for 
cancer within a multimodal pathway or enhanced recovery programme 
were included. Studies from which it was not possible to extract data from 
the published reports available from the British Library, and studies 
reporting outcomes of single interventions were excluded.  
 
6.3.4  Outcome measures 
The primary outcome was defined as LOHS in days. Secondary outcome 
measures were incidence of post-operative morbidity and mortality, rates 
of readmission to hospital, inflammatory response [day 1 serum C-
reactive protein (CRP), interleukin 6 (IL-6), tumour necrosis factor alpha 
(TNFα)], maximum post-operative pain score using a visual analogue 
scale (VAS), time to return of gut function, duration of intravenous fluid 
therapy (IVI), total cost, and post-operative weight loss. The construction 
of the ERP and the evidence underpinning individual elements therein 
were outside the remit of this study and were not addressed in this 
review.  
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6.3.5  Statistical analysis  
The meta-analysis was performed in line with the recommendations of 
the Cochrane Collaboration (Higgins, 2010) and the PRISMA guidelines 
(Liberati et al., 2009). Analysis was performed using Review Manager 
5.1.7 (The Nordic Cochrane Centre, Copenhagen, Denmark). Statistical 
analysis was performed using standardized mean difference (SMD) as 
the summary statistic for continuous variables and odds ratio (OR) for 
dichotomous variables. The SMD is the number of standard deviations’ 
difference of the intervention, as a dimensionless form of the actual 
findings (Higgins, 2010). A random effects model was used when the I2 
value was greater than 50 per cent and a fixed effects model was used 
when it was less than 50 per cent. Results were reported with 95 per cent 
confidence intervals (95% CI). Where values for mean and standard 
deviation were not available, these were imputed from the median and 
range using methods described by Hozo et al., (2005) as appropriate to 
sample size. This involved using the median as a surrogate for mean. 
Where sample size was greater than 70, SD was imputed as range/6 and 
where sample size was 15-69, SD was calculated as range/4. Where the 
interquartile range (IQR) was given, ranges were estimated as the 
median +/- IQR. 
 
6.3.6.  Assessment of bias 
Randomised studies were examined for quality according to risk-of bias 
tables from the Cochrane Handbook (Higgins, 2010), across domains of 
selection, performance, detection, attrition, reporting, and other bias. 
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Studies achieving a score of four or more from a maximum of seven were 
considered to be of higher quality. Non-randomised studies were 
examined for quality using the Newcastle–Ottawa scale (Higgins, 2010) 
across domains of patient selection methods, comparability of study 
groups and assessment of outcome. Studies achieving seven or more 
stars from a maximum of nine were considered to be of higher quality. 
Sensitivity analysis was performed for outcomes combining five or more 
studies. This was performed on two subgroups: i. studies assessed as 
higher quality; ii. randomised studies alone. The I2 test was reported for 
each analysis. Bias was assessed using funnel plots (Egger and Smith, 
1998), with asymmetry implying that results were subject to reporting or 
publication bias between studies and symmetry implying non-bias. 
Studies containing zero events in both arms were excluded from meta-
analysis.  
 
 
6.4  RESULTS 
 
6.4.1  Included studies  
Thirteen studies, published between 2004 and 2014, were analysed 
(Table 1) (He, 2010, Jeong et al., 2011, Jiang et al., 2007, Kiyama et al., 
2003, Liu et al., 2010, So et al., 2008, Tang, 2013, Wang et al., 2010, 
Yamada et al., 2012, Feng et al., 2013, Chen Hu et al., 2012, Kim et al., 
2012) comprising a total of 1,629 (726 ERP and 903 control) patients. 
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One report (Chen Hu et al., 2012) incorporated four arms to the trial and 
reported data on laparoscopic and open procedures separately and so is 
considered in this meta-analysis as two separate studies. Another report, 
(He, 2010) for which only an abstract was available, was deemed by the 
authors to contain sufficient data for inclusion, although the study quality 
could not be assessed formally and so was assumed to be poor. Where 
data was unavailable or means and standard deviations were not stated, 
further data was sought from corresponding authors by e-mail. Three 
corresponding authors supplied supplementary data for analysis (Jeong 
et al., 2011, Jiang et al., 2007, Yamada et al., 2012).  
 
6.4.2  Characteristics of the included studies 
The characteristics of the included studies are shown in Table 1, and the 
details of the main features of the pathways are given in Table 4. Nine 
studies were randomised trials (He, 2010, Jiang et al., 2007, Kiyama et 
al., 2003, Liu et al., 2010, Wang et al., 2010, Feng et al., 2013, Chen Hu 
et al., 2012, Kim et al., 2012), and the remaining four were cohort studies 
(Jeong et al., 2011, So et al., 2008, Tang, 2013, Yamada et al., 2012), of 
which three compared prospectively collected ERP and control data (So 
et al., 2008, Tang, 2013, Yamada et al., 2012), and the fourth compared 
prospectively collected ERP data with retrospectively collected control 
data (Jeong et al., 2011).  
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6.4.3  Study Quality 
Using the Newcastle-Ottawa scale (Higgins, 2010), cohort studies were 
assessed for potential bias (Table 2). From a maximum of nine stars, two 
studies achieved 7 stars and were deemed high quality (Tang, 2013, 
Yamada et al., 2012). The remaining two studies scored 5 and 6 stars 
respectively (Jeong et al., 2011, So et al., 2008). Risk of bias assessment 
for randomised trials is shown in Table 3. Blinding was the most 
consistent risk of bias among randomised trials and, since this type of 
surgical study is not readily amenable to blinding, it was predictable that 
none of the trials were double blinded. The unavailability of full and/or 
English language manuscripts was another potential source of bias, 
reflected by the low scores of three studies (He, 2010, Jiang et al., 2007, 
Kiyama et al., 2003).   
 
6.4.4  Primary outcome measure 
Twelve studies reported LOHS (He, 2010, Jeong et al., 2011, Jiang et al., 
2007, Kiyama et al., 2003, Liu et al., 2010, Tang, 2013, Wang et al., 
2010, Yamada et al., 2012, Feng et al., 2013, Chen Hu et al., 2012, Kim 
et al., 2012). Nine of these reported significantly lower LOHS in the ERP 
patients (He, 2010, Jiang et al., 2007, Kiyama et al., 2003, Liu et al., 
2010, Tang, 2013, Wang et al., 2010, Feng et al., 2013, Kim et al., 2012) 
and three reported no significant difference (Yamada et al., 2012, Jeong 
et al., 2011, Chen Hu et al., 2012). A significantly shorter LOHS was 
demonstrated in ERP patients in the overall analysis [SMD -1.02, (-1.47 
to -0.56), p<0.001, Fig. 2, Table 1]. There was significant heterogeneity 
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between the studies (I2= 93 per cent, p<0.001). Sensitivity analysis also 
demonstrated a significant difference in LOHS between the nine 
randomised trials (He, 2010, Jiang et al., 2007, Kiyama et al., 2003, Liu et 
al., 2010, Wang et al., 2010, Feng et al., 2013, Chen Hu et al., 2012, Kim 
et al., 2012), which showed a significantly shorter LOHS in ERP patients 
[SMD -1.27 (-1.77 to -0.77), p<0.001, Fig. 2, Table 2]. Heterogeneity, 
while slightly lower than that of the overall analysis, remained high 
between these studies (I2= 88 per cent, p<0.001). The six high-quality 
studies (Liu et al., 2010, Wang et al., 2010, Yamada et al., 2012, Feng et 
al., 2013, Kim et al., 2012, Tang, 2013) showed similar findings [SMD -
1.20 (-2.06 to -0.33), p=0.007], with a slightly greater heterogeneity 
observed between studies (I2= 95 per cent, p<0.001, Fig. 2, Table 3). 
Funnel plots for LOHS including all studies, only randomised trials, and 
only higher-quality studies all lacked symmetry, which reflects the 
heterogeneity observed for this outcome (Fig. 2), potentially representing 
publication bias.  
 
6.4.5  Secondary outcome measures 
6.4.5.1  Post-operative morbidity 
No significant difference was demonstrated between ERP and control 
patients in the twelve studies (He, 2010, Jeong et al., 2011, Kiyama et al., 
2003, Liu et al., 2010, So et al., 2008, Tang, 2013, Wang et al., 2010, 
Yamada et al., 2012, Feng et al., 2013, Chen Hu et al., 2012, Kim et al., 
2012) reporting incidence of post-operative morbidity [OR 0.82 (0.64 to 
1.05), p=0.12, Fig. 3, Table 1]. There was no significant heterogeneity 
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between the studies (I2= 36 per cent, p=0.10). Sensitivity analysis also 
demonstrated no significant difference in morbidity, without significant 
heterogeneity between studies (Fig. 3, Tables 2-3). Eight randomised 
trials (He, 2010, Kiyama et al., 2003, Liu et al., 2010, Wang et al., 2010, 
Feng et al., 2013, Chen Hu et al., 2012, Kim et al., 2012) reported 
morbidity, with no significant difference in post-operative morbidity 
between groups [OR 0.76 (0.49 to 1.16), p=0.20]. Heterogeneity was 
borderline significant between these studies (I2= 50 per cent, p=0.05). 
However, analysis of data from the six higher-quality studies (Liu et al., 
2010, Tang, 2013, Wang et al., 2010, Yamada et al., 2012) showed a 
significantly lower incidence of complications in the ERP group [OR 0.56 
(0.37 to 0.84), p=0.005], without heterogeneity between studies (I2= 0 per 
cent, p=0.60, Fig. 3, Table 3). 
Only three deaths within 30 days of surgery were reported and these 
were limited to the control arm of a single study (So et al., 2008). Meta-
analysis was therefore not possible for this outcome, but no significant 
difference between ERP and control cohorts was demonstrated in the 
study in question. 
 
6.4.5.2  Readmission rate 
No significant difference was demonstrated in readmission rates between 
ERP and control groups [OR 1.61 (0.83 to 3.12), p=0.16, Fig. 4, Table 1]. 
There was no significant heterogeneity between the studies (I2= 0 per 
cent, p=0.82). Sensitivity analysis also failed to demonstrate a significant 
difference in readmission rate, without significant heterogeneity between 
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studies (Fig. 4, Table 2). Four randomised trials (Liu et al., 2010, Wang et 
al., 2010, Feng et al., 2013, Kim et al., 2012) reported readmission rate, 
with no significant difference between cohorts [OR 2.01 (0.36 to 11.29), 
p=0.43, Fig. 4, Table 2]. Heterogeneity remained insignificant between 
these studies (I2= 0 per cent, p=0.85). Analysis of the six higher-quality 
studies (Liu et al., 2010, Wang et al., 2010, Feng et al., 2013, Kim et al., 
2012, Tang, 2013, Yamada et al., 2012) showed similar findings [OR 2.45 
(0.89 to 6.74), p=0.08], but with a non-significant trend toward higher 
readmission rate in the ERP group. There was no heterogeneity between 
studies (I2= 0 per cent, p=0.92), (Fig. 4, Table 3). 
 
6.4.5.3  Additional outcomes 
A lesser acute-phase reaction was observed in ERP patients when 
compared with control patients on post-operative day one, as a lower 
serum CRP [SMD -0.56 (-1.09 to -0.03), p=0.04, Table 5] and IL-6 [SMD -
0.62 (-0.94 to -0.29), p<0.001, Table 5]. However, no significant 
difference was observed in serum TNFα level on post-operative day one 
[SMD -0.19 (-1.35 to 0.97), p=0.74, Table 5] or the maximum post-
operative pain score [SMD -1.78 (-4.07 to -0.51), p=0.13, Table 5], 
although a trend toward lower pain scores was observed in ERP patients. 
Gut function returned earlier in ERP patients, as demonstrated by shorter 
time to first passage of flatus [SMD -0.95 (-1.42 to -0.51), p<0.001, Table 
5]. A shorter duration of IVI, seen in ERP patients, was borderline 
significant [SMD -2.70 (-5.35 to -0.05), p=0.05, Table 5], and post-
operative weight loss was significantly less in ERP groups [SMD -0.79 (-
 180 
1.11 to -0.46), p<0.001, Table 5]. Finally, total associated costs were also 
significantly lower in ERP cohorts [SMD -1.02 (-1.59 to -0.45), p<0.001, 
Table 5]. 
 
 
6.5  DISCUSSION  
 
This study represents the most comprehensive systematic review and 
meta-analysis to examine the effects of ERPs in patients undergoing 
surgery for gastric cancer to date. An exhaustive search was performed 
for relevant studies, and almost forty per cent of the data was obtained 
from randomised trials. The principal findings were that ERPs were 
associated with significantly shorter LOHS and reduced cost, without 
increasing post-operative morbidity or hospital readmission rates. Other 
significant benefits included a blunting of the inflammatory response 
(CRP and IL-6), less reliance on intravenous hydration, faster return of 
gut function, and less weight loss.  
Several potential limitations were identified. Full text was unavailable for 
one randomised trial (He, 2010) and, while sufficient data was available 
for inclusion, complete and accurate assessment of the quality of this 
study, including assessment of the risk of bias, was precluded. Two 
randomised trials were only available in their original format, using the 
Japanese (Kiyama et al., 2003) and Mandarin (Jiang et al., 2007) 
languages. Although some detail was available from the published 
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abstract and figures, complete and accurate assessment of quality and 
bias was not completed, which may have resulted in an underestimation 
of quality (Table 3). However, inclusion of such studies reduced concern 
regarding bias toward more mainstream publications. Nine of the thirteen 
studies were randomised trials, but all included fewer than 200 patients, 
which may introduce unreliability (Rerkasem and Rothwell, 2010). While 
the majority of studies were randomised trials, these accounted for only 
40 per cent of patients; the remaining 60 per cent of patients were 
contained within the four non-randomised studies. Systematic reviews of 
retrospective observational studies are known to be confounding-
sensitive (Higgins, 2010). Assessment of potential bias using funnel plots 
must be interpreted with caution where fewer than ten studies were 
included and, in anticipation of similar difficulties, meta-regression was 
not performed (Higgins, 2010). Assessment of study quality included 
measures of potential for bias, in both randomised and non-randomised 
studies. Studies deemed to be of higher quality included 554 patients (34 
per cent), and when analysed in isolation, demonstrated findings were 
wholly comparable to both the dataset as a whole and the randomised 
studies alone. This allowed concerns regarding inclusion of poor quality 
studies to be allayed, while ensuring all available data was assessed 
herein. Operative mortality could not be meta-analysed effectively 
because of the small number of events.  
The interventions that comprised individual ERPs were heterogeneous (, 
Online Resource). While there was overlap between reported 
programmes, there was also much variation. With no contemporary 
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consensus regarding which interventions should be included in an ERP 
encompassing gastric cancer surgery, programmes were developed 
based upon principles from related work in other surgical arenas. While it 
is possible that consistency between programmes may develop with 
further research, the colorectal experience has been that such variation 
persists (Wind et al., 2006).  
Most studies did not state whether patients received neoadjuvant 
chemotherapy (He, 2010, Jeong et al., 2011, Jiang et al., 2007, Kiyama 
et al., 2003, So et al., 2008, Tang, 2013, Yamada et al., 2012, Chen Hu 
et al., 2012, Kim et al., 2012). Patients receiving such therapy have been 
shown to deteriorate nutritionally (Awad et al., 2012) and some evidence 
suggests an increased risk of post-operative complications (Voelter et al., 
2004, Schuhmacher et al., 2010) including mortality (Makary et al., 2003). 
This raised the potential for bias in favour of studies excluding patients 
receiving neoadjuvant chemotherapy.  
In several studies it was not possible to determine whether surgery was 
performed by laparoscopic or open techniques (He, 2010, Jiang et al., 
2007, Kiyama et al., 2003, So et al., 2008, Tang, 2013, Wang et al., 
2010). One study described inclusion of both laparoscopic and open 
procedures (Yamada et al., 2012) and reported no significant related 
difference. Four studies excluded laparoscopic procedures (Jeong et al., 
2011, Liu et al., 2010, Chen Hu et al., 2012, Kim et al., 2012). This 
inconsistency and uncertainty was a potential source of bias, particularly 
if both approaches were used and imbalance existed between cohorts.  
It was also unclear in most studies whether a D1 or D2 lymphadenectomy 
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was performed (He, 2010, Kiyama et al., 2003, Liu et al., 2010, So et al., 
2008, Tang, 2013, Wang et al., 2010, Chen Hu et al., 2012, Kim et al., 
2012). This was a potential source of bias since the incidence of post-
operative morbidity and mortality has been shown in randomised clinical 
trials to be greater following D2 than D1 gastrectomy (Dent et al., 1988, 
Robertson et al., 1994, Bonenkamp et al., 1999, Bonenkamp et al., 1995, 
Cuschieri et al., 1999, McCulloch et al., 2005).  
The studies included were predominantly from Eastern Asia and it is clear 
that there is a paucity of work in this arena emerging from the Western 
world. Care must be taken, therefore, when interpreting the results with a 
view to application in other geographical locations. 
No significant heterogeneity was observed between studies in relation to 
the incidence of complications, incidence of readmission, day 1 serum IL-
6 level, and post-operative weight loss. However, significant 
heterogeneity (I2 = 88-95 per cent) was observed between the twelve 
studies reporting LOHS. This was likely a consequence of the 
heterogeneity between control programmes of individual studies, with 
wide variation in reported conventional practice and mean LOHS ranging 
from 7 to 28 days in control groups. Programmes with a relatively short 
LOHS prior to introduction of an ERP would find it challenging to reduce 
LOHS further. Similar reasons may explain the heterogeneity observed 
between the six studies reporting cost, since LOHS represented a major 
cost component. Heterogeneity was also observed between studies 
examining inflammatory response markers (CRP and TNFα), pain scores, 
intravenous fluid therapy and passage of flatus.  
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6.6 CONCLUSION 
 
In conclusion, this meta-analysis supports the development and use of 
ERPs in the arena of gastric cancer surgery. The implementation of such 
multimodal approaches to perioperative management appears feasible, 
and safe, conferring benefits to health care providers and patients alike.  
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6.7  TABLES AND FIGURES 
6.7.1  Table 1. Study characteristics 
Author
s 
Year Study 
design 
ERP 
patients 
Control 
patients 
Outcomes 
of interest 
Study 
quality* 
Neoadj
uvant 
Rx 
Open or 
laparosc
opic 
D1 
or 
D2 
Feng 
et al.  
 
2013 RT 59 60 1, 2, 3, 4, 
7, 9  
6/7 No Open D2 
He et 
al. 
 
2010 RT 41 41 1, 2, 7, 9  2/7 ? ? ? 
Hu et 
al. 
LAP 
2012 RT 19 22 1, 2, 7, 9 3/7 ? Lap ? 
Hu et 
al. 
OPEN 
2012 RT 21 20 1, 2, 7, 9 3/7 ? Open ? 
Jeong 
et al. 
 
2011 RC 228 403 1, 2, 3, 4, 
9 
5/9 ? Open D2 
Jiang 
et al. 
 
2007 RT 40 40 1, 7, 8, 9, 
10 
0/7 ? ? D2 
Kim et 
al. 
 
2012 RT 22 22 1, 5, 7, 9 4/7 ? Lap ? 
Kiyam
a et al. 
 
2004 RT 47 38 1, 2, 8, 9 3/7 ? ? ? 
Liu et 
al. 
 
2010 RT 33 30 1, 2, 3, 4, 
5, 7, 10 
5/7 No Open ? 
So et 
al. 
 
2008 PC 61 54 2, 3, 4 6/9 ? ? ? 
Tang 
et al 
2013 RC 
 
19 26 1, 2, 4 7/9 ? ? ? 
Wang 
et al. 
 
2010 RT 45 47 1, 2, 3, 4, 
5, 6, 7, 9  
4/7 No ? ? 
Yamad
a et al. 
2012 PC 91 100 1, 2, 3, 4, 
6, 7,  
7/9 ? Both  D2 
 
ERP, enhanced recovery programme. *According to data available. 
Outcomes of interest: 1, length of hospital stay; 2, operative morbidity; 3, 
operative mortality; 4, readmission rate; 5, inflammatory response (day 1 
CRP, IL-6 and TNFα); 6, maximum post-operative pain score; 7, time to 
passage of flatus; 8, duration of intravenous fluid therapy; 9, total cost; 
10, post-operative body weight loss. RT, randomised trial; PC, 
prospective cohort study; RC, retrospective cohort study; ?, unclear from 
paper. 
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6.7.2  Table 2. Assessment of bias for cohort studies 
 
 
Jeong 
et al. 
So et 
al. 
Tang et 
al. 
Yamada 
et al. 
Representativeness of the 
exposed cohort (selection 
bias) 
+ + + + 
 
Selection of the non 
exposed cohort (selection 
bias) 
- + + + 
Ascertainment of exposure 
(selection bias) 
+ + + + 
 
Demonstration that outcome 
of interest was not present 
at start of study (selection 
bias) 
- - + + 
Comparability of cohorts on 
the basis of the design or 
analysis (performance bias) 
- 
- 
- 
- 
- 
- 
- 
- 
Assessment of outcome 
(reporting bias) 
+ + + + 
Was follow-up long enough 
for outcomes to occur 
(detection bias) 
+ + + + 
Adequacy of follow up of 
cohorts (detection bias) 
+ + + + 
 
    
Score /9 (stars) 5 6 7 7 
 
+, Low risk of bias; -, high risk of bias; two stars available for 
comparability. 
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6.7.3  Table 3. Assessment of bias for randomised trials 
 
Feng 
et al. 
He 
et al. 
Hu et 
al.* 
Jiang 
et al. 
Kim 
et al. 
Kiyama 
et al. 
Liu 
et al. 
Wang 
et al. 
Random 
sequence 
generation 
(selection bias) 
+ + ? ? + ? + + 
 
Allocation 
concealment 
(selection bias) 
+ + ? ? + ? + + 
 
Blinding of 
participants and 
personnel 
(performance 
bias) 
- ? - - - - - - 
 
Blinding of 
outcome 
assessment 
(detection bias) 
+ ? - - - - - - 
 
Incomplete 
outcome data 
(attrition bias) 
+ ? + ? - + + + 
 
Selective 
reporting 
(reporting bias) 
+ ? + ? + + + + 
Other bias 
+ ? + ? + + + ? 
 
Score /7 6 2 3 0 4 3 5 4 
 
+, Low risk of bias; -, high risk of bias; ?, unclear risk of bias; 
*assessment applies to both datasets from Hu et al. 
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6.7.4  Table 4. Details of the care pathways for enhanced recovery 
programmes 
 
[See Supplementary Appendix B for 6.7.4]
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6.7.5  Table 5. Summary of effect for secondary outcome measures 
 
Variable No. of 
studies 
No. of patients SMD (95% C.I.) p-value Heterogeneity 
ERP 
(n) 
Control 
(n) 
  I2 (%) p-value 
CRP 5 140 141 -0.56 
(-1.09, -0.03) 
0.04 78 0.001 
IL-6 2 78 77 -0.62 
(-0.94, -0.29) 
<0.001 0 0.36 
TNFα 2 78 77 -0.19 
(-1.35, 0.97) 
0.74 92 <0.001 
Pain 
score 
2 136 147 -1.78 
(-4.07, -0.51) 
0.13 98 <0.001 
Flatus 4 239 241 -0.95 
(-1.42, -0.47) 
<0.001 83 <0.001 
IV fluids 2 87 78 -2.70 
(-5.35, -0.05) 
0.05 97 <0.001 
Weight 
loss 
2 78 77 -0.79 
(-1.11, -0.46) 
<0.001 0 0.62 
Cost 6 555 723 -1.02  
(-1.59, -0.45) 
<0.001 94 <0.001 
 
n, number; ERP, enhanced recovery programme group; control, control 
group; SMD, standardised mean difference; CRP, day one C-reactive 
protein; IL-6, day one interleukin-6; TNFα, day one tumor necrosis factor 
alpha; flatus, time to first passage of flatus; IV fluids, duration of 
intravenous fluid therapy.  
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6.7.6  Table 6. Review Search Algorithm. 
 
1 exp Stomach Cancer/ or (((gastric or stomach) adj1 cancer$) or ((gastric or 
stomach) adj1 carcinoma) or ((gastric or stomach) adj1 adenocarcinoma) or 
((gastric or stomach) adj1 neoplasm$)).mp. 
2 exp surgery 
3 gastrectomy.mp 
4 2 or 3 
5 1 and 4 
6 enhanced recovery.mp. 
7 ERAS.mp. 
8 fast-track.mp. 
9 multimodal treatment.mp. 
10 perioperative care.mp. 
11 early ambulation.mp. 
12 6 or 7 or 8 or 9 or 10 or 11 
13 length of stay.mp. 
14 post-operative morbidity.mp. 
15 mortality.mp. 
16 hospital readmission.mp. 
17 13 or 14 or 15 or 16 
18 clinical trial.mp. 
19 controlled clinical trial.mp. 
20 exp comparative study/ 
21 meta analysis.mp. 
22 multicenter study.mp. 
23 multicentre study.mp. 
24 randomi?ed controlled trial.mp. 
25 18 or 19 or 20 or 21 or 22 or 23 or 24 
26 12 or 17 
27 5 and 25 and 26 
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Studies included in meta-analysis n = 
12 
NB – One study contributed two 
separate datasets (open and 
laparoscopic) resulting in 13 datasets 
 
6.7.7  Figure 1. PRISMA Flow Diagram – ERP in Gastric Cancer 
Surgery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified 
through database 
searching 
n = 1566 
 
Records after duplicates removed 
n = 1590 
Identification+
Screening+
Eligibility+
Included+
Records identified 
through other 
sources 
n = 35 
Full text assessed for eligibility 
n = 46 
Records excluded n = 1544 
• Did not meet inclusion criteria n = 1541 
• Full text unavailable through British 
Library, insufficient data in abstract n = 1 
• Conference abstract with insufficient data 
n = 2 
Records excluded n = 34 
• Single element studied n = 7 
• Distal gastrectomy only n = 2 
• No control group n = 1 
• Did not meet inclusion criteria n = 24 
Records screened by title/abstract 
n = 1590 
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6.7.8  Figure 2. Effect of inclusion in an enhanced recovery 
programme on length of hospital stay.  
Weights are from random-effects analysis. Squares indicate the point 
estimates of the effect of the intervention (standard mean difference, 
SMD) and diamonds the summary estimate from the pooled studies; 95 
per cent confidence intervals are shown as horizontal bars and in 
parentheses. SD, standard deviation; CI, confidence intervals; df, 
degrees of freedom; I2, I-squared statistic for heterogeneity. 
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6.7.9 Figure 3. Effect of inclusion in enhanced recovery programme 
on the incidence of post-operative complications within 30 days.  
Weights are from fixed-effects analysis. Squares indicate the point 
estimates of the effect of the intervention (odds ratio, OR) and diamonds 
the summary estimate from the pooled studies; 95 per cent confidence 
intervals are shown as horizontal bars and in parentheses. Mantel-
Haentzel test; CI, confidence intervals; df, degrees of freedom; I2, I-
squared statistic for heterogeneity. 
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6.7.10  Figure 4. Effect of inclusion in an enhanced recovery 
programme on the incidence of readmission within 30 days.  
Weights are from fixed-effects analysis. Squares indicate the point 
estimates of the effect of the intervention (OR) and diamonds the 
summary estimate from the pooled studies; 95 per cent confidence 
intervals are shown as horizontal bars and in parentheses. Mantel-
Haentzel test; CI, confidence intervals; df, degrees of freedom; I2, I-
squared statistic for heterogeneity. 
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CHAPTER 7 
 
Systematic review and meta-analysis of enhanced 
recovery programmes in oesophageal cancer surgery 
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7.1 SUMMARY 
 
The aim of this systematic review and meta-analysis was to determine 
the influence of enhanced recovery programmes (ERPs) on outcomes 
after oesophageal cancer surgery. PubMed, Embase, the Cochrane 
library, and ClinicalTrials.gov were searched for all studies on outcomes 
after oesophagectomy in enhanced recovery or fast-track programmes. 
The primary outcome measure was post-operative length of hospital stay 
(LOHS), and secondary outcome measures were selected based on their 
inclusion in two or more studies. Statistical analysis was performed using 
standardised mean difference (SMD) and odds ratio (OR) as the 
summary statistics. Eight studies were included, involving 1091 
individuals. Meta-analysis of seven studies reporting LOHS demonstrated 
a significant reduction after ERP, when compared with control patients 
[SMD -1.16, (95% confidence interval (CI) -1.86 to -0.46), p=0.001], but 
with significant heterogeneity between studies [I2=95%, p<0.00001]. This 
was associated with decreases in 30-day mortality (p=0.07), post-
operative morbidity (p<0.0001) and incidence of anastomotic leak 
(p=0.03), and no significant difference in the incidence of pulmonary 
complications (p=0.38) or readmission to hospital (p=0.67).  
The application of multimodal, standardised approaches to perioperative 
oesophagectomy care was feasible, safe and associated with a shorter 
LOHS, reduced post-operative morbidity and mortality, fewer anastomotic 
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leaks and no increase in pulmonary complications or readmission to 
hospital.  
 
7.2  INTRODUCTION 
 
Enhanced recovery programmes (ERPs) are well established in 
colorectal cancer surgical practice and have been shown to be 
associated with reduced post-operative morbidity and shorter lengths of 
hospital stay (LOHS) (Varadhan et al., 2010). However, in upper 
gastrointestinal surgery, and oesophageal cancer resection in particular, 
the role of ERPs is less certain. No systematic review or meta-analysis of 
the implementation of a multimodal pathway in oesophagectomy for 
cancer exists.  
Radical oesophageal cancer surgery involves intestinal resection and 
anastomosis, with periods of starvation implemented to allow for healing 
of the anastomosis, protected from the stress of oral fluids and diet, while 
intestinal motility returns (Lewis et al., 2009). Patients are often 
malnourished at presentation (Nygren et al., 2003) and advanced disease 
and significant cardiorespiratory morbidity are commonly encountered. In 
severely malnourished patients, an increased risk of post-operative 
complications is observed, which can impede recovery (Weimann et al., 
2006). 
With surgical resection remaining the mainstay of radical curative 
treatment for esophageal cancer (Allum et al., 2011), patients are faced 
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with major surgery, which by its very nature carries inherent significant 
risk, even in well-nourished patients (Allum et al., 2011).  
Indeed, UK National Audit figures report an in-hospital mortality of 4.5 per 
cent (95% CI 3.7-5.5) and complication rate of 29.8 per cent (95% CI 
27.9-31.8) in patients undergoing oesophagectomy for cancer (Centre, 
2010). 
Several controversies exist in esophageal cancer surgery, including the 
operative approach (minimally invasive vs. open; transhiatal vs. 
transthoracic vs. tri-incisional), geographical epidemiological variations, 
and the use of neo-adjuvant and adjuvant treatment. 
The aim of this systematic review and meta-analysis was to evaluate 
existing evidence for the implementation of an ERP in oesophagectomy 
for cancer.  
 
 
7.3 METHODS 
 
7.3.1  Data sources, search methods and selection criteria. 
 
A systematic review of published work was conducted in accordance with 
the Preferred Reporting Items for Systematic Review and Meta-Analyses 
(PRISMA) guidelines (Fig. 1) (Liberati et al., 2009). Sources searched 
were: MEDLINE via Ovid (from January 1966 to April 2014), Embase (no 
date restriction), the Cochrane Library database (Cochrane Central 
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Register of Controlled Trials; no date restriction) and World Health 
Organization International Clinical Trials Registry Platform (ICTRP; no 
date restriction). Studies were sought reporting outcomes after 
oesophagectomy in an ERP. 
No limitation was placed on language or publication type, although non-
English language studies without extractable data were excluded. 
Relevant studies were identified using the following MeSH subject 
headings: esophageal cancer and surgery. These results were combined 
with MeSH terms: perioperative care, multimodal treatment, early 
ambulation, length of stay, post-operative morbidity, mortality, hospital 
readmission and the additional non-MeSH terms enhanced recovery, 
ERAS and fast-track. Variants, such as oesophagus, oesophageal and 
oesophagectomy, were also accommodated within the literature search. 
The ClinicalTrials.gov website was searched for randomised controlled 
trials (RCTs) involving enhanced recovery in oesophageal cancer 
surgery. Further articles were identified by hand-searching of references 
and using the PubMed related articles function. The related articles 
results were additionally cross-referenced with full results from previous 
searches. The last search date was 1st April 2014. Outcome events were 
identified for inclusion if they were reported in an extractable and 
comparable form in two or more studies. The review search algorithm is 
shown in Table 4. 
 
7.3.2  Data extraction 
Data were extracted independently by two authors (AJB and DSYC) and 
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any discrepancies resolved to consensus by discussion. The following 
details were extracted from each study: first author, year of publication, 
study design (randomised, comparison, case series, prospective or 
retrospective), number of participants in each group (ERP and Control), 
inclusion criteria, details of pathways, quality of study and outcome 
events.  
 
7.3.3  Inclusion and exclusion criteria 
All studies reporting outcomes in patients undergoing oesophagectomy 
for cancer within a multimodal pathway or ERP were included. Studies 
from which it was not possible to extract data from the published results 
available from the British Library, and studies reporting outcomes of a 
single intervention, were excluded.  
 
7.3.4  Outcome measures 
The primary outcome was defined as LOHS in days. Secondary outcome 
measures were incidence of all post-operative morbidity, operative 
mortality, pulmonary complications, anastomotic leak and readmission to 
hospital. The construction of the ERP and the evidence underpinning 
individual elements therein were outside the remit of this study and were 
not addressed in this review.  
 
7.3.5  Statistical analysis  
The meta-analysis was performed in line with the recommendations of 
the Cochrane Collaboration (Higgins, 2010) and the PRISMA guidelines 
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(Liberati et al., 2009). Analysis was performed using Review Manager 
5.1.7 (The Nordic Cochrane Centre, Copenhagen, Denmark). Statistical 
analysis was performed using odds ratio (OR) as the summary statistic 
for dichotomous variables and standardised mean difference (SMD) for 
continuous variables. The SMD is the number of standard deviations’ 
difference of the intervention as a dimensionless form of the actual 
findings (Higgins, 2010). A random effects model was used when the I2 
value was greater than 50 per cent and a fixed effects model was used 
when it was less than 50 per cent. Results were reported with 95 per cent 
confidence intervals (CI). Where values for mean and standard deviation 
(SD) were not available, these were imputed from the median and range 
using methods described by Hozo et al. (Hozo et al., 2005), as 
appropriate to sample size. This involved using the median as a 
surrogate for mean. Where sample size was greater than 70, SD was 
imputed as range/6 and where sample size was 15-69, SD was 
calculated as range/4.  
 
7.3.6  Heterogeneity 
The randomised study was examined for quality according to risk-of bias 
tables from the Cochrane Handbook, (Higgins, 2010) across domains of 
selection, performance, detection, attrition, reporting, and other bias. 
Achieving a score of four or more from a maximum of seven was 
considered to represent high quality. Non-randomised studies were 
examined for quality using the Newcastle–Ottawa scale (Higgins, 2010) 
across domains of patient selection methods, comparability of study 
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groups and assessment of outcome. Non-randomised studies achieving 
six or more stars from a maximum of nine were considered to be of high 
quality. Sensitivity analysis was performed for post-operative morbidity, 
analysing a subgroup comprised of high quality studies alone. The I2 test 
was reported for each analysis. Bias was assessed using funnel plots 
(Egger and Smith, 1998), with asymmetry implying that results were 
subject to reporting or publication bias between studies and symmetry 
implying non-bias.  
 
 
7.4  RESULTS  
 
7.4.1 Included studies  
Eight studies, published between 1998 and 2014, fulfilled the criteria for 
inclusion and were analysed comprising a total of 473 ERP patients and 
618 controls (Table 1). One report, for which only an abstract was 
available, was deemed by the authors to contain sufficient data for 
inclusion, although its quality could not be formally assessed. Where data 
was unavailable it was sought from corresponding authors by email. No 
supplementary data was received for analysis. 
 
7.4.2  Characteristics of the included studies 
The characteristics of the included studies are shown in Table 1, and the 
details of the main features of the pathways are given in Table 3. One 
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randomised trial was eligible for inclusion. Of the seven included cohort 
studies, two compared retrospectively collected ERP and control data 
(Munitiz et al., 2010, Tang, 2013), one compared prospectively collected 
ERP data with retrospectively collected control data (Brodner et al., 
1998), two compared prospectively collected data (Tomaszek et al., 
2010, Li et al., 2012) and two did not describe how data were collected 
(Cao et al., 2012, You et al., 2012). 
 
7.4.3  Primary outcome measure 
Seven studies reported LOHS (Brodner et al., 1998, Cao et al., 2012, 
Munitiz et al., 2010, Tomaszek et al., 2010, Tang, 2013, Li et al., 2012, 
Zhao et al., 2014). Six of these found a significantly shorter LOHS in the 
ERP group (Cao et al., 2012, Munitiz et al., 2010, Tomaszek et al., 2010, 
Tang, 2013, Li et al., 2012, Zhao et al., 2014) and one showed no 
significant difference (Brodner et al., 1998). A significantly shorter LOHS 
was demonstrated in the ERP group in the grouped analysis (SMD -1.16, 
(-1.86. to -0.46), p=0.001) (Fig. 2). There was significant heterogeneity 
between the studies (I2= 95 per cent, p<0.00001).  
 
7.4.4  Secondary outcome measures: 
7.4.4.1  All post-operative morbidity 
A significant benefit was demonstrated in ERP groups over control 
groups across the seven studies (Fig. 3) (Brodner et al., 1998, Cao et al., 
2012, Munitiz et al., 2010, You et al., 2012, Tang, 2013, Li et al., 2012, 
Zhao et al., 2014) reporting incidence of post-operative morbidity [OR 
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0.47 (0.33 to 0.66), p<0.0001] (Fig. 3, Table 1). There was no significant 
heterogeneity between the studies (I2= 0 per cent, p=0.53). Sensitivity 
analysis also demonstrated a significant benefit in terms of post-operative 
morbidity following removal of the low quality study from analysis [OR 
0.50 (0.35 to 0.72), p=0.0002]. Heterogeneity between studies remained 
insignificant (I2= 0 per cent, p=0.54), (Fig. 3, Table 2).  
 
7.4.4.2  Operative mortality 
Five studies reported operative mortality (Tang, 2013, Brodner et al., 
1998, Cao et al., 2012, Munitiz et al., 2010). A significantly lower mortality 
was observed in the ERP groups compared with control groups [OR 0.40 
(0.15 to 1.07), p=0.07] (Fig. 4), with no significant heterogeneity between 
the studies (I2= 0 per cent, p=0.51). 
 
7.4.4.3  Specific complications 
Six studies reported anastomotic leak rates (Brodner et al., 1998, Cao et 
al., 2012, Munitiz et al., 2010, Tang, 2013, Li et al., 2012, Zhao et al., 
2014), with a significant difference demonstrated between ERP and 
control groups [OR 0.55 (0.33 to 0.94), p=0.03] in favour of the ERP 
groups (Fig. 5). There was no significant heterogeneity between the 
studies (I2= 7 per cent, p=0.37).  
No significant difference was demonstrated between ERP and control 
groups of four studies (Munitiz et al., 2010, Brodner et al., 1998, Cao et 
al., 2012, Li et al., 2012) specifically reporting the incidence of pulmonary 
complications [OR 0.78 (0.45 to 1.36) p=0.38], (Fig. 6). Again, no 
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significant heterogeneity was demonstrated between the studies (I2= 0 
per cent, p=0.52).  
 
7.4.4.4  Readmission rate 
Readmission rate did not significantly differ between ERP and control 
groups [OR 1.10 (0.70 to 1.72), p=0.67], (Fig. 7). There was no significant 
heterogeneity between the six studies (Cao et al., 2012, Li et al., 2012, 
Munitiz et al., 2010, Tang et al., 2010, Tomaszek et al., 2010, Zhao et al., 
2014) reporting this outcome (I2= 0 per cent, p=0.91).  
 
7.4.4.5  Additional outcomes 
Other significant benefits that were reported in only one study and were, 
therefore, not comparable in meta-analysis included reductions in time to 
passage of flatus and faeces (Zhao et al., 2014); time to return of bowel 
sounds, time to mobility, discharge from intensive care facilities (Brodner 
et al., 1998); contrast aspiration (Tang, 2013) and pain scores (two 
studies but not reported in comparable form) (Brodner et al., 1998, Zhao 
et al., 2014). 
A funnel plot for LOHS lacked symmetry. This reflects the heterogeneity 
observed for this outcome (Fig. 2), potentially representing publication 
bias. However, when fewer than ten studies are included, the funnel plot 
is known to be difficult to interpret (Higgins, 2010). 
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7.4.4.6 Assessment of bias 
Using the Newcastle-Ottawa scale (Higgins, 2010), non-randomised 
studies were assessed for potential bias. From a maximum of nine stars, 
six studies achieved six or more stars and were deemed high quality 
(Table 2a). The unavailability of a full, English language manuscript 
precluded full and accurate assessment of bias for the remaining study, 
reflected by its low score of one, from nine stars. Comparability was the 
most consistent risk of bias with just one of the papers controlling for 
factors (Zhao et al., 2014). Using risk-of bias tables from the Cochrane 
Handbook (Higgins, 2010), the randomised study scored five from a 
maximum of seven stars and was deemed high quality (Table 2b). 
 
 
7.5  DISCUSSION 
 
This systematic review and meta-analysis is the first to specifically 
examine the effects of ERPs in patients undergoing surgery for 
oesophageal cancer. The authors performed an exhaustive search for 
relevant studies.  
The principal findings were that ERPs significantly shortened LOHS and 
reduced post-operative morbidity, specifically anastomotic leak, without 
significantly increasing pulmonary complications or rates of readmission 
to hospital.  
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The authors acknowledge several potential limitations. Full text was 
unavailable for one study owing to its foreign-language publication in a 
Chinese journal (You et al., 2012). While enough data was available for 
inclusion in the analysis of a single parameter, accurate and full 
assessment of this study’s quality, including assessment of the risk of 
bias, was not possible. However, this study’s inclusion reduced concern 
regarding bias toward western and mainstream publications, although 
only one comparable outcome was obtained.  
One of the eight studies included was a randomised trial, and five studies 
included retrospective data or failed to clearly state otherwise. Systematic 
reviews examining retrospective studies are known to be confounding-
sensitive (Higgins, 2010). Assessment of potential bias using funnel plots 
must be interpreted with caution, owing to the inclusion of fewer than ten 
studies. In anticipation of similar difficulties, meta-regression analysis was 
not performed (Higgins, 2010). However, assessment of study quality 
included a measure of potential for bias. Seven of the eight studies were 
deemed high quality and included 974 (89 per cent) of 1091 patients. The 
remaining study (You et al., 2012) provided data for just one outcome 
measure, post-operative morbidity. Sensitivity analysis with this study 
removed showed almost identical findings to analysis of the dataset as a 
whole, suggesting that little or no bias was introduced by this study’s 
inclusion.  
Studies included data reaching as far back as 1998 (Brodner et al., 1998) 
and collected over as many as ten years (Munitiz et al., 2010). This type 
of sprawled comparison group is likely to have resulted from the limited 
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number of resections performed at individual centres and the need to 
recruit sufficient numbers of patients for study. It has the potential to 
introduce technological bias as technique and technology were likely to 
have advanced over the study period, potentially improving outcomes in 
the ERP patients, all of whom were more recently treated than their 
respective control patients. This factor may have contributed to an 
improved anastomotic leak rate and post-operative morbidity rate in ERP 
groups. A major technological factor was the use of an open or minimally 
invasive surgical approach. In two studies the approach was unclear (You 
et al., 2012, Zhao et al., 2014), three studies included only open 
operations (Brodner et al., 1998, Cao et al., 2012, Munitiz et al., 2010) 
and three included both open and minimally invasive procedures (Tang, 
2013, Tomaszek et al., 2010, Li et al., 2012), although the latter approach 
comprised only 1.5 per cent of patients in one such study (Tomaszek et 
al., 2010). Inclusion of minimally invasive oesophagectomy (MIO) and 
laparoscopic-assisted techniques may have introduced bias, trends 
toward reduced LOHS, post-operative morbidity and mortality in favour of 
MIO having been demonstrated upon meta-analysis (Biere et al., 2009). 
Oesophageal cancer epidemiology shows wide geographical variation, 
influenced by genetic, behavioural and environmental factors, as yet 
unquantified. It follows that the use of chemoradiotherapy, and the 
literature informing it, also varies with by geographical population. In 
Europe, peri-operative chemotherapy (Cunningham et al., 2006, Ychou et 
al., 2011), and more recently, preoperative chemoradiotherapy (van 
Hagen et al., 2012) have been demonstrated to be superior to surgery 
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alone. In North America, a major trial failed to demonstrate a similar 
benefit from preoperative chemotherapy (Kelsen et al., 1998), while in 
Japan, pre-operative chemotherapy represents the standard of care in 
stage II/III disease (Shitara and Muro, 2009).  
The studies included in this review were from geographically diverse 
populations, across Asia (Cao et al., 2012, You et al., 2012, Zhao et al., 
2014, Li et al., 2012), North America (Tomaszek et al., 2010) and 
Western Europe (Brodner et al., 1998, Munitiz et al., 2010, Tang, 2013), 
potentially reducing their comparability, but concomitantly permitting a 
broad perspective on the global use of ERPs in oesophageal cancer. Five 
included studies did not state whether patients received neoadjuvant 
chemotherapy (Brodner et al., 1998, Munitiz et al., 2010, You et al., 2012, 
Tang, 2013, Zhao et al., 2014). In a further two studies, 61 and 67 per 
cent of patients received neo-adjuvant treatment respectively (Tomaszek 
et al., 2010, Li et al., 2012), and the remaining study stated the inclusion 
of such patients but did not quantify the number included (Cao et al., 
2012). Patients receiving such therapy have been shown to deteriorate 
nutritionally (Awad et al., 2012) and some evidence suggests an 
increased risk of post-operative complications (Voelter et al., 2004) 
including mortality (Makary et al., 2003). This presented the potential for 
bias in favour of studies excluding patients receiving neoadjuvant 
therapy.  
The time frame used for readmission rate was not stated in two papers 
(Munitiz et al., 2010, Tang, 2013), which may have introduced bias. 
However, data from these studies comprised less than 30 per cent of the 
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dataset for this outcome and analysis with these studies removed did not 
alter the findings. A thirty-day readmission rate was analysed from the 
remaining two studies (Cao et al., 2012, Tomaszek et al., 2010).  
The proportions of patients undergoing transhiatal (THO), transthoracic 
(TTO) and tri-incisional approaches for open oesophagectomy were 
unclear in two reports (You et al., 2012, Tang, 2013) and varied in the 
remaining four. Two studies included all three approaches, two favoring 
THO (Cao et al., 2012, Zhao et al., 2014), and two favoring TTO 
(Tomaszek et al., 2010, Li et al., 2012). The largest study (Tomaszek et 
al., 2010) reported a significant difference in surgical approach between 
treatment groups. The remaining two studies included only TTO (Brodner 
et al., 1998, Munitiz et al., 2010). THO is known to be associated with 
shorter LOHS and lower operative mortality (Hulscher et al., 2001), but 
higher incidence of anastomotic leak (Hulscher et al., 2001, Rindani et 
al., 1999) when compared with TTO. This disparity between studies, 
coupled with a variation in the number of patients contributed to this 
meta-analysis by individual studies, may have introduced bias in these 
outcomes.  
The interventions that comprised individual ERPs were heterogeneous 
(Table 4). While there was overlap between studies’ programmes, the 
variation between them reflects the absence of consensus over which 
interventions should be included in an ERP for oesophageal cancer 
surgery. Consistency between programmes may be forthcoming with 
further experience and published evidence, although this has not been 
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the observed in colorectal cancer ERPs despite extensive experience 
and evidence (Wind et al., 2006).  
No significant heterogeneity between studies in grouped analysis was 
demonstrated for post-operative morbidity, anastomotic leak rate, 
pulmonary complications or readmission to hospital, reflecting the 
comparability of the studies for these outcomes. However, significant 
heterogeneity was observed between the four studies reporting LOHS. 
This was likely a consequence of the heterogeneity between control 
programmes of individual studies, with wide variation in reported 
conventional practice and mean LOHS ranging from 7.5 to 15 days. 
Programmes with a comparatively short LOHS before the introduction of 
an ERP would find it challenging to reduce LOHS further.  
In some instances, data were reported using the median and range or 
interquartile range. Imputing the mean and SD for these values was not 
statistically ideal and medians may have been reported in preference to 
means in order to mask skewed data. 
 
 
7.6  CONCLUSION 
In conclusion, the present meta-analysis of the literature to date supports 
the development and use of ERPs in oesophageal cancer surgery. The 
implementation of such multimodal approaches to perioperative 
management appears feasible and safe, conferring benefits to health 
care providers and patients alike.  
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7.7  TABLES AND FIGURES 
7.7.1  Table 1. Study characteristics 
 
Authors Year Study 
design 
ERP 
patients 
Control 
patients 
Outcomes 
of interest 
Study 
quality* 
NeoAdj 
Rx 
Approach 
Brodner 
et al. (13) 
 
1998 RC 42 49 1, 2, 3, 6 6/9 Not 
stated 
Open 
Cao et al. 
(15) 
2012 UC 55 57 1, 2, 3, 4, 
5, 6 
7/9 Included 
(number 
not 
stated) 
Open 
 
Li et al. 
(17) 
2012 PC 59 47 1, 2, 3, 4, 
5, 6 
 Included 
(67%) 
Open 
(77.4%)  
and MIO 
Munitiz et 
al. (11) 
 
2010 RC 74 74 1, 2, 3, 4, 
5, 6 
6/9 Not 
stated 
Open 
 
Tang et 
al. (12) 
 
2013 RC 
 
36 27 1, 2, 3, 4, 5 7/9 Not 
stated 
Open and 
LAO 
Tomasze
k et al. 
(14) 
 
2009 RC 110 276 1, 4, 5 7/9 Included, 
(60.8%) 
Open 
(98.5%) 
and MIO  
You et al. 
(16) 
2012 UC 63 54 2 1/9 Not 
stated  
Not stated  
         
Zhao et 
al. (19) 
2014 RT 34 34 1, 2, 4, 5 5/9 Not 
stated  
Not stated  
 
TOTAL 
   
473 
 
618 
    
 
ERP, enhanced recovery programme. *According to data available. 
NeoAdj Rx, neoadjuvant therapy. Outcomes of interest: 1, length of 
hospital stay; 2, operative morbidity; 3, operative mortality; 4, readmission 
rate; 5, anastomotic leak; 6, pulmonary complications; RC, retrospective 
cohort study; UC, Cohort study - unclear data collection; PC, prospective 
cohort study; RT, randomised trial; MIO, minimally invasive 
oesophagectomy; LAO, laparoscopic-assisted oesophagectomy. 
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7.7.2  Assessment of bias 
7.7.2.1  Table 2a. Assessment of bias for non-randomised studies 
 
Brodner 
et al. 
Cao et 
al. 
Li et al. Munitiz 
et al. 
Tang 
et al. 
Tomaszek 
et al. 
You 
et al. 
Representativeness 
of the exposed 
cohort (selection 
bias) 
 
+ + + + + + ? 
Selection of the 
non exposed 
cohort (selection 
bias) 
 
+ + + + + + ? 
Ascertainment of 
exposure (selection 
bias) 
 
+ + + + + + ? 
Demonstration that 
outcome of interest 
was not present at 
start of study 
(selection bias) 
 
+ + + + + + ? 
Comparability of 
cohorts on the 
basis of the design 
or analysis 
(performance bias) 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
? 
? 
Assessment of 
outcome (reporting 
bias) 
 
- + - - + + ? 
Was follow-up long 
enough for 
outcomes to occur 
(detection bias) 
 
+ + + + + + ? 
Adequacy of follow 
up of cohorts 
(detection bias) 
+ + + + + + + 
 
       
Score /9 (stars) 6 7 6 6 7 7 1 
 
+, Low risk of bias; -, high risk of bias; ?, unclear risk of bias. Two stars 
available for comparability. 
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7.7.2.2  Table 2b. Assessment of bias for randomised trial 
 
Zhao et 
al. 
Random sequence generation 
(selection bias) + 
Allocation concealment 
(selection bias) + 
Blinding of participants and 
personnel (performance bias) - 
Blinding of outcome 
assessment (detection bias) - 
Incomplete outcome data 
(attrition bias) + 
Selective reporting (reporting 
bias) + 
Other bias + 
 
Score /7 5 
 
+, Low risk of bias; -, high risk of bias; ?, unclear risk of bias. 
 
 
 
7.7.3  Table 3. Details of the care pathways for enhanced recovery 
programmes 
[See Appendix B for 7.7.3] 
 
 215 
7.7.4  Table 4. Review search algorithm 
1 exp esophageal cancer/ or (((?sophagus) adj1 cancer$) or 
((?sophagus) adj1 carcinoma) or ((?sophagus) adj1 adenocarcinoma) 
or ((?sophagus) adj1 neoplasm$)).mp. 
2 exp surgery 
3 ?sophagectomy.mp 
4 2 or 3 
5 1 and 4 
6 enhanced recovery.mp. 
7 ERAS.mp. 
8 fast-track.mp. 
9 multimodal treatment.mp. 
10 perioperative care.mp. 
11 early ambulation.mp. 
12 6 or 7 or 8 or 9 or 10 or 11 
13 length of stay.mp. 
14 post-operative morbidity.mp. 
15 mortality.mp. 
16 hospital readmission.mp. 
17 13 or 14 or 15 or 16 
18 clinical trial.mp. 
19 controlled clinical trial.mp. 
20 exp comparative study/ 
21 meta analysis.mp. 
22 multicenter study.mp. 
23 multicentre study.mp. 
24 randomi?ed controlled trial.mp. 
25 18 or 19 or 20 or 21 or 22 or 23 or 24 
26 12 or 17 
27 5 and 25 and 26 
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Studies included in meta-analysis n = 8 
LOHS n = 7 
All complications n = 7 
Mortality n = 5 
Pulmonary complications n = 4 
Records identified 
through database search 
n = 1084 
 
Records after duplicates removed 
n = 1106 
Identification+
Screening+
Eligibility+
Included+
Records identified 
through other sources 
n = 28 
Records screened by title or abstract 
n = 1106 
Full text assessed for eligibility 
n = 31 
Records excluded n = 1075 
• Did not meet inclusion criteria n = 
1073 
• Full text unavailable through British 
Library, insufficient data in abstract n 
= 1 
• Conference abstract with insufficient 
data n = 1 
Records excluded n = 23 
• Single element studied n = 9 
• No control group n = 4 
• Did not meet inclusion criteria n = 9 
• No comparable extractable outcome 
measures n = 1 
7.7.5  Figure 1. PRISMA Flow Diagram – ERAS in Oesophageal 
Cancer Surgery 
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7.7.6  Fig. 2. Forest plot for length of hospital stay 
 
 
Effect of inclusion in an enhanced recovery programme (ERP) on LOHS. 
SD, standard deviation; CI, confidence intervals; df, degrees of freedom; 
I2, I-squared statistic for heterogeneity. Weights are from random-effects 
analysis. Squares indicate the point estimates of the effect of the 
intervention (SMD) and diamonds the summary estimate from the pooled 
studies; 95 per cent confidence intervals are shown as horizontal bars 
and in parentheses. 
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7.7.7  Fig. 3. Forest plot for postoperative morbidity 
 
 
Effect of inclusion in an enhanced recovery programme (ERP) on the 
incidence of postoperative morbidity within 30 days. M-H, Mantel-
Haentzel test; CI, confidence intervals; df, degrees of freedom; I2, I-
squared statistic for heterogeneity. Weights are from fixed-effects 
analysis. Squares indicate the point estimates of the effect of the 
intervention (OR) and diamonds the summary estimate from the pooled 
studies; 95 per cent confidence intervals are shown as horizontal bars 
and in parentheses. 
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7.7.8  Fig. 4. Forest plot for operative mortality 
 
 
Effect of inclusion in an enhanced recovery programme (ERP) on the 
incidence of operative mortality. M-H, Mantel-Haentzel test; CI, 
confidence intervals; df, degrees of freedom; I2, I-squared statistic for 
heterogeneity. Weights are from fixed-effects analysis. Squares indicate 
the point estimates of the effect of the intervention (OR) and diamonds 
the summary estimate from the pooled studies; 95 per cent confidence 
intervals are shown as horizontal bars and in parentheses. 
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7.7.9  Fig. 5. Forest plot for anastomotic leak 
 
 
Effect of inclusion in an enhanced recovery programme (ERP) on the 
incidence of anastomotic leak. M-H, Mantel-Haentzel test; CI, confidence 
intervals; df, degrees of freedom; I2, I-squared statistic for heterogeneity. 
Weights are from fixed-effects analysis. Squares indicate the point 
estimates of the effect of the intervention (OR) and diamonds the 
summary estimate from the pooled studies; 95 per cent confidence 
intervals are shown as horizontal bars and in parentheses. 
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7.7.10  Fig. 6. Forest plot for pulmonary complications 
 
 
Effect of inclusion in an enhanced recovery programme (ERP) on the 
incidence of pulmonary complications. M-H, Mantel-Haentzel test; CI, 
confidence intervals; df, degrees of freedom; I2, I-squared statistic for 
heterogeneity. Weights are from fixed-effects analysis. Squares indicate 
the point estimates of the effect of the intervention (OR) and diamonds 
the summary estimate from the pooled studies; 95 per cent confidence 
intervals are shown as horizontal bars and in parentheses. 
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7.7.11  Fig. 7. Forest plot for readmission to hospital 
 
 
Effect of inclusion in an enhanced recovery programme (ERP) on the 
incidence of readmission to hospital within 30 days. Mantel-Haentzel test; 
CI, confidence intervals; df, degrees of freedom; I2, I-squared statistic for 
heterogeneity. Weights are from fixed-effects analysis. Squares indicate 
the point estimates of the effect of the intervention (OR) and diamonds 
the summary estimate from the pooled studies; 95 per cent confidence 
intervals are shown as horizontal bars and in parentheses. 
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CHAPTER 8 
 
Outcomes following introduction of an enhanced recovery 
programme in gastric cancer surgery 
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8.1   SUMMARY 
 
Enhanced recovery programmes (ERPs) are widely accepted in 
colorectal surgery, but few studies have investigated their use in gastric 
cancer surgery. 
The aim of this study was to examine the outcomes of gastric cancer 
surgery in a UK regional cancer centre with specific reference to the 
introduction of an ERP.  
Consecutive 117 patients (median age 71 years, 68 male) undergoing 
gastrectomy for cancer between May 20th 2008 and August 20th 2013 
were studied prospectively before and after the introduction of an ERP 
(October 2010). The primary outcome measure was Length of hospital 
stay (LOHS). Secondary outcome measures were critical care burden, 
30-day operative morbidity (graded according to Clavien-Dindo) and 
mortality. 
LOHS was significantly shorter in the ERP group (11 vs. 14 days, 
p=0.004), as was the overall duration of critical care admission (0 vs. 1 
day, p<0.0001). Multivariable analysis revealed inclusion in the ERP to be 
an independent and significant predictor of LOHS (p=0.028).  There was 
no negative effect on morbidity (37.5% vs. 37.8%, p=0.972), major 
morbidity (CD≥3, 8.8% vs. 18.9%, p=0.115), mortality (2.5% vs. 8.1%, 
p=0.163) or readmission rate (7.5% vs. 5.4%, p=0.676) following 
introduction of the ERP. A significant cost-saving was observed in the 
ERP group (median admission cost 1440 vs. 1869 GBP, p=0.001). 
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An ERP in gastrectomy for cancer appeared feasible, safe and cost 
effective. 
 
 
8.2  INTRODUCTION 
 
Radical gastrectomy is a potentially curative, but high-risk, invasive 
procedure for gastric cancer. While remaining the mainstay of radical 
curative treatment for gastric cancer, (Allum et al., 2011) surgical 
resection is complex in nature and associated with significant risk of post-
operative morbidity and mortality, even in well-nourished patients (Allum 
et al., 2011). Indeed, UK National Audit figures report an in-hospital 
mortality of 6.0 per cent (95% CI 4.8-7.4) and complication rate of 19.4 
per cent in patients undergoing gastrectomy for cancer (Centre, 2010). 
Furthermore, 7.4 per cent of patients undergoing gastrectomy for cancer 
in the UK require further surgery for a complication (Centre, 2010).  
Enhanced recovery programmes (ERPs) are well established in 
colorectal surgery and have demonstrated clear benefits of employing 
holistic multimodal perioperative strategies in resectional cancer surgery. 
Such improvements are achieved in the modern ERP through 
aggregation of the benefits of a number of interventions to optimise 
physiological, psychological and healthcare system factors surrounding 
major gastrointestinal surgery. Interventions are combined within a 
standardised pathway incorporating clear goals for patients and staff 
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members alike. Benefits include reductions in post-operative morbidity 
and lengths of hospital stay (Varadhan et al., 2010). However, little 
attention has been given to the potential role of ERPs in upper 
gastrointestinal (UGI) cancer surgery. Few studies exist reporting 
outcomes following implementation of ERPs in gastric cancer surgery, 
and sample sizes in existing reports are modest (He, 2010, Jeong et al., 
2011, Jiang et al., 2007, Kiyama et al., 2003, Liu et al., 2010, So et al., 
2008, Tang, 2013, Wang et al., 2010, Yamada et al., 2012). The 
systematic review and meta-analysis of the implementation of ERPs for 
gastrectomy for cancer contained within this thesis showed ERPs to be 
beneficial in reducing length of stay in hospital, post-operative pain 
scores, duration of intravenous fluid requirement, post-operative weight 
loss and overall cost. Moreover, no increase in post-operative morbidity 
or hospital readmission rate was observed.  
Nutrition is a central component of gastrointestinal ERPs and radical 
gastrectomy commonly entails protracted periods of starvation following 
intestinal resection and anastomosis. Such periods without oral nutrition 
are employed to allow time for return to normal intestinal motility and to 
protect anastomoses from the stress of oral fluids and diet (Lewis et al., 
2009). Consideration of nutritional requirements is particularly salient in 
patients requiring upper gastrointestinal cancer surgery, in whom pre-
operative malnutrition is frequently present (Nygren et al., 2003). Indeed, 
severe malnutrition is associated with a higher incidence of post-
operative complications and potential prolongation of the recovery period 
(Weimann et al., 2006).  
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The aim of this study was, therefore, to analyse the influence of a 
standardised multimodal peri-gastrectomy pathway for gastric cancer by 
comparison of intervention and control groups.  
  
 
8.3  METHODS 
 
8.3.1  Programme 
Multimodal programmes for total and sub-total gastrectomy were 
constructed following an information gathering process inclusive of 
surgical, oncological, radiological, dietetic, nursing and physiotherapy 
staff members (Figure 1 – Summary of the ERP). The literature was 
consulted to inform specific aspects of the pathway. Programme 
development was led by three consultant surgeons (WL, GC, GB) 
operating within the regional cancer network. Pathway booklets were 
created, which served as a unified multidisciplinary patient record, within 
which all documentation was centralised during the individual patient 
journey. 
 
8.3.2  Population 
Groups were drawn from a consecutive series of patients receiving 
surgical treatment for gastric cancer within the South East Wales Cancer 
Network, which serves a population of approximately 1.4 million. The 
control group comprised patients undergoing open surgery between 20th 
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May 2008 and 30th September 2010 at two of three NHS Trusts within 
the network. The network was centralised to a single site on 1st August 
2010 and, thereafter, a third NHS Trust also contributed patients to the 
centralised service. The ERP was implemented for all patients from 1st 
October 2010 onward, and the ERP group comprised patients 
undergoing surgery between this date and 20th August 2013.  
 
8.3.3  Surgery 
All patients underwent surgery according to decisions of a regional 
multidisciplinary team (MDT). Surgical procedure included subtotal 
gastrectomy and total gastrectomy (Table 2), all with D2 
lymphadenectomy. Some patients received neoadjuvant therapy (Table 
2) and all procedures were performed using an open approach. 
 
8.3.4  Data collection 
All data were collected prospectively by named researchers, by 
attendance at MDT meetings and prospective review of all surgical 
patients during their hospital admission. Data is, therefore, highly robust. 
Data collected included age, gender, Welsh Index of Multiple Deprivation 
overall (WIMD) and health (H-WIMD) deprivation rank (2008), radiological 
and histopathological stage of disease (TNM7) (Sobin LH, 2009b), 
surgical procedure performed, operative morbidity related to the Clavien-
Dindo grade (CD) (Dindo et al., 2004), 30-day mortality, 30-day 
readmission, critical care length of stay in days (CC LOS) and total length 
of hospital stay (LOHS) in days. 
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8.3.5  Inclusion and exclusion criteria 
Patients were included on an intention to treat basis. Patients with benign 
disease were excluded.  
 
8.3.6  Outcome measures 
The primary outcome was defined as length of hospital stay (LOHS) in 
days. Secondary outcome measures were incidence of post-operative 
morbidity, according to the Clavien-Dindo classification (Dindo et al., 
2004), post-operative mortality and rates of readmission to hospital.  
 
8.3.7  Statistical analysis  
Statistical analysis was performed using the Predictive Analytics 
SoftWare (PASW [SPSS] Statistics v18.0.3, IBM Corporation, Armonk, 
New York, USA). Grouped data were expressed as median (range) and 
non-parametric analyses were used throughout. Statistical significance 
was determined as p<0.05. Categorical data were compared using the χ2 
test, except where groups contained counts of fewer than five, when 
Fisher’s exact test (Fisher, 1922) was used. Grouped continuous data 
were compared using the Mann-Whitney U-test (Mann and Whitney, 
1947). Further analysis of LOHS by group was performed using the 
Mantel-Cox log rank method of Kaplan and Meier (Kaplan and Meier, 
1958). This incorporated LOHS into the model in place of survival, using 
discharge from hospital as the event and resulting in the construction of 
LOHS plots.  
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8.4  RESULTS  
 
8.4.1  Details of the patients 
A total of 117 consecutive patients undergoing gastrectomy for cancer 
were included in the study. Patient characteristics and surgical data are 
shown by group in Table 1. 
 
8.4.2  Primary outcome measure  
All measured lengths of stay were significantly shorter in the ERP group 
than in the Control group (Table 2). This was observed for the total length 
of stay in hospital (11 vs. 14 days, p=0.004, Figure 1), the overall duration 
of admission to critical care facilities (0 vs. 1 day, p<0.0001) and length of 
stay in level 2 (p=0.002) and level 3 environments (p<0.0001).  
Multivariable analysis demonstrated inclusion in the ERP to be the sole 
independent, significant predictor of LOHS (p=0.028, Table 5). 
 
8.4.3  Secondary outcome measures  
8.4.3.1  Post-operative morbidity 
Rates of overall morbidity were comparable between groups (37.5% vs. 
37.8%, p=0.972, Table 5). Major morbidity (Clavien-Dindo Score ≥3) 
rates were lower in the ERP group, but this did not reach statistical 
significance (8.8% vs. 18.9%, p=0.115). 
Additional specific complications showed similar, but non-significant 
trends toward lower rates in the ERP group, including respiratory infection 
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(15.0% vs. 24.3%, p=0.222), respiratory failure (2.5% vs. 10.8%, 
p=0.058), and anastomotic leak (2.5% vs. 8.1%, p=0.163). 
 
8.4.3.2  Post-operative mortality 
A 30-day mortality of 2.5% (n=2) was observed in the ERP group and 
8.1% (n=3) in the Control group. This did not, however, reach statistical 
significance (p=0.163). 
 
8.4.3.3  Readmission rate 
The readmission rate was 7.5% (n=6) in the ERP group and 5.4% (n=2) 
in the Control group. Reasons for readmission are shown in Table 6. No 
significant difference was demonstrated in readmission rates between 
ERP and control patients (p=0.676).  
 
8.4.3.4  Cancellation rate 
A trend was observed toward a lower rate of cancellation resulting directly 
from unavailability of critical care facilities, though it did not reach 
statistical significance (6.1% vs. 16.7%, p=0.073). 
 
 
8.5  DISCUSSION 
 
This study represents the largest European series of patients undergoing 
surgery for gastric cancer within an ERP in relation to outcomes. 
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The principal findings were that ERPs were associated with significantly 
shorter lengths of stay in hospital and in critical care facilities, as well as 
reduced cost, without increasing post-operative morbidity or hospital 
readmission rates. Other significant benefits included a lower critical care 
related cancellation rate. 
 
This study has several strengths. All data were collected prospectively by 
an established and experienced MDT whose results are well audited and 
stand up to international comparisons (Centre, 2010). The study groups 
were drawn from a large consecutive series, minimising concern over 
selection bias.  
 
Several potential limitations were identified. This was a retrospective 
cohort study and, as such, randomisation was not undertaken. This limits 
the quality of the study when compared with a well-conducted 
randomised trial. However, a randomised trial is difficult to perform well in 
this area without access to separate clinical areas and medical and 
nursing staffs. These were not available in this unit. 
The cancer network studied underwent significant change in August 
2010, when all oesophagogastric cancer surgery was centralised to the 
unit studied. This is responsible for the disparity in group size in this 
cohort study.  
A small number of patients within the control group were treated post-
centralisation, compared with all patients in the ERAS group. This 
introduced the potential for confounding variables to influence outcomes 
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in the post-centralisation period. It is difficult to be certain how much 
influence on outcomes was exerted by ERAS and the centralisation of 
services respectively. Furthermore, two additional surgeons were 
introduced to the unit when centralisation occurred. This may have 
influenced outcomes according to recognised learning curve 
phenomenon (Hopper et al., 2007). 
However, the inclusion of centralisation as a variable in multivariable 
regression analysis alleviated concerns regarding its influence. While 
ERP emerged as an independent and significant predictor outcome on 
LOHS, centralisation did not. 
 
In the absence of contemporary consensus regarding which interventions 
should be included in an ERP encompassing gastric cancer surgery, the 
ERP was developed based upon principles from related work in other 
surgical arenas. While it is possible that consistency between 
programmes may develop with further research, the colorectal 
experience has been that such variation persists (Wind et al., 2006). 
 
No data were collected on pain or return of gut function. These have 
been reported in some studies (Feng et al., 2013, He, 2010, Chen Hu et 
al., 2012, Jiang et al., 2007, Kim et al., 2012, Liu et al., 2010, Wang et al., 
2010, Yamada et al., 2012). 
 
There is limited evidence in the literature for ERPs in gastrectomy for 
cancer, as demonstrated in the meta-analysis performed as chapter six in 
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this thesis. The majority has emerged from Asia and significant risk of 
bias exists throughout the literature base. However, the conclusion that 
ERPs are safe and feasible is supported by the findings in this Western 
population, with clear agreement between the results of our study and the 
meta-analysed data.  
While the reported mean LOHS following gastrectomy for cancer varied 
widely, it was uniformly reduced by the introduction of an ERP. The 
LOHS in control groups ranged from 7.1 to 28.2 days, and in ERP groups 
was reduced to 5.4 to 18.1 days. LOHS in our unit lay within this range, 
reducing from 14 to 11 days with the introduction of the ERP.  
Our results also agreed with the meta-analytical findings regarding 
operative morbidity, with no significant decrease in overall morbidity 
observed. However, a clear trend was seen in the meta-analysis toward a 
lower rate of operative morbidity in the ERP groups. This was mirrored in 
terms of major morbidity (Clavien-Dindo Score ≥3) in our study, with a 
reduction of more than 50%, from 18.9% to 8.8% with the introduction of 
the ERP. This did not reach statistical significance, perhaps as a result of 
type II error.  
 
The readmission rate within this study did not increase significantly, in 
line with the results of the meta-analysis. This is an important finding, 
demonstrating that patients are not being discharged from hospital 
prematurely.  
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8.6  CONCLUSION 
 
In conclusion, this study supports the use of our ERPs in gastric cancer 
surgery. The implementation of these multimodal approaches to 
perioperative management appears feasible, safe and cost effective, 
conferring benefits to health care providers and patients alike.  
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8.7  TABLES AND FIGURES  
8.7.1 Table 1. Details of the patients  
Variable Total ERP  Control 
n 117 80 37 
Gender (m:f, %) 68:32 68:32 69:31 
Age in years (range) 71 (39-86) 71 (44-83) 71 (39-86) 
Histology HGD 2 1 1 
ACA 115 79 36 
SCC 0 0 0 
Rad stage 0 1 0 1 
I 28 22 6 
II 33 22 11 
III 49 32 17 
IV 6 4 2 
pTNM 0 5 5 0 
I 24 18 6 
II 22 11 11 
III 32 19 13 
IVa 20 15 5 
No 
resection 
14 12 2 
Nodes positive 1 (0-24) 0 (0-24) 1.5 (0-17) 
ERP, enhanced recovery programme group; Control, control group; n, 
number; m, male; f, female; HGD, high grade dysplasia; ACA, 
adenocarcinoma; SCC, squamous cell carcinoma; Rad stage, radiological 
TNM7 stage; pTNM, histopathological TNM7stage
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8.7.2  Table 2. Lengths of stay according to treatment group.  
 
Variable Total ERP Control p-value 
LOHS 12 (2-60) 11 (3-52) 14 (2-60) 0.006 
Ward LOS 11 (0-54) 10.5 (3-48) 13 (0-54) 0.014 
CC LOS 1 (0-22) 0 (0-15)
  
1 (0-22) <0.0001 
ITU LOS 0 (0-11) 0 (0-9)
  
0 (0-11) <0.0001 
HDU LOS 1 (0-11) 0 (0-6)
  
1 (0-11) 0.002 
LOHS, length of hospital stay; LOS, length of stay in each clinical area 
(CC, critical care; ITU, intensive therapy unit; CC, critical care; HDU, high 
dependency unit) 
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8.7.3  Table 3. Morbidity by Clavien-Dindo (CD) grade according to 
treatment group (See section 1.9 for details of the CD classification 
system).  
 
CD Grade ERP Control  
0 50 (63%) 23 (62%) 
I 8 (10%) 0 (0%) 
II 15 (19%) 7 (19%) 
IIIa 2 (3%) 1 (3%) 
IIIb 1 (1%) 0 (0%) 
IVa 1 (1%) 1 (3%) 
IVb 0 (0%) 2 (5%) 
V 3 (4%) 3 (8%) 
Any morbidity 30 (37%)  14 (38%) 
 
CD, Clavien-Dindo; ERP, Enhanced recovery programme group; Control, 
control group;  
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8.7.4  Table 4. Univariable analysis of factors influencing LOHS.  
 
Variable X2 df p-value 
NodesPos 107.928 13 <0.0001 
Centralisation  7.039 1 0.008 
ERAS 8.457 1 0.004 
pTNM7 14.741 5 0.012 
pT7 10.025 6 0.124 
pN7 4.520 4 0.340 
Histology 0.495 1 0.482 
pM7 1.646 3 0.649 
radTNMstage 1.634 3 0.652 
Gender 0.082 1 0.775 
Age 0.260 47 0.992 
 
X2 Chi square statistic; Df, degrees of freedom, NodesPos, number of 
positive nodes; Centralisation, operated upon in the centralised unit; 
ERAS, operated upon within enhanced recover after surgery framework; 
pTNM7, histopathological TNM7 stage; pT7 / pN7 / pM7; 
histopathological T / N / M stage; Histology, histopathological cell type; 
radTNMstage, radiological TNM7 stage.
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8.7.5  Table 5. Multivariable analysis of factors influencing LOHS. 
 
Variable Hazard ratio 95% CI p-value 
ERP 0.579 0.356-0.942 0.028 
 
 
CI, confidence interval; ERP, operated upon within enhanced recover 
programme;  
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8.7.6  Table 6. Reasons for re-admission within 30 days. 
 
Patient number  ERAS n=4 (7.5%) Control n=2 (5.4%) 
1 Abdominal collection Acute kidney injury 
2 Abdominal collection Constipation 
3 Pain 
4 Pancreatic pseudocyst 
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8.7.7  Figure 1 – Summary of the ERP 
 
 
 
 
 
Pre5 Patient education; 
CPX; 
Post-op level of care requirement predicted (usually HDU); 
Carbohydrate drinks until 2hr and full diet until 6hr pre-op; 
No premedication. 
Intra5 Standardised anaesthetic approach 
Post5op+Day+
Day+1+
Day+2+
Day+3+
Day+4+
Day+5+onward+ Sit out 6hr; Walk x3; 
 
Day+X+ Discharge 
 
Total+Gastrectomy+ Subtotal+
Level 1-2 care; 
H2O, then feed 10ml/hr 
via jejunostomy. 
Level 1 care; 
H2O, then feed 10ml/hr 
via jejunostomy; 
Oral fluids. 
Sit out x2; Walk x2 
Achieve 40ml enteral 
feed (jej) 
Sit out x4; Walk x3 
Achieve 40ml enteral 
feed (jej) 
Sit out x4; Walk x3 
Achieve 80ml enteral feed (jej) 
Sit out 6hr; Walk x3; 
Reduce IVI 
 
Sit out 6hr; Walk x3 
Reduce IVI; 
Urinary catheter out 
 
Sit out 6hr; Walk x3; 
Urinary catheter out 
 
 
Sit out 6hr; Walk x3 
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8.7.8  Figure 2. Kaplan-Meier plot to demonstrate the influence of 
treatment in ERP (ERAS) on LOHS.  
 
 
 
Variable X2 df p-value 
ERAS 8.457 1 0.004 
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CHAPTER 9 
 
Outcomes following introduction of an enhanced recovery 
programme in oesophageal cancer surgery 
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9.1  SUMMARY 
 
The aim of this study was to examine the outcomes of oesophageal 
cancer surgery in a UK regional cancer centre with specific reference to 
the introduction of an ERP.  
One hundred and seventeen consecutive patients (median age 63 years, 
94 male) diagnosed with oesophageal cancer between May 2008 and 
August 2013 were studied prospectively before and after the introduction 
of an ERP (October 2010). The primary outcome measure was total 
length of hospital stay (LOHS). Secondary outcome measures were 
critical care length of stay (CCLOS), 30-day operative morbidity (graded 
according to Clavien-Dindo), 30-day operative mortality, 30-day 
readmission to hospital.  
From 117 studied patients, 81 were treated in the ERP and 36 were 
controls. Median LOHS was significantly shorter in the ERP group (14 vs. 
18.5 days, p=0.032). CCLOS was also significantly lower in the ERP 
group (CCLOS 1 vs. 3 day, p<0.0001) as well as level two and three LOS 
analysed separately (p<0.005). The ERP was associated with a 
significant reduction in major post-operative morbidity (CD ≥3, 18.5% vs. 
38.9%, p=0.019). No significant difference was observed in the incidence 
of specific complications (p>0.05), 30-day readmission to hospital (8.6% 
vs. 13.9%, p=0.388) or 30-day mortality rate (3.7% vs. 2.8%, p=0.799) 
between the ERP and CON groups respectively. Cost analysis 
demonstrated ERP to be associated with a significant cost saving 
(median 2109 vs. 3498 GBP, p<0.0001).  
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A non-significant trend toward fewer cancellations related to critical care 
pressures was observed in the ERP group (7.4% vs. 19.4%, p=0.059). 
An ERP in oesophageal cancer surgery was feasible, safe and cost 
effective. 
 
 
9.2  INTRODUCTION 
 
Oesophagectomy is a potentially curative, but high-risk, invasive 
procedure for oesophageal cancer. While remaining the mainstay of 
radical curative treatment for oesophageal cancer (Allum et al., 2011), 
surgical resection is complex in nature and associated with significant risk 
of post-operative morbidity and mortality, even in well-nourished patients 
(Allum et al., 2011). Indeed, UK National Audit figures report an in-
hospital mortality of 6.0 per cent (95% CI 4.8-7.4) and complication rate 
of 19.4 per cent in patients undergoing oesophagectomy for cancer 
(Centre, 2010). Furthermore, 7.4 per cent of patients undergoing 
oesophagectomy for cancer in the UK require further surgery for a 
complication (Centre, 2010). 
Enhanced recovery programmes (ERPs) are well established in 
colorectal surgery and have demonstrated clear benefits of employing 
holistic multimodal perioperative strategies in resectional cancer surgery. 
Such improvements are achieved in the modern ERP through 
aggregation of the benefits of a number of interventions to optimise 
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physiological, psychological and healthcare system factors surrounding 
major gastrointestinal surgery. Interventions are combined within a 
standardised pathway incorporating clear goals for patients and staff 
members alike. Benefits include reductions in post-operative morbidity 
and lengths of hospital stay (Varadhan et al., 2010). However, little 
attention has been given to the potential role of ERPs in upper 
gastrointestinal (UGI) cancer surgery. Few studies exist reporting 
outcomes following implementation of ERPs in oesophageal cancer 
surgery, and sample sizes in existing reports are modest (He, 2010, 
Jeong et al., 2011, Jiang et al., 2007, Kiyama et al., 2003, Liu et al., 
2010, So et al., 2008, Tang, 2013, Wang et al., 2010, Yamada et al., 
2012). The systematic review and meta-analysis of the implementation of 
ERPs for oesophagectomy for cancer contained within this thesis showed 
ERPs to be beneficial in reducing length of stay in hospital, post-
operative pain scores, duration of intravenous fluid requirement, post-
operative weight loss and overall cost. Moreover, no increase in post-
operative morbidity or hospital readmission rate was observed.  
Nutrition is a central component of gastrointestinal ERPs and radical 
oesophagectomy commonly entails protracted periods of starvation 
following intestinal resection and anastomosis. Such periods without oral 
nutrition are employed to allow time for return to normal intestinal motility 
and to protect anastomoses from the stress of oral fluids and diet (Lewis 
et al., 2009). Consideration of nutritional requirements is particularly 
salient in patients requiring upper gastrointestinal cancer surgery, in 
whom pre-operative malnutrition is frequently present (Nygren et al., 
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2003). Indeed, severe malnutrition is associated with a higher incidence 
of post-operative complications and potential prolongation of the recovery 
period (Weimann et al., 2006).. 
The aim of this study was, therefore, to analyse the influence of a 
standardised multimodal peri-oesophagectomy pathway for oesophageal 
cancer by comparison of intervention and control groups.  
  
 
9.3  METHODS 
 
9.3.1  Programme 
A multimodal programme for oesophagectomy was constructed following 
an information gathering process inclusive of surgical, oncological, 
radiological, dietetic, nursing and physiotherapy staff members (Figure 1). 
The literature was consulted to inform specific aspects of the pathway. 
Programme development was led by three consultant surgeons (WL, GC, 
GB) operating within the regional cancer network. A pathway booklet was 
created, which served as a unified multidisciplinary patient record, within 
which all documentation was centralised during the individual patient 
journey. 
 
9.3.2  Population 
Groups were drawn from a consecutive series of patients receiving 
surgical treatment for oesophageal cancer within the South East Wales 
 249 
Cancer Network, which serves a population of approximately 1.4 million. 
The control group comprised patients undergoing open surgery between 
20th May 2008 and 30th September 2010 at two of three NHS Trusts 
within the network. The network was centralised to a single site on 1st 
August 2010 and, thereafter, a third NHS Trust also contributed patients 
to the centralised service. The ERP was implemented for all patients from 
1st October 2010 onward, and the ERP group comprised patients 
undergoing surgery between this date and 20th August 2013.  
 
9.3.3  Surgery 
All patients underwent surgery according to decisions of a regional 
multidisciplinary team (MDT). Some patients received neoadjuvant 
therapy (Table 2) and all procedures were performed using an open 
approach. 
 
9.3.4  Data collection 
All data were collected prospectively by named researchers, by 
attendance at MDT meetings and prospective review of all surgical 
patients during their hospital admission. Data is, therefore, highly robust. 
Data collected included age, gender, Welsh Index of Multiple Deprivation 
overall (WIMD) and health (H-WIMD) deprivation rank (2008), radiological 
and histopathological stage of disease (TNM7) (Sobin LH, 2009b), 
surgical procedure performed, operative morbidity related to the Clavien-
Dindo grade (CD, see section 1.9) (Dindo et al., 2004), 30-day mortality, 
30-day readmission, critical care length of stay in days (CC LOS) and 
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total length of hospital stay (LOHS) in days. 
 
9.3.5  Inclusion and exclusion criteria 
Patients were included on an intention to treat basis. Patients with benign 
disease were excluded.  
 
9.3.6  Outcome measures 
The primary outcome was defined as length of hospital stay (LOHS) in 
days. Secondary outcome measures were incidence of post-operative 
morbidity, according to the Clavien-Dindo classification (Dindo et al., 
2004), post-operative mortality and rates of readmission to hospital.  
 
9.3.7  Statistical analysis  
Statistical analysis was performed using the Predictive Analytics 
SoftWare (PASW [SPSS] Statistics v18.0.3, IBM Corporation, Armonk, 
New York, USA). Grouped data were expressed as median (range) and 
non-parametric analyses were used throughout. Statistical significance 
was determined as p<0.05. Categorical data were compared using the χ2 
test, except where groups contained counts of fewer than five, when 
Fisher’s exact test (Fisher, 1922) was used. Grouped continuous data 
were compared using the Mann-Whitney U-test ((Mann and Whitney, 
1947). Further analysis of LOHS by group was performed using the 
Mantel-Cox log rank method of Kaplan and Meier (Kaplan and Meier, 
1958). This incorporated LOS into the model in place of survival, using 
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discharge from hospital as the event and resulting in the construction of 
LOHS plots.  
 
 
9.4  RESULTS  
 
9.4.1  Details of the patients 
A total of 117 consecutive patients undergoing oesophagectomy for 
cancer were included in the study. Patient characteristics and surgical 
data are shown by group in Table 1. 
 
9.4.2  Primary outcome measure  
All measured lengths of stay were significantly shorter in the ERP group 
than in the Control group (Table 2). This was observed for the total length 
of stay in hospital (14 vs. 18.5 days, p=0.003, Figure 2), the overall 
duration of admission to critical care facilities (p<0.0001) and 
independent lengths of stay in level 2 (p=0.038) and level 3 environments 
(p<0.0001).  
Multivariable analysis demonstrated inclusion in the ERP to be the 
strongest independent, significant predictor of LOHS (p=0.001, Table 4). 
TNM stage was the only other independent predictor of LOHS (p=0.003). 
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9.4.3  Secondary outcome measures  
9.4.3.1  Post-operative morbidity 
Rates of overall morbidity were comparable between groups (56.8% vs. 
52.8%, p=0.687, Table 3), but the rate of major morbidity (Clavien-Dindo 
Score ≥3) was significantly lower in the ERP group than the CON group 
(18.5% vs. 38.9%, p=0.019, Table 3). 
A similar but non-significant trend toward lower incidence of respiratory 
failure was observed in the ERP group (8.6% vs. 16.7%, p=0.202). No 
significant difference was observed in the incidence of respiratory 
infection (24.7% vs. 27.8%, p=0.724) or anastomotic leak (13.6% vs. 
13.9%, p=0.964). None was statistically significant. 
 
9.4.3.2  Post-operative mortality 
A 30-day mortality of 3.7% (n=3) was observed in the ERP group and 
5.6% (n=2) in the Control group. This was not statistically significant 
(p=0.648). 
 
9.4.3.3  Readmission rate 
The readmission rate was 8.6% (n=7) in the ERP group and 13.9% (n=5) 
in the Control group. Reasons for readmission are shown in Table 6. No 
significant difference was demonstrated in readmission rates between 
ERP and control patients (p=0.388).  
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9.4.3.4  Cancellation rates 
A trend was observed toward a lower rate of cancellation resulting directly 
from unavailability of critical care facilities, though it did not reach 
statistical significance (6.6% vs 16.7%, p=0.073). 
 
 
9.5  DISCUSSION 
 
This study represents the largest European series of patients undergoing 
surgery for oesophageal cancer within an ERP in relation to outcomes. 
The principal findings were that ERPs were associated with significantly 
shorter LOHS, reduced incidence of post-operative morbidity and 
reduced cost, without an increase in rates of hospital readmission, 
specific morbidity or mortality. Other significant benefits included a lower 
critical care related cancellation rate. 
 
This study has several strengths. All data were collected prospectively by 
an established and experienced MDT whose results are well audited and 
stand up to international comparisons (Centre, 2010). The study groups 
were drawn from a large consecutive series, minimising concern over 
selection bias.  
 
Several potential limitations were identified. This was a retrospective 
cohort study and, as such, randomisation was not undertaken. This limits 
 254 
the quality of the study when compared with a well-conducted 
randomised trial. However, a randomised trial is difficult to perform well in 
this area without access to separate clinical areas and medical and 
nursing staffs. These were not available in this unit. 
The cancer network studied underwent significant change in August 
2010, when all oesophagogastric cancer surgery was centralised to the 
unit studied. A small number of patients within the control group were 
treated post-centralisation, compared with all patients in the ERAS group.  
This introduced the potential for confounding variables to influence 
outcomes in the post-centralisation period. It is difficult to be certain how 
much influence on outcomes was exerted by ERAS and the centralisation 
of services respectively. Furthermore, two additional surgeons were 
introduced to the unit when centralisation occurred. This may have 
influenced outcomes according to recognised learning curve 
phenomenon (Hopper et al., 2007). 
However, the inclusion of centralisation as a variable in multivariable 
regression analysis alleviated concerns regarding its influence. While 
ERP emerged as an independent and significant predictor of LOHS, 
centralisation did not. 
 
In the absence of contemporary consensus regarding which interventions 
should be included in an ERP encompassing gastric cancer surgery, the 
ERP was developed based upon principles from related work in other 
surgical arenas. While it is possible that consistency between 
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programmes may develop with further research, the colorectal 
experience has been that such variation persists (Wind et al., 2006). 
There is very limited evidence in the literature for ERPs in 
oesophagectomy for cancer, as demonstrated in the meta-analysis 
performed as chapter seven in this thesis. The majority has emerged 
from Asia and significant risk of bias exists throughout the literature base. 
However, the conclusion that ERPs are safe and feasible is supported by 
the findings in this Western population, with clear agreement between the 
results of our study and the meta-analysed data.  
 
While the reported mean LOHS following oesophagectomy for cancer 
varied widely, it was uniformly reduced by the introduction of an ERP. 
The LOHS in control groups ranged from 7.5 to 15.0 days, and in ERP 
groups was reduced to 6.3 to 11 days. LOHS in our unit was reduced 
from 18.5 to 14 days with the introduction of the ERP.  
Our results did not demonstrate a significant reduction in overall 
morbidity, although a trend toward a slightly reduced rate in the ERP was 
shown (57% vs. 53%). In the meta-analysis, inclusion in an ERP was 
associated with a significantly lower rate of operative morbidity (OR 0.47 
(0.33 to 0.66), p<0.0001). This was mirrored in terms of major morbidity 
(Clavien-Dindo Score ≥3) in our study, with a reduction of more than 
50%, from 38.9% to 18.5% with the introduction of the ERP. This did not 
reach statistical significance, perhaps as a result of type II error.  
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The readmission rates within this study were not significantly different, in 
line with the results of the meta-analysis. In fact the readmission rate in 
our study showed a trend toward being lower in the ERP group. This is 
an important finding, demonstrating that patients are not being 
discharged from hospital prematurely.  
 
 
9.6  CONCLUSION 
 
In conclusion, this study supports the use of our ERPs in oesophageal 
cancer surgery. The implementation of these multimodal approaches to 
perioperative management appears feasible, safe, and cost effective, 
conferring benefits to health care providers and patients alike.  
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9.7  TABLES AND FIGURES  
9.7.1 Table 1. Details of the patients  
 
Variable Total ERP  Control 
n 117 81 36 
Gender (m:f, %) 80:20 80:20 81:19 
Age in years (range) 63 (24-80) 63 (24-76) 64 (37-80) 
Histology HGD 1 1 0 
ACA 101 67 34 
SCC 15 13 2 
Rad stage 0 (HGD) 3 2 1 
I 37 26 11 
II 34 22 12 
III 43 31 12 
IV 0 0 0 
pTNM 0 2 1 1 
I 32 22 10 
II 26 19 7 
III 31 22 9 
IVa 8 6 2 
No 
resection 
18 11 7 
Nodes positive 0 (0-24) 0 (0-24) 1.0 (0-13) 
 
ERP, enhanced recovery programme group; Control, control group; n, 
number; m, male; f, female; HGD, high grade dysplasia; ACA, 
adenocarcinoma; SCC, squamous cell carcinoma; Rad stage, radiological 
TNM7 stage; pTNM, histopathological TNM7stage
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9.7.2  Table 2. Lengths of stay according to treatment group.  
 
Variable Total ERP Control p-value 
LOHS 15 (4-119) 14 (4-47) 18.5 (4-119) p=0.032 
Ward LOS 13 (0-86)  13 (0-41) 14.5 (2-86)  p=0.463 
CC LOS 1 (0-70)
  
1 (0-37) 3 (0-70) p<0.0001 
ITU LOS 0 (0-70)  0 (0-17)
  
2 (0-70) p<0.0001 
HDU LOS 1 (0-20) 1 (0-20)
  
2 (0-8)  p=0.038 
ERP, Enhanced recovery programme group; Control, control group; 
LOHS, length of hospital stay; LOS, length of stay in each clinical area 
(CC, critical care; ITU, intensive therapy unit; HDU, high dependency 
unit) 
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9.7.3  Table 3. Morbidity by Clavien-Dindo (CD) grade according to 
treatment group (See section 1.9 for details of the CD classification 
system).  
 
CD Grade ERP Control  
0 35 (43%) 17 (47%) 
I 7 (9%) 0 (0%) 
II 24 (30%) 5 (14%) 
IIIa 3 (4%) 5 (14%) 
IIIb 3 (4%) 2 (6%) 
IVa 5 (6%) 5 (14%) 
IVb 1 (1%) 0 (0%) 
V 3 (4%) 2 (6%) 
Any morbidity 46 (57%)  19 (53%) 
CD, Clavien-Dindo; ERP, Enhanced recovery programme group; Control, 
control group;  
 260 
9.7.4  Table 4. Univariable analysis of factors influencing LOHS.  
 
Variable X2 df p-value 
pT7 67.324 6 <0.0001 
pTNM7 47.756 5 <0.0001 
pN7 25.549 4 <0.0001 
Age 63.760 36 0.003 
ERAS 8.964 1 0.003 
NodesPos 15.800 9 0.071 
Centralisation  3.029 1 0.082 
radTNMstage 3.542 3 0.315 
Histology 1.890 2 0.389 
Gender 0.389 1 0.529 
pM7 1.070 3 0.784 
 
X2 Chi square statistic; Df, degrees of freedom, pTNM7, histopathological 
TNM7 stage; pT7 / pN7 / pM7; histopathological T / N / M stage; ERAS, 
operated upon within enhanced recover after surgery framework; 
NodesPos, number of positive nodes; Centralisation, operated upon in 
the centralised unit; radTNMstage, radiological TNM7 stage; Histology, 
histopathological cell type. 
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9.7.5  Table 5. Multivariable analysis of factors influencing LOHS. 
 
Variable Hazard ratio 95% CI p-value 
ERP 0.380 0.218-0.660 0.001 
pTNM stage 0.076 0.013-0.431 0.003 
 
 
CI, confidence interval; pTNM stage, histopathological TNM7 stage; ERP, 
operated upon within enhanced recover programme;  
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9.7.6  Table 6. Reasons for re-admission within 30 days. 
 
Patient number  ERAS n=7 (8.6%) Control n=5 (13.9%) 
1 Pneumonia Anastomotic leak 
2 Pneumonia Vomiting 
3 Pneumonia Persistent chyle leak 
4 Pleural effusion Hernia 
5 Acute urinary retention Disease progression (symptomatic) 
6 Wound infection  
7 Disease progression 
(spinal metastases) 
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9.7.7  Figure 1 – ERAS pathway 
 
 
 
 
 
 
 
Oesophagectomy+
Pre5 Patient education; 
CPX; 
Post-op level of care requirement predicted (usually HDU); 
Carbohydrate drinks until 2hr and full diet until 6hr pre-op; 
No premedication. 
Intra5 Standardised anaesthetic approach 
Post5op+Day+ Level 2-3 care; H2O, then feed 10ml/hr via jejunostomy. 
Day+1+ Sit out x2; Walk x1; Achieve 40ml/hr enteral feed (jej) 
Day+2+ Sit out x2; Walk x2; Achieve 80ml/hr enteral feed (jej) 
Day+3+ Sit out x4; Walk x3; Reduce IVI 
Day+4+ Sit out x4; Walk x3; Reduce IVI 
Day+5+onward+ Sit out 6hr; Walk x3 Reduce IVI; 
Urinary catheter out 
Gastrograffin swallow on day 5-7 
Day+11+ Discharge  
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9.6.8  Figure 2 - Kaplan-Meier plot to demonstrate the influence of 
treatment in ERP (ERAS) on LOHS. 
 
 
 
Variable X2 df p-value 
ERAS 8.964 1 0.003 
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CHAPTER 10 
 
General discussion and prospect 
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10.1 General discussion and prospect 
 
Surgery remains the mainstay of curative treatment for gastric and 
oesophageal cancer. However, oesophagogastric cancer surgery is 
associated with high risk and outcomes remain poor in comparison to 
many other malignancies. Centralisation of services and meticulous 
stage-directed management have permitted improved outcomes (Chan et 
al., 2013), but better outcome prediction and further improvements to 
perioperative risk stratification and management are required.  
 
This thesis examines existing and novel physiological and body 
composition risk assessment modalities and perioperative management 
programmes in oesophagogastric cancer surgery. It examines the utility 
of CT and BIA body composition measures, as well as CPX testing, in 
predicting outcomes following major oesophagogastric surgery. It goes 
on to explore the impact of the introduction of enhanced recovery 
programmes in this arena.  
 
10.1.1 Bioelectrical impedance analysis 
Despite documented surface electrode measurement of bioelectrical 
tissue properties reaching back over 40 years, little use has been made 
of BIA technology in the surgical arena. The findings reported in this 
thesis demonstrated that BIA-measures of fat-free mass (FFM) and 
muscle mass (MM) provided useful predictive information regarding 
length of hospital stay (LOHS) and survival after oesophagogastric 
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cancer surgery. Both FFM and MM were shown to be independent and 
significant predictors of LOHS. 
Methods of minimising muscle wasting and promoting weight 
maintenance or even weight gain pre-operatively should be sought, with 
assessment of the impact of such methods on outcomes. 
Modern BIA analysers permit the performance of a simple and quick 
reading, yielding a wide range of variables spanning direct physical 
conduction measures, such as resistance and reactance, through to 
complex derived measures of fluid volumes, mineral stores, ion levels 
and body composition, such as those studied in this thesis. Each of these 
variables may have significant utility in the arena of surgery, 
oesophagogastric and beyond. In particular, future work should 
investigate the impact of fluid volumes, such as extracellular and 
intracellular volumes, on outcomes in the perioperative period. These 
measures are to some degree accessible to the clinical team during the 
patient journey and targeted fluid management, with individual BIA-
directed goals may be the next area for marginal gain in the perioperative 
care of these patients. 
 
10.1.2 CT-measured psoas muscle density 
In addition to derived measures of body composition, such as those in 
BIA that employ complex calculations based on published algorithms, 
radiological imaging modalities can offer further insight into a patient’s 
body composition.  
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Oesophagogastric cancer staging requires an extensive set of 
radiological investigations, which represents a valuable resource for the 
multidisciplinary team in the preoperative assessment of patients for 
surgery. The findings in this thesis suggest that CT-measured psoas 
muscle density (PMD) holds significant and independent predictive value 
in relation to survival, a greater density predicting longer survival. PMD 
did not appear to offer useful predictions of perioperative outcomes of 
morbidity, mortality and LOHS. As the use of this type of measurement to 
profile patients’ body composition grows in popularity, emerging 
technology and methods should be further explored as potential areas for 
improved risk and outcome prediction. The most extensive work in this 
area has come from Englesbe and colleagues, who have led on the 
concept of morphometric analysis, or analytic morphomics, in the 
assessment of the surgical patient (Englesbe et al., 2012, Englesbe et al., 
2010, Englesbe et al., 2013, Harbaugh et al., 2013, Lee et al., 2011a, Lee 
et al., 2011b, Sabel et al., 2011). The application of this type of detailed 
analysis of existing available radiology should be encouraged in 
oesophagogastric cancer, with full exploration of their value in outcome 
prediction. 
 
10.1.3 Cardiopulmonary exercise testing 
CPX is increasingly being used in pre-operative assessment as a 
demonstration of the capacity of a patient to cope with the physiological 
stresses of surgical intervention.  
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Chapters four and five within this thesis represent the largest series to 
date of patients with gastric and oesophageal cancer respectively, 
undergoing CPX testing as a pre-operative assessment for surgery.  
In gastric cancer, VE/VCO2 was found to be of greater predictive value 
than other CPX variables for operative morbidity and survival. Indeed, a 
VE/VCO2 cut-off of 34 emerged as a significant predictor of survival. 
Conversely, in patients with oesophageal cancer, VO2 peak was found to 
be of greater predictive value than other CPX variables for operative 
morbidity, LOHS and survival. Multivariable analysis demonstrated VO2 
peak to be an independent, significant predictor of LOHS, and a cut-off of 
22 ml/kg/min emerged as a significant predictor of survival. A high 
VE/VCO2 was also associated with operative morbidity in this cohort. 
A clear point to emerge from this thesis regarding CPX is the importance 
of interpreting results from CPX testing, and indeed additional 
assessment modalities, in combination rather than in isolation. 
Convincing evidence of suitably reliable individual cutoffs to determine 
the appropriate treatment modality in isolation have not been identified 
and the holistic interpretation of available data by an experienced MDT 
continues to provide the most appropriate assessment of the 
contemporary oesophagogastric cancer patient as an individual. 
Future work should further explore the variables examined herein, 
performing CPX with blinding of anaesthetist and surgeon responsible for 
surgery. This may remove the confounding effect of non-blinding by 
reducing the differences in consequent perioperative management 
employed to accommodate and minimise the risks identified by CPX. 
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However, logistical factors would present significant challenges to 
performing this type of study within our centre and ethical implications 
may well be unsurpassable.  
A specific group of interest would be those patients whose CPX results 
suggested that they were borderline physiologically fit to undergo 
surgery. Randomising patients within this sub-group to either surgery or 
definitive chemoradiotherapy could provide meaningful evidence on 
patient selection for surgery in this challenging group of patients.  
A number of patients studied within our unit experienced difficulty with the 
performance of the CPX test. It is a recognised limitation of CPX testing 
that in some cases, the patient may be either unable or unwilling to 
achieve maximal cardiovascular effort, often for physical reasons 
including joint disease, poor coordination and inflexibility. A less studied 
CPX variable exists that may offer a way to overcome this difficulty. The 
oxygen uptake efficiency slope (OUES) has been demonstrated as an 
objective, effort-independent estimation of cardiorespiratory functional 
reserve in cardiac patients and normal subjects (Baba et al., 1996, Baba 
et al., 1999b, Baba et al., 1999a). No study exists in the literature 
exploring the prognostic value of OUES in oesophagogastric surgical 
patients, and only a single, passing reference to OUES in surgical 
patients was identified outside of cardiothoracic surgery (Colson et al., 
2012).  
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10.1.4 Systematic review and meta-analysis of ERPs 
This thesis contains the most comprehensive systematic review and 
meta-analysis to date to examine the effects of ERPs in patients 
undergoing surgery for gastric cancer and oesophageal cancer 
respectively.  
Following the success of ERPs in colorectal surgery, it is perhaps 
surprising that similar approaches to formally structure the peri-operative 
management of oesophagogastric cancer patients have been slow to 
emerge. 
In both the gastric and oesophageal meta-analyses, significant reductions 
in length of hospital stay (LOHS, p=0.001, p<0.001) were observed within 
ERPs. These were not associated with any increase in morbidity, 
mortality or readmission and, in fact, a reduction in morbidity was 
observed in oesophageal ERPs (p<0.0001). Clear cost benefits were also 
shown in gastric cancer ERPs (p<0.001). It was concluded that ERPs in 
oesophagogastric cancer surgery appear feasible and safe. 
Further high-quality randomised trials of ERPs in this arena are needed, 
particularly from the Western World, to address the paucity of studies 
from Europe and North America in comparison to Asia. Future meta-
analysis of the literature would then be more reliably applicable to the 
Western developed world, as well as the East. 
 
10.1.5 Oesophagogastric ERP outcomes 
As discussed directly above, it is surprising that few studies have 
reported the impact of multimodal peri-operative care programmes in 
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oesophagogastric cancer. This thesis examines outcomes in the largest 
European series of gastric and oesophageal cancer operated within an 
ERP or fast-track surgery programme. 
The findings mirror those from the wider literature, as demonstrated in the 
meta-analyses herein. LOHS following gastrectomy and oesophagectomy 
was three and four and a half days shorter respectively within ERPs 
compared with control patients (p=0.004, p=0.032), without negative 
effects on morbidity, mortality or readmission rate. Additional cost 
benefits, averaging a saving of over 400 GBP per gastrectomy and 
almost 1400 GBP per oesophagectomy, were observed in the ERP group 
(p=0.001, p<0.0001). These results led to the conclusion that ERPs for 
oesophagogastric cancer in this unit, similarly to the wider literature, 
appear feasible, safe and cost effective.  
Comparing the relative value of the ERPs for gastric and oesophageal 
cancer surgery in our unit, both appear to be similarly valuable. With 
regard to the above-mentioned significant reductions in LOHS, ERP 
inclusion was the strongest factor influencing LOHS within multivariable 
analysis. The effect on the incidence of major morbidity was greater 
within the oesophageal ERP than the gastric ERP, with a statistically 
significant reduction seen within the oesophageal ERP. The effect on 
specific complications, mortality and readmission was very similar 
between ERPs. The influence on cost was also more profound in the 
oesophageal ERP, predominantly as a result of the greater reliance upon 
critical care for oeosophagectomy prior to the introduction of the ERP and 
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also the greater reduction in length of stay achieved within the 
oesophageal ERP, as compared with the gastric ERP (4.5 vs. 3 days).  
While ERPs for gastric and oesophageal cancer were both particularly 
beneficial, the oesophageal ERP was, therefore, shown to offer slightly 
greater benefits to patients, in terms of morbidity and LOHS, and also to 
healthcare provider, in terms of morbidity, LOHS and cost, than the 
gastric ERPs.  
Future work should seek to disseminate the practice described within 
these programmes and further refine the detail within them, actively 
incorporating evidence-based advances in the peri-operative 
management of these high-risk and complex surgical patients. 
 
10.2 CONCLUSION 
 
In conclusion, the findings in this thesis have offered new and deepened 
insights into areas of pre-operative risk assessment and outcome 
prediction. Future work should seek to build on the utility identified using 
these predictive approaches, harnessing available technology to develop 
multimodal, reproducible, evidence-based tools for risk and outcome 
prediction. This could offer clinicians and patients a more accurate 
assessment of the possible outcomes and help to accurately identify 
those patients most likely to benefit from surgical intervention.  
Additional work on the perioperative management of patients in ERPs 
should seek to aggregate the marginal gains, which continue to emerge 
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within the literature, into programmes that offer a structured and 
coordinated approach to the management of these complex patients, 
whose post-operative journey is made difficult by nutritional factors, 
analgesic challenges and often operative morbidity. 
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Appendix C: 
p. 332 - Scientific Review Approval Letter  
p. 334 - Patient participation consent form 
p. 335 - Information leaflet (English language version) 
p. 337 - Information leaflet (Welsh language version) 
 


Cardiff'and'Vale'University'Health'Board.'Dept'of'Upper'Gastrointestinal'Surgery'
April 2014, v.2 
CONSENT FORM 
Bioelectrical Impedence Analysis (BIA) in Surgical Patients 
Name of Researcher: Mr W G Lewis 
Px ID:  
Please initial each box 
1. I confirm that I have read and understand the information 
sheet dated April 2014, version 3 for the above study. I 
have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.   
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time without giving any reason, 
without my medical care or legal rights being affected.  
3. I understand that relevant sections of my medical notes 
and data collected during the study may be looked at by 
individuals from regulatory authorities or from the NHS 
Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have 
access to my records.  
4. I agree to my GP being informed of my participation in the 
study.  
5. I agree to take part in the above study.  
 
___________________ ___/___/20___ ______________ 
Name of patient    Date   Signature 
 
___________________ ___/___/20___ ______________ 
Name of person    Date    Signature   
taking consent  
Copies: 1 - participant; 1 - researcher file; 1 - medical notes. 
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